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A B S T R A C T
Background
The four approaches to hysterectomy for benign disease are abdominal hysterectomy (AH), vaginal hysterectomy (VH), laparoscopic
hysterectomy (LH) and robotic-assisted hysterectomy (RH).
Objectives
To assess the effectiveness and safety of different surgical approaches to hysterectomy for women with benign gynaecological conditions.
Search methods
We searched the following databases (from inception to 14 August 2014) using the Ovid platform: Cochrane Central Register of
Controlled Trials (CENTRAL); MEDLINE; EMBASE; Cumulative Index to Nursing and Allied Health Literature (CINAHL) and
PsycINFO. We also searched relevant citation lists. We used both indexed and free-text terms.
Selection criteria
We included randomised controlled trials (RCTs) in which clinical outcomes were compared between one surgical approach to
hysterectomy and another.
Data collection and analysis
At least two review authors independently selected trials, assessed risk of bias and performed data extraction. Our primary outcomes
were return to normal activities, satisfaction, quality of life, intraoperative visceral injury and major long-term complications (i.e. fistula,
pelvi-abdominal pain, urinary dysfunction, bowel dysfunction, pelvic floor condition and sexual dysfunction).
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Main results
We included 47 studies with 5102 women. The evidence for most comparisons was of low or moderate quality. The main limitations
were poor reporting and imprecision.
Vaginal hysterectomy (VH) versus abdominal hysterectomy (AH) (nine RCTs, 762 women)
Return to normal activities was shorter in the VH group (mean difference (MD) -9.5 days, 95% confidence interval (CI) -12.6 to -
6.4, three RCTs, 176 women, I2 = 75%, moderate quality evidence). There was no evidence of a difference between the groups for the
other primary outcomes.
Laparoscopic hysterectomy (LH) versus AH (25 RCTs, 2983 women)
Return to normal activities was shorter in the LH group (MD -13.6 days, 95% CI -15.4 to -11.8; six RCTs, 520 women, I2 = 71%, low
quality evidence), but there were more urinary tract injuries in the LH group (odds ratio (OR) 2.4, 95% CI 1.2 to 4.8, 13 RCTs, 2140
women, I2 = 0%, low quality evidence). There was no evidence of a difference between the groups for the other primary outcomes.
LH versus VH (16 RCTs, 1440 women)
There was no evidence of a difference between the groups for any primary outcomes.
Robotic-assisted hysterectomy (RH) versus LH (two RCTs, 152 women)
There was no evidence of a difference between the groups for any primary outcomes. Neither of the studies reported satisfaction rates
or quality of life.
Overall, the number of adverse events was low in the included studies.
Authors’ conclusions
Among women undergoing hysterectomy for benign disease, VH appears to be superior to LH and AH, as it is associated with faster
return to normal activities. When technically feasible, VH should be performed in preference to AH because of more rapid recovery
and fewer febrile episodes postoperatively. Where VH is not possible, LH has some advantages over AH (including more rapid recovery
and fewer febrile episodes and wound or abdominal wall infections), but these are offset by a longer operating time. No advantages
of LH over VH could be found; LH had a longer operation time, and total laparoscopic hysterectomy (TLH) had more urinary tract
injuries. Of the three subcategories of LH, there are more RCT data for laparoscopic-assisted vaginal hysterectomy and LH than for
TLH. Single-port laparoscopic hysterectomy and RH should either be abandoned or further evaluated since there is a lack of evidence
of any benefit over conventional LH. Overall, the evidence in this review has to be interpreted with caution as adverse event rates were
low, resulting in low power for these comparisons. The surgical approach to hysterectomy should be discussed and decided in the light
of the relative benefits and hazards. These benefits and hazards seem to be dependent on surgical expertise and this may influence the
decision. In conclusion, when VH is not feasible, LH may avoid the need for AH, but LH is associated with more urinary tract injuries.
There is no evidence that RH is of benefit in this population. Preferably, the surgical approach to hysterectomy should be decided by
the woman in discussion with her surgeon.
P L A I N L A N G U A G E S U M M A R Y
Surgical approach to hysterectomy for benign gynaecological diseases
Review question
Cochrane authors evaluated which is the most effective and safe surgery for hysterectomy in women with benign gynaecological disease.
Background
Hysterectomy for benign gynaecological disease, mostly abnormal uterine bleeding, prolapse or uterine fibroids, is one of the most
frequent gynaecological procedures (30% of women by the age of 60; 590,000 procedures annually in the USA). It can be performed
through several approaches. Abdominal hysterectomy involves removal of the uterus through an incision in the lower abdomen. Vaginal
hysterectomy involves removal of the uterus via the vagina, without an abdominal incision. Laparoscopic hysterectomy involves ’keyhole
surgery’ through small incisions in the abdomen. The uterus may be removed vaginally or, after morcellation (cutting it up), through
one of the small incisions. There are various types of laparoscopic hysterectomy, depending on the extent of the surgery performed
2Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
laparoscopically compared to that performed vaginally. More recently, laparoscopic hysterectomy has been performed robotically. In
robotic surgery, the operation is done by a robot, while the (human) surgeon steers the robot from a chair in the corner of the operating
room. It is important to be well informed about the relative benefits and harms of each approach to make best informed choices for
each woman needing hysterectomy for a benign disease.
Study characteristics
We analysed 47 randomised controlled trials (RCTs). A RCT is a type of study in which the people being studied are randomly allocated
one or other of the different treatments being investigated. This type of study is usually the best way to evaluate whether a treatment
is truly effective, i.e. truly helps the patient. A systematic review systematically summarises the available RCTs on a subject.
A total of 5102 women participated. Comparisons were vaginal versus abdominal hysterectomy (nine trials, 762 women), laparoscopic
versus abdominal hysterectomy (25 trials, 2983 women), laparoscopic versus vaginal hysterectomy (16 trials, 1440 women) and
laparoscopic versus robot-assisted hysterectomy (two trials, 152 women); in addition there were studies in which three comparisons were
made (four trials, 410 women). There were also studies included in which different types of laparoscopic hysterectomies were compared,
including single-port versus multi-port (three trials, 203 women), total laparoscopic hysterectomy versus laparoscopic-assisted vaginal
hysterectomy (one trial, 101 women) and mini-laparoscopic versus conventional laparoscopic hysterectomy (one trial, 76 women). The
main outcomes were return to normal activities, satisfaction, quality of life and surgical complications.
Key results
We found that vaginal hysterectomy resulted in a quicker return to normal activities than abdominal hysterectomy. There was no
evidence of a difference between them for our other main outcomes.
Laparoscopic hysterectomy also resulted in a quicker return to normal activities than abdominal hysterectomy. However, laparoscopic
hysterectomies had a greater risk of damaging the bladder or ureter. There was no evidence of a difference between laparoscopic and
vaginal hysterectomy or between laparoscopic and robot-assisted hysterectomy for our main outcomes.
We conclude that vaginal hysterectomy should be performed whenever possible. Where vaginal hysterectomy is not possible, both a
laparoscopic approach and abdominal hysterectomy have their pros and cons and these should be incorporated in the decision-making
process.
The evidence is current to August 2014.
Quality of the evidence
The evidence for most comparisons was of low or moderate quality. The main limitations were poor reporting of study methods and
wide confidence intervals around the estimate of effect.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vaginal hysterectomy versus abdominal hysterectomy for benign gynaecological disease
Patient or population: pat ients with benign gynaecological disease
Settings: hospital
Intervention: vaginal versus abdominal hysterectomy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Abdominal hysterec-
tomy
Vaginal hysterectomy
Return to normal activ-
ities (days)
The mean return to nor-
mal act ivit ies (days) in
the AH group was
42.7 days
The mean return to nor-
mal act ivit ies (days) in
the VH group was
9.5 lower
(12.6 to 6.4 lower)
- 176
(3 studies)
⊕⊕⊕©
moderate1
-
Urinary tract (bladder
or ureter) injury
0 per 1000 0 per 1000
(0 to 0)
OR 3.09
(0.48 to 19.97)
439
(4 studies)
⊕⊕⊕©
moderate2,3
There were no urinary
tract injuries in one
study
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
AH: abdominal hysterectomy; CI: conf idence interval; OR: odds rat io; VH: vaginal hysterectomy
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1There was a large dif ference in return to normal act ivit ies between the dif ferent studies; the analysis had high heterogeneity
(I2 = 75%) but consistent direct ion of ef fect.4
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2In 2 studies there was doubt about the method used for random sequence generat ion.
3There were only three events altogether, all in the VH arms.
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B A C K G R O U N D
Description of the condition
Hysterectomy is the surgical removal of the uterus. It is the most
frequently performed major gynaecological surgical procedure,
with millions of procedures performed annually throughout the
world (Garry 2005). Hysterectomy can be performed for benign
and malignant indications. Approximately 90% of hysterectomies
are performed for benign conditions, such as fibroids causing
abnormal uterine bleeding (Flory 2005). Other indications in-
clude endometriosis/adenomyosis, dysmenorrhoea, dyspareunia
and prolapse.
Abnormal menstrual bleeding affects women of all ages and is
the most common gynaecological reason for referral to secondary
care (Spencer 1999). There are a variety of potential causes for
abnormal or heavy menstrual bleeding; these include the above-
mentioned fibroids, endometrial polyps of hyperplasia, adeno-
myosis, infectious diseases, (early) pregnancy complications or
(pre)malignant conditions of the endometrium. However, in a
large proportion of women no definitive diagnosis will be con-
firmed. Several more or less invasive therapies exist for heavy men-
strual bleeding; oral contraceptives or the levonorgestrel-releasing
intrauterine system (LNG-IUS) are often offered as a first-line
treatment when uterine abnormalities are ruled out. A recent re-
view showed that the LNG-IUS is the first-line medical therapy
for heavy menstrual bleeding, with combined hormonal contra-
ceptives as second choice (Lethaby 2015). During the last decade,
several new techniques for endometrial ablation have been devel-
oped. The effectiveness of these techniques has been described in
another Cochrane review (Lethaby 2013). As a result of this vari-
ety of treatment options, a patient with heavy menstrual bleeding
finds herself confronted with a wide range of possible medical and
surgical interventions. Since hysterectomy is the only treatment
that provides permanent symptom relief, a rather large proportion
of women with the abovementioned conditions will eventually
choose to have their uterus removed. This is demonstrated by the
fact that rates of hysterectomy have declined less than expected
with the introduction of new treatment modalities (Pynnä 2014).
Description of the intervention
Approaches to hysterectomy may be broadly categorised into
four options: abdominal hysterectomy (AH); vaginal hysterec-
tomy (VH); laparoscopic hysterectomy (LH) where at least some
of the operation is conducted laparoscopically (Garry 1994), and
robotic-assisted hysterectomy (RH).
• Abdominal hysterectomy: The AH has traditionally been
the surgical approach for gynaecological malignancy, when other
pelvic pathology is present such as endometriosis or adhesions,
and in the context of an enlarged uterus. It remains the ’fallback
option’ if the uterus cannot be removed by another approach.
Mini-AH refers to an approach to hysterectomy where the
abdominal incision does not exceed 7 cm (Sesti 2008a).
• Vaginal hysterectomy: VH was originally used only for
prolapse but has become more widely utilised for menstrual
abnormalities such as dysfunctional uterine bleeding, when the
uterus has a fairly normal size. Compared to AH, VH was (and
still is) regarded as less invasive and seems to have the advantages
of fewer blood transfusions, less febrile morbidity (fever) and less
risk of injury to the ureter. However, the disadvantages are more
bleeding complications and greater risk of bladder injury
(Mäkinen 2013; Moen 2014a).
• Laparoscopic hysterectomy: LH usually refers to a
hysterectomy where at least part of the operation is undertaken
laparoscopically (Garry 1994). This approach requires general
laparoscopic surgical expertise. The proportion of hysterectomies
performed by LH has gradually increased and, although the
surgery tends to take longer, its proponents argue that the main
advantages are the possibility of diagnosing and treating other
pelvic diseases such as endometriosis, of carrying out adnexal
surgery including the removal of the ovaries, the ability to secure
thorough intraperitoneal haemostasis (direct laparoscopic vision
enables careful sealing of bleeding vessels at the end of the
procedure), and a more rapid recovery time from surgery
compared to AH (Garry 1998). Three sub-categorisations of LH
have been described (Reich 2003), as follows:
◦ Laparoscopic-assisted vaginal hysterectomy (LAVH) is
where part of the hysterectomy is performed by laparoscopic
surgery and part vaginally, but the laparoscopic component of
the operation does not involve division of the uterine vessels.
◦ Laparoscopic hysterectomy (which we have
abbreviated to LH(a)) is where the uterine vessels are ligated
laparoscopically but part of the operation is performed vaginally.
◦ Total laparoscopic hysterectomy (TLH) is where the
entire operation (including suturing of the vaginal vault) is
performed laparoscopically and there is no vaginal component
except for the removal of the uterus. TLH requires the highest
degree of laparoscopic surgical skills.
• Single-port laparoscopic hysterectomy and mini-
laparoscopic hysterectomy: In the last decade, single-port
laparoscopic hysterectomy (SP-LH) and mini-laparoscopic
hysterectomy (mini-LH, where the incisions do not exceed 3
mm, Ghezzi 2011) have been introduced into the endoscopic
field.
• Robotic-assisted hysterectomy: RH has been performed
since 1998. In this review RH is considered as a separate
approach, which may have its own learning curve, surgical
pitfalls and accompanying costs.
A total hysterectomy is the removal of the entire uterus including
the cervix. When the cervix is not removed this is known as a
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subtotal or supracervical hysterectomy. Subtotal hysterectomies are
most easily performed abdominally or laparoscopically, although
it is possible to conserve the cervix in a VH or LAVH (Lethaby
2012).
The first reported elective hysterectomy was performed through a
vaginal approach byConradLangenbeck in 1813.The first elective
abdominal hysterectomy, a subtotal operation (where the cervix
was conserved), was performed by Charles Clay in Manchester
in 1863 (Sutton 1997). These approaches remained the only two
options until the latter part of the 20th century. The first laparo-
scopic hysterectomy (LAVH)was reported byHarry Reich in 1989
(Reich 1989). He also reported the first total laparoscopic hys-
terectomy (TLH) in 1993. Robotic-assisted hysterectomies have
been performed since 1998.
Several patient factors may influence the surgeon’s choice of ap-
proach to hysterectomy. For example, multiparous women with
heavy menstrual bleeding who opt for hysterectomy may well be
suitable for a vaginal approach. However, in the same case but with
the suspicion of endometriosis based on dysmenorrhoea, dyspare-
unia or both, the surgeon will more likely be inclined to an ab-
dominal or laparoscopic approach. With regards to enlarged my-
omatous uteri, surgeons’ experience and skills will largely deter-
mine the surgical approach to hysterectomy.
In common with the overall hysterectomy rate, the proportion of
hysterectomies currently being performed by different approaches
varies markedly across countries, within countries, and even be-
tween individual surgeons working within the same unit. As men-
tioned, each gynaecologist will have different indications for the
approach to hysterectomy for benign disease, based largely on their
own array of surgical skills and the patient characteristics such as
uterine size and descent, extra-uterine pelvic pathology, previous
pelvic surgery and other features such as obesity, nulliparity and
the need for oophorectomy. Even though VH has been widely
considered to be the operation of choice for abnormal uterine
bleeding, the VALUE study has shown that, in 1995 in the UK,
67% of the hysterectomies performed for this indication were AH
(Maresh 2002). Previous caesarean section, for example, is often
considered to be a contraindication for VH. However, this is not
supported by cumulative data from four studies indicating no sig-
nificant difference in complication rates in hysterectomy patients
following caesarean section (8 of 430 (1.86%) versus 11 of 1227
(0.89%), P value = 0.12) (Agostini 2005).
Mäkinen 2001 reported a prospective study on the learning curve
in 10,110 hysterectomies for benign indications, of which 5875
were AH, 1801 were VH and 2434 were LH. As far as injuries
to adjacent organs were concerned, the surgeons’ experience sig-
nificantly correlated inversely with the occurrence of urinary tract
injuries in LH and the occurrence of bowel injuries in vaginal hys-
terectomy. In a following study the overall complication rates fell
significantly in LHandmarkedly inVHover the course of 10 years
(Mäkinen 2013). Encouraging vaginal surgery amongst gynaecol-
ogists has been shown to be an effective method of increasing VH
rates (Mäkinen 2013;Moen 2014a). Finland had a VH rate as low
as 7% in the 1980s. Following annual meetings on gynaecological
surgery where vaginal and laparoscopic surgery were encouraged,
and individual training provided, the VH rate increased to 44% in
2006 (Mäkinen 2013). In the same period of time, ureter injuries
decreased, which represents an impressive national learning curve.
In addition, the rate of LH increased (from 24% to 36%), with
decreasing complication rates (Mäkinen 2013).
How the intervention might work
This review will focus on the benefits and harms of the differ-
ent surgical approaches to hysterectomy for benign indications.
From the patient’s perspective, quality of life may well be the most
important outcome, especially in surgery for benign indications.
Consequently, we will choose patient-reported outcome measures
(PROMs) as primary outcomes. Injuries to adjacent organs are
of concern in hysterectomy and their rates of occurrence differ
with the various approaches to hysterectomy and surgical experi-
ence level (Brummer 2011; Mäkinen 2001; Mäkinen 2013). It is
important to have adequate knowledge of the differences in ad-
verse outcomes in several approaches to hysterectomy, in order to
inform patients properly and to gain informed consent based on
an adequate amount of data. Furthermore, operation times differ
with the different approaches to hysterectomy. Longer operating
times are even more likely with RH. In general it is presumed
that the vaginal and laparoscopic approach will lead to a quicker
recovery compared with open surgery, mainly because of less pain
and quicker mobilisation due to smaller incisions.
In the current era of limited healthcare resources, the costs of
surgery will likely play a more important role in decision making.
Several studies have looked at the subject of the cost-effectiveness
of several types of hysterectomy (Bijen 2009; Pynnä 2014; Sarlos
2010; Tapper 2014). Overall, it is expected that VH will have the
lowest costs, followed by AH and LH. Due to the high purchase
costs and the use of expensive disposables, RH is likely to be the
least cost-effective. However, there is lack of well-designed studies
that also take societal costs (e.g. the costs of sick leave) into con-
sideration.
Apart from the surgical approach to hysterectomy, other aspects
of the surgical technique may have an effect on the outcome of
surgery. Examples of this include total versus subtotal (where the
cervix is not removed) hysterectomy (Lethaby 2012); Doderlein
VH or LAVH versus standard VH or LAVH; techniques to sup-
port the vaginal vault; bilateral elective oophorectomy versus ovar-
ian conservation (Orozco 2014); and other strategies used mainly
by those conducting laparoscopic surgery with the aim of reduc-
ing the likelihood of complications, including the use of vaginal
delineators, rectal probes and illuminated ureteric stents. These
other aspects are not within the scope of this review (other than
for assessing trial quality).
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Why it is important to do this review
Since there are multiple approaches to hysterectomy, each with
their procedure-specific advantages and disadvantages, it is impor-
tant to know which procedure is superior with respect to patient-
related outcomes. In general, randomised controlled trials (RCTs)
deliver the highest quality of evidence. When the quality of RCTs
of surgical interventions is sufficiently good, this yields informa-
tion unrivalled in its quality compared to studies of other designs
that assess surgical interventions. It was interesting to note that in
1998 there was not a single RCT comparing AH and VH (Garry
1998). The introduction of the newer approaches to hysterectomy
(LH, SP-LH and RH) has stimulated much greater interest in the
scientific evaluation of all forms of hysterectomy. However, the
more approaches exist, the more complex it becomes to decide on
the best approach for each individual woman.This decision cannot
be made without up-to-date evidence. Nor can it be made with-
out knowing and respecting the informed preferences of patients.
This review summarises the existing evidence presented in all pub-
lished RCTs on benign conditions for hysterectomy. After finding
and appraising the existing evidence, and integrating its inferences
with clinical expertise, clinicians need to attempt a decision that
reflects their patient’s values and circumstances (Hoffmann 2014).
This is an update of a Cochrane review first published in 2004,
and previously updated in 2006, 2008 and 2009.
O B J E C T I V E S
To assess the effectiveness and safety of different surgical ap-
proaches to hysterectomy for women with benign gynaecological
conditions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), in which one
surgical approach to hysterectomy was compared to another ap-
proach.
We excluded non-randomised studies, as they are associated with
a higher risk of bias.
Types of participants
Studies of women undergoing hysterectomy for benign disease
(uterine fibroids, heavy menstrual bleeding, metrorrhagia of (sus-
picion of ) adenomyosis) were eligible for inclusion. We excluded
studies ofwomenwith gynaecological cancer.When trials included
both women with benign and malignant disease, we requested
from the authors a breakdown of data in order to include only
women with benign disease. If this information was not forthcom-
ing, we excluded the trial.
We defined dropouts as cases in which hysterectomy was cancelled
after randomisation or randomised cases were excluded from anal-
ysis by the researchers. We did not regard loss to follow-up as
dropout.
Types of interventions
Surgical approaches to removal of the uterus, where at least one
approach was compared with another, were eligible for inclusion.
Approaches were as follows:
• Abdominal hysterectomy (AH, including mini-AH): AH
involves removal of the uterus through an incision in the lower
abdomen.
• Vaginal hysterectomy (VH): VH involves removal of the
uterus via the vagina, with no abdominal incision.
• Laparoscopic hysterectomy (LH, including mini-LH and
single-port (SP)-LH): LH involves the use of laparoscopy to
perform hysterectomy. We made the distinction between the
subcategories of LH based on whether ligation of the uterine
vessels was undertaken laparoscopically and whether suturing of
the vaginal vault was undertaken vaginally (see Table 1) and this
is further explained in the Background section. Thus we further
subdivided LH in the analysis into LAVH, LH(a), TLH and
non-categorisable LH (where there is insufficient information or
the types of LH are too heterogeneous to otherwise sub-
categorise). There are two other main classifications of LH
available in the literature (Nezhat 1995; Richardson 1995) and
these are summarised in Table 2 and Table 3, but we did not use
these in the meta-analysis. We defined SP-LH as LH through
one single port. Mini-LH involves the approach to LH through
ports not exceeding 3 mm.
• Robotic hysterectomy (RH): RH involves a hysterectomy
approach using a robotic system, allowing more ergonomic
movements that are easier to perform and are more precise in
filtering tremor. One surgeon is seated in a robot console and
handles the laparoscope and two to three laparoscopic
instruments. RH is generally performed in a similar fashion to a
TLH with suturing of the vaginal vault via the robot.
We thus excluded trials comparing, for example, different vessel
sealing techniques within one approach.
Subtotal versus total hysterectomy is the scope of another
Cochrane review (Lethaby 2012); we excluded trials making this
comparison from the present review. We also excluded trials evalu-
ating different surgical approaches to subtotal hysterectomy.How-
ever, if a minority of the women (less than 33%) had a subtotal
hysterectomy and the comparisonwasmade versus any of the three
approaches outlined above then we included the trial.
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Clinical data had to be reported in the included studies, thus
excluding studies reporting only differences in laboratory results.
If no relevant clinical outcomes were reported (i.e. not in the
methods and results section), this was a criterion for exclusion.
Types of outcome measures
We assessed the following outcomes:
Primary outcomes
• Return to normal activities
• Satisfaction and quality of life
• Intra-operative visceral injury
◦ Bladder injury
◦ Ureter injury
◦ Urinary tract (bladder or ureter) injury
◦ Bowel injury
◦ Vascular injury
• Major long-term complications
◦ Fistula
◦ Pelvi-abdominal pain
◦ Urinary dysfunction
◦ Bowel dysfunction
◦ Pelvic floor condition (prolapse)
◦ Sexual dysfunction
Secondary outcomes
• Operation time
• Other intra-operative complication
• ◦ (Sequelae of ) bleeding, including
⋄ Substantial bleeding
⋄ Transfusion
⋄ Pelvic haematoma
◦ Unintended laparotomy for approaches not involving
routine laparotomy
• Short-term outcomes and complications
◦ Length of hospital stay
◦ Infections
⋄ Vaginal cuff
⋄ Abdominal wall or wound
⋄ Urinary tract infection
⋄ Chest infection
⋄ Febrile episodes or unspecified infections
◦ Thromboembolism
• ◦ Unintended laparotomy for approaches not involving
routine laparotomy
• Short-term outcomes and complications
◦ Length of hospital stay
◦ Infections
⋄ Vaginal cuff
⋄ Abdominal wall or wound
⋄ Urinary tract infection
⋄ Chest infection
⋄ Febrile episodes or unspecified infections
◦ Thromboembolism
◦ Postoperative ileus
◦ Wound dehiscence
• Costs
We sought data on the cost of treatment but we intended to de-
scribe these data qualitatively and not to include the informa-
tion in the meta-analysis since ’cost’ could be defined differently
in different studies depending upon whether studies incorporate
the cost of sequelae. Different healthcare systems could produce
markedly different results.
We used all types of outcome measures for meta-analysis or de-
scribed them in the review. This included composite outcome
measures.
Search methods for identification of studies
We searched for all published and unpublished RCTs in August
2014, without language restriction and in consultation with the
Cochrane Menstrual Disorders and Subfertility Group (MDSG)
Trials Search Co-ordinator.
Electronic searches
We will repeat the search for trials every two years and up-
date the review if new trials are found. We searched the fol-
lowing electronic databases, trial registers and websites: the
Cochrane Menstrual Disorders and Subfertility Group (MDSG)
Specialised Register of Controlled Trials, the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, EM-
BASE, PsycINFO and CINAHL (Cumulative Index to Nurs-
ing and Allied Health Literature). We combined the MEDLINE
search with the Cochrane highly sensitive search strategy for iden-
tifying randomised trials, which appears in the Cochrane Hand-
book for Systematic Reviews of Interventions (Version 5.1.0 chap-
ter 6, 6.4.11) (Higgins 2011). We combined the EMBASE,
PsycINFO and CINAHL searches with trial filters developed by
the Scottish Intercollegiate Guidelines Network (SIGN) (http://
www.sign.ac.uk/methodology/filters.html#random).
The appendices display detailed search strategies, as follows:
• Cochrane MDSG Specialised Register (Appendix 1);
• Cochrane Central Register of Controlled Trials
(CENTRAL) in all fields (on Ovid platform July 2014)
(Appendix 2);
• Ovid MEDLINE(R) (1946 to 2014 week 32) (Appendix 3);
• EMBASE (1980 to 2014 Week 32) (Appendix 4);
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• CINAHL (Appendix 5);
• Biological Abstracts (1969 to August 2008, not included in
searches beyond 2008) (Appendix 6);
• PsycINFO (1806 to August Week 1 2014) (Appendix 7).
Other electronic sources of trials included:
• trial registers for ongoing and registered trials:
◦ http://www.clinicaltrials.gov;
◦ http://www.who.int/trialsearch/Default.aspx;
• DARE (Database of Abstracts of Reviews of Effects) on The
Cochrane Library (http://onlinelibrary.wiley.com/o/cochrane/
cochrane cldare articles fs.html);
• Web of Knowledge (http://wokinfo.com/);
• OpenGrey (http://www.opengrey.eu/);
• LILACS (Literaturo Latino Americana e do Ciências da
Saúde) database (http://regional.bvsalud.org/php/index.php?
lang=en);
• PubMed; and
• Google Scholar.
We searched the Clinical Trials Register, a registry of federally and
privately funded US clinical trials, with the same keywords only
for the initial Cochrane review in 2006 (Appendix 8).
Searching other resources
We searched the reference lists of articles retrieved by the search
and contacted experts in the field to obtain additional data. We
handsearched relevant journals and conference abstracts that are
not covered in theMDSG register in liaison with the Trials Search
Co-ordinator.
Data collection and analysis
Selection of studies
Two review authors performed an initial screen of titles and ab-
stracts retrieved by the search. We retrieved the full texts of all
potentially eligible studies. Two review authors independently ex-
amined these full-text articles for compliance with the inclusion
criteria and selected studies eligible for inclusion in the review.
At least two of four review authors (ET, EC, AL, NJ) performed
the selection of trials for inclusion in the initial Cochrane review
(Johnson 2005b). Two different review authors (TN and KK) per-
formed the selection of trials for the first update in 2009 (Nieboer
2009) and three review authors (JA, TN and KK) performed this
for the current update.
We corresponded with study investigators as required, to clarify
study eligibility. We resolved disagreements as to study eligibility
by discussion or by referral to a third review author.
We documented the selection process with a PRISMA flow chart
(Figure 1).
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Figure 1. Study flow diagram.
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We excluded trials from the review if theymade comparisons other
than those specified above. A selection of these trials is detailed
in the table Characteristics of excluded studies. Classically we ex-
cluded studies if they did not report on differences in clinical
outcomes, but did report laboratory results or different anaesthe-
sia techniques or sealing techniques of vessels (e.g. electrosurgical
bipolar vessel sealing) in hysterectomy patients. Trials are reported
in the table Characteristics of excluded studies if there are other
reasons for exclusion than those mentioned above.
Data extraction and management
Two review authors (at least two review authors from ET, EC, AL,
NJ, TN, JA, KK) independently extracted data from eligible stud-
ies using a data extraction form designed and pilot-tested by the
authors. We resolved any disagreements by discussion or by refer-
ral to a third review author. Data extracted included study char-
acteristics and outcome data (see data extraction table for details,
Appendix 9).Where studies hadmultiple publications we collated
multiple reports of the same study, so that each study rather than
each report is the unit of interest in the review, and such studies
have a single study ID with multiple references.
We corresponded with study investigators for further data on
methods, results or both, as required.
Assessment of risk of bias in included studies
Two review authors (at least two review authors from ET, AL, TN,
JA and KK) independently assessed the included studies for risk
of bias using the Cochrane ’Risk of bias’ assessment tool (Higgins
2011) for: selection bias (random sequence generation and allo-
cation concealment); performance bias (blinding of participants
and personnel); detection bias (blinding of outcome assessors); at-
trition bias (incomplete outcome data); reporting bias (selective
reporting); and other bias. We resolved disagreements by discus-
sion or by referral to a third review author. We described all judge-
ments fully and presented the conclusions in the ’Risk of bias’ ta-
bles, which we incorporated into the interpretation of the review
findings by means of sensitivity analyses (see below).
If randomisation and allocation concealment were not sufficiently
reported, we labelled these as unclear or high risk of bias (depend-
ing on the extent of description and whether themethod described
was satisfactory).
If blinding was not performed or not reported, we judged this as
high risk of bias.
We considered dropout rates and/or loss to follow-up below 5%
as low risk of bias. If dropouts or losses to follow-up were not
reported or were between 10% and 15%, we judged this as unclear
risk of bias. If the dropouts or losses to follow-up were substantial
(i.e. more than 15%), we labelled this as high risk of bias.
If primary and/or secondary outcomes were not (pre)defined and/
or a selection of outcomes was reported, we labelled this as unclear
or high risk of bias.
Finally, we evaluated the studies included for any other potential
bias, such as baseline data not comparable between groups or no
description of surgeon experience. (Lack) of surgeon’s experience
could be particularly important when interpreting the results on,
for instance, adverse events or operation time. This seems partic-
ularly important for the laparoscopic procedures, as studies have
suggested that this technique has a specific learning curve. How-
ever, there is no clear-cut consensus based on current evidence as
to how many procedures a surgeon needs to perform (for all types
of hysterectomies) to pass this learning curve. Therefore, if a study
stated that a surgeon had sufficient experience (without mention-
ing a specific number) we did not consider this as a potential risk
of bias. Depending on the extent of any other bias identified in
the study, we judged this as unclear or high risk of bias. If three
or more potential other biases were identified, we marked this as
high risk of bias.
Measures of treatment effect
Weperformed statistical analysis in accordance with the guidelines
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We analysed the data using an intention-to-treat
model, where data were available.
We expressed dichotomous data as the numbers of events in the
control and intervention groups of each study and calculated
Mantel-Haenszel odds ratios (OR) with 95% confidence intervals
(95% CI). An increase in the odds of a particular outcome is dis-
played graphically in the meta-analyses to the right of the centre
line, and a decrease in the odds of an outcome is displayed graph-
ically to the left of the centre line.
For continuous data (e.g. length of hospital stay), if all studies re-
ported exactly the same outcomes, we calculated the mean differ-
ence (MD) between treatment groups. If similar outcomes were
reported on different scales (e.g. change in haemoglobin), we cal-
culated the standardised mean difference (SMD). We reversed the
direction of effect of individual studies, if required, to ensure con-
sistency across trials. We treated ordinal data (e.g. quality of life
scores) as continuous data. We presented 95% CIs for all out-
comes.
Where data to calculateORs orMDswere not available, we utilised
the most detailed numerical data available that facilitated similar
analyses of included studies (e.g. test statistics, median and (in-
terquartile) ranges, P values). We did not repeat or check values
of skewness or kurtosis from the individual studies. We did not
include outcome variables that were reported only graphically in
the review. We compared the magnitude and direction of effect
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reported by studies with how they were presented in the review,
taking account of legitimate differences.
Unit of analysis issues
The primary analysis was per woman randomised.We briefly sum-
marised data that did not allow valid analysis (e.g. descriptive data)
in additional tables and did not carry out meta-analysis.
Dealing with missing data
We assessed the included studies for the number of women lost to
follow-up and exclusions from analysis after randomisation (drop-
outs). We did not impute missing variables for meta-analysis.
Assessment of heterogeneity
We considered whether the clinical and methodological charac-
teristics of the included studies were sufficiently similar for meta-
analysis to provide a clinically meaningful summary. We assessed
statistical heterogeneity by the measure of the I2 statistic. We took
an I2 measurement greater than 50% to indicate substantial het-
erogeneity (Higgins 2003; Higgins 2011).
Where statistical heterogeneity (i.e. I2 > 50%) was apparent after
pooling of data, we noted this and interpreted statistically signifi-
cant results cautiously after further analysis using a random-effects
statistical model.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publication
bias and other reporting biases, we aimed to minimise their poten-
tial impact by ensuring a comprehensive search for eligible studies
and by being alert for duplication of data. If there were 10 or more
studies in an analysis, we planned to use a funnel plot to explore
the possibility of small study effects (a tendency for estimates of
the intervention effect to be more beneficial in smaller studies).
Data synthesis
We stratified the analyses by the type of comparison and the sub-
categories within hysterectomy approaches.
We used a fixed-effect model to calculate a pooled estimate of
effect in meta-analyses. If significant statistical heterogeneity was
confirmed by the I2 statistic (I2 > 50%), we used a random-effects
model.
Subgroup analysis and investigation of heterogeneity
We analysed the overall category laparoscopic hysterectomy (LH)
and, where possible, the sub-categorisation of LH (Table 1).
We took any statistical heterogeneity into account when interpret-
ing the results, particularly if there was any variation in the di-
rection of effect. Where there was substantial heterogeneity (I2 >
50%), we considered whether this was related to the subcategory
of approach to hysterectomy.
Sensitivity analysis
We performed sensitivity analyses to examine the stability of the
results in relation to the following factors.
• Exclusion of trials that we judged as at unclear risk of bias
with regard to adequate sequence generation in the ’Risk of bias’
table.
• Exclusion of trials comparing a surgical approach
performed by one surgeon (or group of surgeons) with another
surgical approach performed by a second (group of ) surgeon(s).
• The effect of analysing studies of LH subcategories
compared to studies of LH pooled as an overall category.
Assessment of quality of evidence
We created Summary of findings tables andmeasured and reported
the overall quality of the evidence for the primary outcomes (re-
turn to normal activities, urinary tract, bowel and vascular injuries,
bleeding and unintended laparotomy) based on the GRADE cri-
teria. We classified the quality of the evidence for each comparison
as high, moderate, low or very low (Guyatt 2008).
R E S U L T S
Description of studies
Results of the search
In our initial search, we identified 4946 articles. Of these, 85 ar-
ticles were potentially eligible and we retrieved them in full text.
We identified nine of these as published abstracts from conference
proceedings. The data from two abstracts were published in RCTs
included in this review (Cucinella 2000; Hahlin 1994), and we in-
cluded two studies after additional information was received from
the authors (Darai 2001; Miskry 2003). We excluded two studies
because they proved not to be randomised studies (Møller 2001;
Park 2003). For three studies no inclusion or exclusion decision
could be made because insufficient information was available (and
there was no response to our request for additional information
on study design) (Davies 1998; Pabuccu 1996; Petrucco 1999).
We included 47 studies that met our inclusion criteria. We ex-
cluded 36 further studies from the review for reasons that are
listed in the Characteristics of excluded studies table. We identi-
fied no additional studies through searching reference lists. See the
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study tables: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification
and the PRISMA flow chart (Figure 1).
Where Olsson 1996 is mentioned in the review, we have used
the data from Ellstrom 1998b where applicable. The eVALuate
trial population was studied in two papers (Garry 2004; Sculpher
2004), and study quality was summarised under Garry 2004.
There were two more studies on different outcomes and outcome
measures from the same randomised study population: Persson
2006 and Persson 2008were summarised under Persson 2006; and
the long-term follow-up study by Nieboer 2012 was summarised
under Kluivers 2007. Both Persson 2006 and Kluivers 2007 were
already included in the 2009 update. One additional study was
identified, which is awaiting classification (Sesti 2014).
Included studies
See Characteristics of included studies for an overview of the in-
cluded studies.
Study design
All of the included trials had a parallel-group design. Thirty-seven
of the trials were single-centre studies (nine from Italy; two from
Sweden; four from Taiwan; three from the USA; two each from
the UK, Korea, China, India, Brazil, France and Germany; and
one each from Finland, the Netherlands, Switzerland, Thailand
and Hong Kong). Of the 10 multicentre trials, four trials recruited
from two centres (Darai 2001 based in France; Langebrekke 1996
based in Norway; Miskry 2003 based in the UK; Paraiso 2013
based in the USA). Three trials recruited from three centres (
Summitt 1998 based in the USA; Lumsden 2000 based in the UK;
Muzii 2007 based in Italy). One trial from Italy recruited from
four centres (Marana 1999); one Swedish trial recruited from five
centres (Persson 2006); and a trial based in the UKwith additional
centres in South Africa (Garry 2004) recruited from 30 centres.
Participants
The 47 studies involved 5102 women.
The reported mean age of participants in the study groups ranged
from 38 (Summitt 1992) to 55 years (Agostini 2006).
All of the included studies recruited women who needed a hys-
terectomy for benign causes; seven studies specifically included
women who underwent hysterectomy for symptomatic uterine fi-
broids (Benassi 2002; Ferrari 2000; Hwang 2002; Long 2002;
Ribeiro 2003; Sesti 2008a; Tsai 2003).
• Vaginal hysterectomy (VH) versus abdominal hysterectomy
(AH)
Benassi 2002 included women with symptomatic enlarged fibroid
uteri. Silva Filho 2006 included women with myoma and a uterine
size less than 300 cm3. Chakraborty 2011 and Miskry 2003 in-
cluded women who needed hysterectomy for a benign condition.
• Laparoscopic hysterectomy (LH) versus AH (including LH
with bilateral salpingo-oophorectomy (LH-BSO) versus AH-BSO,
and LAVH versus minilaparotomy-AH)
Fourteen of the 21 studies that compared LHwith AH specifically
included women who were scheduled for an abdominal hysterec-
tomy or who had contraindications for a vaginal hysterectomy
(Ellstrom 1998; Falcone 1999; Ferrari 2000; Harkki-Siren 2000;
Kluivers 2007; Kongwattanakul 2012; Lumsden 2000; Marana
1999;Muzii 2007;Olsson1996; Seracchioli 2002; Summitt 1998;
Tsai 2003; Yuen 1998).
• LH (including all forms of LH) versus VH
Studies (n = 3) either included women if their uterine size was
larger than a certain number (e.g. more than 280 g (Darai 2001;
Soriano 2001) or between 300 g and 1500 g (Roy 2012)) or studies
(n = 5) excluded women if their uterine size was greater than, for
instance, 14 (Ghezzi 2010) or 16 weeks of pregnancy (Richardson
1995; Sesti 2008b; Summitt 1992). One study specifically in-
cludedwomenwith symptomatic or rapidly growingmyoma (Sesti
2008b).
• VH versus LH (vLH as it was called in the trial) and AH
versus LH (aLH as it was called in the trial)
Garry 2004 included women scheduled for hysterectomy for non-
malignant conditions.
• LH (including laparoscopic-assisted vaginal hysterectomy
(LAVH)) versus AH (including mini-AH) versus VH
Four of the five trials specifically included women with uterine fi-
broids: e.g. leiomyomas of less than15 cm (Ottosen 2000), leiomy-
omas ofmore than 8 cm and amaximumof threemyomas (Hwang
2002), symptomatic myoma (Sesti 2008a), or any fibroid (Ribeiro
2003). The fifth study included women who were scheduled for
hysterectomy with a uterine volume of 10 to 12 weeks of gestation
and who had delivered at least one child (Zhu 2009).
• Robotic-assisted hysterectomy (RH) versus LH
Both Paraiso 2013 and Sarlos 2012 included patients who were
scheduled for a hysterectomy for benign conditions. In Sarlos
2012, uterine weight had to be less than 500 g.
• Single-port laparoscopic hysterectomy (SP-LH) versus LH
The three trials included women who had an indication for hys-
terectomy, no evidence of gynaecologic malignancy and an appro-
priate status for laparoscopic surgery (ASA 1 or 2) (Chen 2011;
Jung 2011; Song 2013). Uterine size was also used as an exclusion
criterion: more than 12 weeks gestation (Jung 2011); more than
20 weeks (Song 2013), and greater than 120 mm x 80 mm x 80
mm (Chen 2011).
• LAVH versus total laparoscopic hysterectomy (TLH)
In Long 2002, women were included if they had contraindica-
tions for vaginal hysterectomy (a uterine weight greater than 280
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g, previous pelvic surgery, pelvic inflammatory disease, need for
adnexectomy, lack of uterine descent and limited vaginal access).
• LAVH versus TLH versus VH
In Roy 2011, women were included if they had benign pathology
of the uterus and medical therapy had failed.
• LH versus mini-LH
Ghezzi 2011 included women with benign gynaecological condi-
tions requiring hysterectomy.
Interventions
Surgical procedures
• VH versus AH (five trials)
Five trials compared VH with AH (Benassi 2002; Chakraborty
2011;Miskry 2003; Silva Filho 2006); one included a laparoscopic
arm as well (Ottosen 2000). Hysterectomies were performed by
standard technique for each route.
• LH versus AH (21 trials)
Twenty-one trials compared LH to AH (Ellstrom 1998; Falcone
1999; Ferrari 2000; Garry 2004; Harkki-Siren 2000; Hwang
2002; Kluivers 2007; Kunz 1996; Langebrekke 1996; Lumsden
2000;Marana 1999;Muzii 2007; Perino 1999;Raju 1994;Ribeiro
2003; Seracchioli 2002; Sesti 2008a; Schutz 2002; Summitt 1998;
Tsai 2003; Yuen 1998). These included four trials that randomised
women to LH, AH and VH (Garry 2004; Hwang 2002; Ottosen
2000; Ribeiro 2003). Raju 1994 compared LH and bilateral salp-
ingo-oophorectomy (LH-BSO) with AH-BSO. Ellstrom 1998
stratified the two randomised groups (LH and AH) into total and
subtotal hysterectomies. Muzii 2007 performed mini-laparotomy
for AH (with a moving surgical field or window using three sepa-
rate retractors). Sesti 2008a compared LAVH and AH.
• LH versus VH (10 trials)
Ten trials included a comparison of laparoscopic hysterectomy
(LH) with vaginal hysterectomy (VH) (Agostini 2006; Candiani
2009; Darai 2001; Garry 2004; Ghezzi 2010; Richardson 1995;
Roy 2012; Sesti 2008b; Soriano 2001; Summitt 1992), including
four trials randomising women to LH, AH and VH and including
the trial comparing TLH, LAVH and VH. Garry 2004 was a
very large RCT comparing LH (called vLH in the trial) with VH
and LH (called aLH in the trial) with AH; it was essentially two
concurrent RCTs as part of the same study.
• RH versus LH (two trials)
Paraiso 2013 andSarlos 2012 compared conventional laparoscopic
to robotically assisted hysterectomy.
• SP-LH versus LH (three trials)
Chen2011 compared SP-LAVHversus LAVH,whereas Jung 2011
and Song 2013 compared SP-LH versus TLH.
• LAVH versus TLH (one trial)
Long 2002 compared two types of laparoscopic hysterectomy,
which was LAVH versus TLH.
• LH versus mini-LH (one trial)
Ghezzi 2011 compared two types of laparoscopic hysterectomy,
which was mini-LH versus LH.
• LH subcategories
Although all the trials used variations of the terms ’laparoscopic-
assisted vaginal hysterectomy’ (LAVH) or ’laparoscopic hysterec-
tomy’, their definition varied according to what stages of the hys-
terectomy were completed laparoscopically and the point at which
the operation continued vaginally. We included all trials with hys-
terectomies that had some laparoscopic component in the over-
all LH category. Using the Richardson 1995 ’Staging of laparo-
scopic hysterectomy’ table (see Table 2) we were able to cate-
gorise 39 of the 45 included studies that involved LH according
to the amount of laparoscopic content. We also subcategorised
these trials involving LH as either LAVH, LH(a) or TLH, depend-
ing on the extent of the surgery performed either laparoscopically
or vaginally (see Table 1). If any trial included women undergo-
ing different Richardson LH stages in the LH arm, we arbitrar-
ily categorised the stage firstly, as the stage to which the surgeons
had intended to go; secondly, if that information was not avail-
able, to the LH stage that most women underwent surgery; or
thirdly, to the most advanced LH stage that women underwent.
According to Richardson staging, one trial involved stage zero
LH (Ottosen 2000), four trials were stage two (Agostini 2006;
Kunz 1996; Marana 1999; Raju 1994), nine trials were stage three
(Chen 2011; Ferrari 2000; Muzii 2007; Roy 2011; Roy 2012;
Sesti 2008a; Sesti 2008b; Song 2013; Tsai 2003), 10 trials were
stage four where the uterine artery was transected laparoscopically
(Darai 2001; Ellstrom 1998; Olsson 1996; Persson 2006; Schutz
2002; Soriano 2001; Summitt 1992; Summitt 1998; Yuen 1998;
Zhu 2009), and 14 trials were stage five (Candiani 2009; Falcone
1999; Ghezzi 2010; Ghezzi 2011; Harkki-Siren 2000; Hwang
2002; Jung 2011;Kluivers 2007; Langebrekke 1996; Paraiso 2013;
Perino 1999; Ribeiro 2003; Sarlos 2012; Seracchioli 2002). For
two trials we were unable to sub-categorise the LH procedures and
we described these as ’non-categorisable LH’ (Chakraborty 2011;
Kongwattanakul 2012). Richardson 1995 had LHs of all stages
from 0 to 5, and two trials did not stipulate the LH stages per-
formed (Garry 2004; Lumsden 2000). In Long 2002, the LAVH
treatment arm was a stage three whilst the TLH arm was a stage
five.
Surgeons’ experience
The surgeons’ experience or level of training was reported in 33
of the trials. Eighteen of these trials specified that the same group
of surgeons performed operations for both interventions (Benassi
2002; Candiani 2009; Chen 2011; Ghezzi 2010; Ghezzi 2011;
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Hwang 2002; Jung 2011; Kongwattanakul 2012; Lumsden 2000;
Paraiso 2013; Roy 2011; Roy 2012; Sarlos 2012; Seracchioli 2002;
Sesti 2008a; Sesti 2008b; Silva Filho 2006; Song 2013). In seven of
these trials, the experience was specified in detail, e.g. in Candiani
2009 at least 50 of both procedures and in Jung 2011 at least 100
LH and 30 SP-LH. In five trials, surgeons for one intervention
were different to those performing the other intervention (Kluivers
2007; Langebrekke 1996; Long 2002; Olsson 1996; Raju 1994).
In some trials the surgeons consisted only or partly of residents
operating under supervision (e.g. Kluivers 2007; Ottosen 2000;
Schutz 2002; Summitt 1998). In five trials specific information
on surgical experience was lacking (Agostini 2006; Darai 2001;
Falcone 1999; Perino 1999; Zhu 2009).
Outcomes
With respect to our primary outcomes, 16 studies reported on time
needed to return to normal activities (Harkki-Siren 2000; Hwang
2002; Langebrekke 1996; Miskry 2003; Olsson 1996; Ottosen
2000; Paraiso 2013; Persson 2006; Raju 1994; Richardson 1995;
Roy 2011; Roy 2012; Sarlos 2012; Schutz 2002; Seracchioli 2002;
Summitt 1998).
Two studies reported on satisfaction (Benassi 2002; Lumsden
2000), and seven studies reported on quality of life (Garry 2004;
Kluivers 2007; Lumsden 2000; Olsson 1996; Persson 2006; Roy
2011; Silva Filho 2006). Song 2013 reported the cosmetic satis-
faction after single-port andmulti-port laparoscopic hysterectomy
as primary outcome.
Twenty-three studies reported on intra-operative visceral injury
(Benassi 2002; Chakraborty 2011; Darai 2001; Garry 2004;
Jung 2011; Kluivers 2007; Kongwattanakul 2012; Langebrekke
1996; Long 2002; Lumsden 2000; Marana 1999; Olsson 1996;
Ottosen 2000; Perino 1999; Persson 2006; Raju 1994; Ribeiro
2003; Richardson 1995; Roy 2011; Sarlos 2012; Summitt 1992;
Summitt 1998; Tsai 2003).
Six studies reported on major long-term complications (Long
2002; Lumsden 2000; Olsson 1996; Ottosen 2000; Perino 1999;
Summitt 1992).
. Forty-five trials assessed the length of postoperative hospital stay
and 10 included an analysis of costs. An assessment of quality of
life was reported in 11 trials; four trials included sexual activity
or body image in the analysis (Candiani 2009; Garry 2004; Long
2002; Song 2013).
Most of the trials assessed the operation times and intra or post-
operative complications. Lumsden 2000 and Garry 2004 split
the complications into major and minor. Ellstrom 1998 reported
on the difference in erythrocyte volume fraction. Febrile mor-
bidity was measured in 13 trials, pulmonary function in one
trial (Ellstrom 1998), and 12 trials reported any operations that
were converted to abdominal surgery (Darai 2001; Garry 2004;
Kluivers 2007; Marana 1999; Muzii 2007; Ottosen 2000; Persson
2006;Richardson 1995; Seracchioli 2002; Soriano 2001; Summitt
1992; Summitt 1998).
Excluded studies
See Characteristics of excluded studies for an overview of the ex-
cluded studies, including the reasons why they were excluded from
the review.
Risk of bias in included studies
An overview of the risk of bias is provided in Figure 2 and Figure 3.
Two studies fulfilled all criteria for adequate management of risk
of bias (Ghezzi 2011; Miskry 2003). Several studies fulfilled all
criteria, except one (Candiani 2009; Garry 2004; Ottosen 2000;
Paraiso 2013; Schutz 2002; Sesti 2008a; Song 2013). Three studies
met none of the criteria for adequate management of risk of bias
(Long 2002, LH versus LAVH; Roy 2011, TLH versus LAVH
versus VH; Roy 2012, LH versus VH; and Zhu 2009, AH versus
LH versus VH).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each methodological quality item for
each included study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each methodological quality item
presented as percentages across all included studies.
Allocation
Sequence generation
Seventeen studies randomised using a computer (Agostini 2006;
Candiani 2009; Chen 2011; Ferrari 2000; Garry 2004; Ghezzi
2010; Ghezzi 2011; Hwang 2002; Miskry 2003; Muzii 2007;
Ottosen 2000; Raju 1994; Schutz 2002; Sesti 2008a; Sesti 2008b;
Song 2013; Summitt 1998). Langebrekke 1996 and Richardson
1995 used a table of random digits for randomisation. Ten
trials used a computer-generated randomisation code (Benassi
2002; Darai 2001; Falcone 1999; Lumsden 2000; Marana 1999;
Seracchioli 2002; Soriano 2001; Summitt 1992; Roy 2012; Tsai
2003; Yuen 1998); one performed randomisation through a com-
puter-generated randomisation schedule with random block sizes
(Paraiso 2013). Eleven trials did not report the randomisation
method (Chakraborty 2011; Ellstrom 1998; Harkki-Siren 2000;
Jung 2011; Kunz 1996; Long 2002; Olsson 1996; Perino 1999;
Ribeiro 2003; Roy 2011; Zhu 2009). Overall, we considered 35
studies to have low risk of bias and 12 studies to have unclear risk
of bias.
Allocation concealment
Twenty studies used sealed, opaque envelopes (Agostini 2006;
Candiani 2009; Chen 2011; Ferrari 2000; Ghezzi 2010;
Ghezzi 2011; Harkki-Siren 2000; Hwang 2002; Kluivers 2007;
Langebrekke 1996; Miskry 2003; Muzii 2007; Olsson 1996;
Ottosen 2000; Persson 2006; Raju 1994; Sesti 2008a; Sesti 2008b;
Song 2013; Summitt 1998). For instance, Persson 2006 numbered
the envelopes according to a random list, and Kluivers 2007 sealed
the envelopes after which they were shuffled and numbered by
a third party. Two trials used a telephone (Garry 2004; Schutz
2002). Twenty trials did not report whether allocation was con-
cealed (Benassi 2002; Chakraborty 2011; Darai 2001; Ellstrom
1998; Falcone 1999; Jung 2011;Kunz 1996; Long 2002; Lumsden
2000; Marana 1999; Paraiso 2013; Perino 1999; Ribeiro 2003;
Roy 2011; Seracchioli 2002; Soriano 2001; Summitt 1992; Roy
2012; Tsai 2003; Yuen 1998; Zhu 2009). We identified no studies
as having high risk of bias; in 21 studies it was unclear and 26
studies had low risk of bias.
Blinding
One trial reported sham abdominal dressings until discharge from
hospital after VH (Miskry 2003). Another trial comparing mini-
LH and LH covered the incisions with the same size of plasters
(Ghezzi 2011). Paraiso 2013 reported blinding of patients for the
intervention. In Kongwattanakul 2012 and Sesti 2008a, the re-
searchers were blinded. One trial reported blinding of the inter-
viewer one month after surgery (Silva Filho 2006). All other trials
included in this review did not apply any blinding of participants,
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clinicians or researchers, resulting in high risk of performance and
detection bias. Overall, three studies had low risk of bias, three
unclear risk of bias and 41 studies high risk of bias.
Incomplete outcome data
We considered attrition bias low in 32 trials, unclear in seven trials
and high in eight trials.
Dropouts
Twenty-eight trials reported no dropouts. Nineteen trials reported
dropouts, with the dropout rate ranging from 1.7% to 20%. Table
4 lists the trials that reported dropouts with the dropout circum-
stances. Infive trials the dropoutswere excluded from the data anal-
ysis (Long 2002; Lumsden 2000; Persson 2006; Summitt 1998;
Yuen 1998), whereas the other three either included the data in
the analysis where possible (Falcone 1999; Kluivers 2007; Paraiso
2013; Sarlos 2012), or performed a sensitivity analysis for themiss-
ing data (Garry 2004). Three trials had women withdraw pre-op-
eratively: Falcone 1999 (4 out of 48), Garry 2004 (34 out of 1380)
and Persson 2006 (1 out of 119). In the Lumsden 2000 study,
seven women withdrew pre-operatively and case records were not
available for three more. Two and one women respectively refused
their assigned procedure in the Summitt 1998 and Kluivers 2007
studies; in the Yuen 1998 study, four women declined their as-
signed operation and a further two women refused to participate
postoperatively. In the Long 2002 trial, excluded post-randomi-
sation were: three women undergoing conversion to laparotomy,
seven with incomplete records and three with combined proce-
dures. A further 53 were excluded because they did not have in-
dications of uterine fibroids or adenomyosis. In the Persson 2006
trial, five patients allocated to AH and one to LH withdrew after
giving informed consent prior to the operation or withdrew in the
postoperative period before the five-week follow-up. In the Paraiso
2013 trial, six patients dropped out before the intervention was
performed after randomisation. These were analysed in the allo-
cated intervention arm.
Loss to follow-up
In eight trials the follow-up period was not specified (and consid-
ered an unclear risk of bias), the number analysed in the follow-
up period was not reported, or the loss to follow-up was between
5% to 10% of the patient population (Persson 2006; Sarlos 2012;
Summitt 1992; Tsai 2003; Yuen 1998; Zhu 2009). Seven stud-
ies lost more than 10% of their patient population in the follow-
up period (Candiani 2009; Kluivers 2007; Long 2002; Lumsden
2000; Roy 2011; Roy 2012; Schutz 2002).
Intention-to-treat
Twenty-eight trials reported no dropouts. Of the 19 RCTs report-
ing dropouts, seven reported analysis by intention-to-treat (ITT),
defined as all randomised women reported upon according to
their group of randomised allocation (Falcone 1999; Garry 2004;
Kluivers 2007; Paraiso 2013; Persson 2006; Sarlos 2012; Sesti
2008a). The remaining RCTs reporting dropouts did not report
ITT analysis of all randomised women. One further trial that had
no dropouts did not analyse by ITT but according to the treat-
ment received, which was different to the assigned treatment in
two cases: the operation was converted from LH to AH and these
women were analysed in the AH group (Tsai 2003).
Selective reporting
In 29 studies insufficient information was available to determine
whether primary or secondary outcomes had been predefined.
These studies had therefore an unclear risk of reporting bias. Eigh-
teen studies had low risk of bias. We considered no studies to have
a high risk of bias.
Other potential sources of bias
We judged the risk of potential other bias as follows: low risk of
bias in 24 studies, unclear risk of bias in 17 studies and high risk of
bias (three or more other potential sources of bias) in six studies.
Differences in baseline characteristics
In three studies, baseline characteristics between intervention
groupswere not comparable (Chakraborty 2011;Hwang 2002), or
baseline characteristics were not reported (Kongwattanakul 2012).
In Kluivers 2007, the AH group had more residents as a first sur-
geon than the other two groups. In the other studies no other
bias could be identified. In the Long 2002 trial, women were ran-
domised to treatment groups before a large number (i.e. 66) of the
women were excluded. Therefore, the women in each treatment
group may not have been a true representation of the original ran-
domised groups.
Surgeon’s experience
The surgeon’s experience or level of training was reported in 30
of the trials and was not considered as a potential source of bias.
In the remaining 17 studies the surgeon’s experience was not re-
ported or specified or varied substantially between groups. The
studies by Benassi 2002, Chakraborty 2011, Chen 2011, Ellstrom
1998, Ferrari 2000, Hwang 2002, Kunz 1996 and Tsai 2003 did
not report or specify the surgeon’s experience for the interventions
evaluated. In five trials, surgeons for one intervention were dif-
ferent to those performing the other intervention: Olsson 1996
(LH carried out by two out of five senior registrar grade surgeons
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trained in LH, AH carried out by two out of 10 senior registrar
grade surgeons trained in AH); Langebrekke 1996 (LH performed
exclusively by the two authors, AH performed by any skilled gy-
naecologist in the department); Raju 1994 (LAVH performed by
one of the authors, AH by one of the authors or a senior registrar
grade surgeon); Kluivers 2007 (LH was performed or supervised
(resident 39%) by three out of 10 experienced gynaecologists (at
least 100 LHs), AH performed or supervised by all 10 gynaecolo-
gists); and Long 2002 (one surgeon performed all LAVH, another
performed all TLH). Residents were the first surgeon in 39% of
LH and 88% of AH. In Agostini 2006, the five surgeons were
experienced in vaginal surgery but laparoscopic experience was
not reported. In Ottosen 2000, 15 gynaecological surgeons with
assistants performed the operations; their experience varied and
there were cases of residents performing operations under super-
vision. In Schutz 2002, 71% of LH were performed by the at-
tending physician and 29% by a resident under supervision, and
40% of AH were performed by the attending physician and 60%
by the resident under supervision. One trial used only gynaeco-
logical residents to perform all the operations with the assistance
of the attending physician (Summitt 1998). It is unlikely that any
of the latter three trials used the same group of surgeons for both
intervention groups. In three other trials it was unclear if the sur-
geons performing the operations were different: Darai 2001 (all
experienced in laparoscopic and vaginal surgery but no mention
of who performed each intervention); Perino 1999 (LH by team
of three laparoscopic surgeons with experience of more than 100
LHs, no details provided for AH arm); and Falcone 1999 (one
of the senior authors performed all the LH operations with the
assistance of a pelvic surgery fellow or resident, but no mention of
the AH group). In four of the trials, surgeons of all grades and ex-
perience carried out the operations. In Garry 2004, each surgeon
recruited to the trial had to have performed 25 of each procedure,
however cases could be used for teaching if the main assistant was
the designated surgeon.
Source of funding
Three studies received funding frompharmaceutical or surgical in-
strumentation companies: Falcone 1999 received part of the fund-
ing from Ethicon Endosurgery Inc; Harkki-Siren 2000 received
a part of its funding from the Research Foundation of the Orion
Corporation; Summitt 1998 received all of its funding from US
Surgical Corporation, USA.
Other bias
If a trial lacked information, such as a description of one of the
interventions or details on the inclusion or exclusion criteria, we
considered this a possible source of other bias.
Effects of interventions
See: Summary of findings for the main comparison
Vaginal hysterectomy versus abdominal hysterectomy for
benign gynaecological disease; Summary of findings 2
Laparoscopic hysterectomy versus abdominal hysterectomy
for benign gynaecological disease; Summary of findings 3
Laparoscopic hysterectomy versus vaginal hysterectomy for benign
gynaecological disease
1 Vaginal hysterectomy (VH) versus abdominal
hysterectomy (AH)
Primary outcomes
1.1 Return to normal activities
For vaginal versus abdominal hysterectomy, patients returned to
normal activities sooner after VH (mean difference (MD) -12.33,
95% confidence interval (CI) -19.89 to -4.77; three randomised
controlled trials (RCTs), 176 women, I2 = 75%, moderate quality
evidence) (Figure 4; Analysis 1.1).
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Figure 4. Forest plot of comparison: 1 VH versus AH, outcome: 1.1 Return to normal activities (days).
1.2 Satisfaction and quality of life
There was no evidence of a difference in patient satisfaction be-
tween vaginal and abdominal hysterectomy, although the point
estimate clearly favoured VH (odds ratio (OR) 2.69, 95%CI 0.50
to 14.42, one RCT, 119 women, I2 = n/a, moderate quality evi-
dence) (Analysis 1.2).
Silva Filho 2006 found better quality of life after vaginal hysterec-
tomy, compared to abdominal hysterectomy, in the SF-36 sub-
scales for functional capacity (meansVHversus AH: 95 versus 73),
physical aspects (means VH versus AH: 100 versus 38), and pain
(means VH versus AH: 84 versus 51). Additionally, a higher rate
of patients who underwent vaginal hysterectomy would choose
the same treatment again (Analysis 1.8).
1.3 Intra-operative visceral injury
There were three times as many urinary tract injuries after vaginal
versus abdominal hysterectomy, although there was no evidence
of a difference (OR 3.09, 95% CI 0.48 to 19.97, four RCTs, 439
women, I2 = 0%, moderate quality evidence) (Analysis 1.3). No
ureter, bowel or vascular injuries occurred in either group.
1.4 Major long-term complications
No urinary dysfunction occurred in either group (OR n/a, one
RCT, 80 women) (Analysis 1.4).
Fistula formation, pelvic-abdominal pain, bowel dysfunction,
pelvic floor condition (prolapse) and sexual dysfunction were not
studied.
Secondary outcomes
1.5 Operation time
Four trials showed evidence of a difference: three in favour of
vaginal hysterectomy, one in favour of abdominal hysterectomy
(four RCTs, 359 women) (Analysis 1.5). The direction of the
treatment effect differed amongst studies, therefore we did not
pool the results.
Three trials reported descriptive data on operation times for this
comparison. The trial by Hwang 2002 reported data as a median
and range and found a shorter median operating time for VH
(74 minutes, range 40 to 120) versus AH (98 minutes, range
85 to 150). Miskry 2003 reported mean and range (VH 68.8
minutes (30 to 180) versus AH 68.2 minutes (45 to 174), whereas
Ribeiro 2003 reportedmean only (VH 78minutes versus AH 109
minutes) (Analysis 1.8).
1.6 Intra-operative complications (other than visceral injury)
There was no evidence of a difference between the groups in the
need for blood transfusion (OR 0.82, 95% CI 0.34 to 1.96, five
RCTs, 495women, I2 =19%) andoccurrence of pelvic haematoma
(OR 0.99, 95% CI 0.34 to 2.89, five RCT, 535 women, I2 = 0%)
(Analysis 1.6).
Substantial bleedings were not studied for this comparison.
Unintended laparotomy was not compared in meta-analysis be-
cause AH involves routine laparotomy.
1.7 Short-term outcomes and complications
Hospital stay was shorter in vaginal hysterectomy compared to
standard abdominal hysterectomy (MD -1.07, 95% CI -1.22 to
-0.92; four RCTs; 295 women; I2 = 0%) as well as compared
to minilaparotomy AH (MD -2.10, 95% CI -2.19 to -2.01; one
RCT; 100 women; I2 = n/a) (Analysis 1.7).
Wound/abdominal wall infection (OR0.21, 95%CI 0.04 to 1.00,
three RCTs, 355 women, I2 = 0%), urinary tract infection (OR
0.59, 95% CI 0.08 to 4.61, three RCTs, 176 women, I2 = 0%)
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and febrile episodes or unspecified infections (OR 0.62, 95% CI
0.36 to 1.08, five RCTs, 495 women, I2 = 15%) all occurred less
after VH than after AH, but there was no evidence of a difference.
The number of women included in studies that reported on chest
infection (OR 1.00, 95% CI 0.13 to 7.60, one RCT, 60 women,
I2 = n/a) or low backache (OR 0.57, 95% CI 0.20 to 1.65, one
RCT, 200 women, I2 = n/a) were too low to make meaningful
comparisons. There were no thromboembolisms in either group
(one RCT, 119 women) (Analysis 1.6).
No data on perioperative mortality, postoperative ileus and wound
dehiscence were reported for this comparison.
1.8 Cost
No studies reported this outcome in this comparison.
2 Laparoscopic hysterectomy (LH) versus abdominal
hysterectomy (AH)
Primary outcomes
2.1 Return to normal activities
Return to normal activities was quicker after laparoscopic-assisted
vaginal hysterectomy (LAVH) than after AH (MD -8.40, 95% CI
-12.15 to -4.65; one RCT; 80 women; I2 = n/a) and was quicker
after LH than after AH(MD-15.17, 95%CI -17.21 to -13.14; five
RCTs; 440 women; I2 = 48%) (Analysis 2.1). One study reported
only the mean days and did not find evidence of a difference
(Schutz 2002). For three additional RCTs the data could not be
pooled. Median duration of return to normal activities was shorter
for LH in these three trials (Langebrekke 1996; Persson 2006;
Raju 1994) (Figure 5; Analysis 2.1)
Figure 5. Forest plot of comparison: 2 LH versus AH, outcome: 2.1 Return to normal activities (days).
2.2 Satisfaction and quality of life
There was no evidence of a difference in patient satisfaction be-
tween LH and AH (OR 0.65, 95%CI 0.32 to 1.30, one RCT, 166
women, I2 = n/a, low quality evidence) (Lumsden 2000) (Analysis
2.2).
For LH versus AH, Garry 2004 demonstrated that quality of life
(measured by the SF12 scoring system) was better for LH at six
weeks; body image was improved for LH versus AH at six weeks,
but not at four and 12 months; and sexual frequency was higher
at six weeks following LH. Kluivers 2007 found a treatment effect
favouring LH in the RAND-36 scale for vitality in the first 12
weeks postoperatively. In the long-term follow-up (four years) of
Kluivers 2007,Nieboer 2012 found that the total RAND-36 score
favoured LH, as well as the RAND-36 sub-scale scores for vitality,
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physical functioning and social functioning. Lumsden 2000 used
the EuroQol 5D thermometer, and there was no evidence of a
difference at one month, six months or a year after surgery. Olsson
1996 asked the patients six to eight weeks after surgery whether
the duration of postoperative hospital stay had been adequate and
9% (LH) versus 17% (AH) of patients reported that the stay had
been too short. Persson 2006 applied four psychometric tests, but
there was no evidence of a difference between the interventions in
the first six months after surgery (Analysis 2.24).
2.3 Intra-operative visceral injury
Although there was no proof of a difference in intra-operative
visceral injury,most point estimates indicatedmore harmafter LH,
i.e. bladder injury (OR1.89, 95%CI 0.91 to 3.90, 12 RCTs, 2038
women, I2 = 0%) (Analysis 2.3), ureter injury (OR 3.46, 95% CI
0.94 to 12.71, seven RCTs, 1417 women, I2 = 0%) (Analysis 2.4),
and vascular injury (OR 1.76, 95% CI 0.52 to 5.87, two RCTs,
956 women, I2 = 0%) (Analysis 2.7); with the exception of bowel
injury (OR 0.21, 95% CI 0.03 to 1.33, four RCTs, 1175 women,
I2 = 0%) (Analysis 2.6).
When we pooled bladder and ureter injuries as ’urinary tract in-
jury’, there was evidence of a difference (OR 2.44, 95% CI 1.24
to 4.80, 13 RCTs, 2140 women, I2 = 0%, low quality evidence)
(Analysis 2.5).
2.4 Major long-term complications
Comparisons of long-term complications were either underpow-
ered (fistula formation (OR 3.07, 95% CI 0.32 to 29.96, two
RCTs, 245 women, I2 = 0%, low quality evidence) (Analysis 2.8)
and urinary dysfunction (OR 0.94, 95% CI 0.48 to 1.84, two
RCTs, 246 women, I2 = 0%, low quality evidence) (Analysis 2.9))
or were lacking (pelvi-abdominal pain, bowel dysfunction, pelvic
floor condition (prolapse), sexual dysfunction).
Secondary outcomes
2.5 Operation time
There was no evidence of a difference in operation time between
LAVH versus AH (MD 0.27, 95% CI -23.39 to 23.93; four
RCTs; 466 women; I2 = 96%) (Analysis 2.10). Other subcate-
gories of laparoscopic hysterectomy (LH(a) and total laparoscopic
hysterectomy (TLH)) took longer than abdominal hysterectomies
(LH(a) versus AH: MD 33.45, 95% CI 14.82 to 52.08; five
RCTs, 420 women, I2 = 90% (Analysis 2.10); TLH versus AH:
MD 28.74, 95% CI 2.64 to 54.85; two RCTs, 161 women, I2 =
87%) (Analysis 2.10). Operation time was eight minutes shorter
in LAVH compared to mini-AH (MD -8.00 minutes, 95% CI -
10.56 to -5.44, one RCT, 100 women, I2 = n/a, moderate quality
evidence) (Analysis 2.10). These analyses used a random effects
model. We considered clinical and methodological differences be-
tween the studies that might account for the high heterogeneity;
training and experience of surgeons may play a role.
Eleven additional trials could not be pooled because of the de-
scriptive format in which the data were presented. Except for Yuen
1998, all trials showed that abdominal hysterectomy had a shorter
median operation time (Falcone 1999; Ferrari 2000; Garry 2004,
Hwang 2002; Langebrekke 1996;Muzii 2007; Persson 2006; Raju
1994, Ribeiro 2003; Schutz 2002) (Analysis 2.25).
2.6 Intra-operative complications (other than visceral injury)
There was no evidence of a difference in the number of women
with substantial bleeding between laparoscopic and abdominal
hysterectomy (OR 0.45, 95% CI 0.15 to 1.37, five RCTs, 1266
women, I2 = 0%) (Analysis 2.11).
Overall, laparoscopic versus abdominal hysterectomydidnot show
evidence of a difference in the need for blood transfusions (OR
0.58, 95% CI 0.30 to 1.10, 20 RCTs, 2638 women, I2 = 32%,
moderate quality evidence) (Analysis 2.12). Pelvic haematomas
occurred less after laparoscopic hysterectomy, but again there was
no evidence of a difference (OR 0.75, 95% CI 0.38 to 1.47, eight
RCTs, 782women, I2 = 0%, lowquality evidence) (Analysis 2.13).
Unintended laparotomy was not compared in meta-analysis be-
cause AH involves routine laparotomy. In two trials there was no
proof of a difference in unintended conventional laparotomies be-
tween the interventions (OR 0.49, 95% CI 0.08 to 2.82, two
RCTs, 181 women, I2 = n/a) (Analysis 2.14).
2.7 Short-term outcomes and complications
Hospital stay was generally shorter in LH compared to AH: LAVH
versus AH (MD -2.64, 95% CI -4.16 to -1.12; four RCTs, 466
women, I2 = 97%), LH(a) versus AH (MD -1.82, 95% CI -2.34
to -1.31; four RCTs, 380 women, I2 = 70%), TLH versus AH
(MD -2.53, 95% CI -5.08 to 0.01; two RCTs, 161 women, I2
= 95%) and LAVH versus minilaparotomy AH (MD -1.10, 95%
CI -1.20 to -1.00; one RCT, 100 women, I2 = n/a) (Analysis
2.15). These analyses used a random effects model.We considered
clinical and methodological differences between the studies that
might account for the high heterogeneity; training and experience
of surgeons may play a role.
Data from 11 trials on hospital stay could not be included in the
meta-analysis, because of the presentation of median numbers in-
stead of means. In all of these trials, median duration of hospital
stay was shorter. There was evidence of a difference, proving hos-
pital stay was shorter for laparoscopic hysterectomy, in six trials
(Falcone 1999; Ferrari 2000; Langebrekke 1996; Persson 2006;
Raju 1994; Yuen 1998), whereas in one study there was no ev-
idence of a difference (Muzii 2007). In the other four trials no
statistical testing was applied (Analysis 2.26).
There were fewer wound or abdominal wall infections in laparo-
scopic hysterectomy (OR 0.29, 95% CI 0.12 to 0.71; six RCTs,
611 women, I2 = 5%, low quality evidence) (Analysis 2.17) and
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fewer febrile episodes or unspecified infections for the comparisons
LAVH versus AH (OR 0.25, 95% CI 0.09 to 0.73; four RCTs,
339 women, I2 = 0%) and LH(a) versus AH (OR 0.55, 95% CI
0.33 to 0.90; seven RCTs, 572 women, I2 = 47%) (Analysis 2.20).
There was no evidence of a difference in the occurrence of vaginal
cuff infection (OR 1.43, 95% CI 0.67 to 3.04, nine RCTs, 852
women, I2 = 0%, low quality evidence) (Analysis 2.16), urinary
tract infections (OR 1.04, 95% CI 0.54 to 2.00, eight RCTs, 659
women, I2 = 0%, low quality evidence) (Analysis 2.18), chest in-
fection (OR 0.31, 95% CI 0.07 to 1.35, three RCTs, 294 women,
I2 = 17%, low quality evidence) (Analysis 2.19), and thromboem-
bolic events (OR 0.89, 95% CI 0.23 to 3.39, three RCTs, 1125
women, I2 = 0%, low quality evidence) (Analysis 2.21).
With regard to the subcategory LAVH versus mini-LH, no ev-
idence of a difference was found for wound or abdominal wall
infections (OR 0.20, 95% CI 0.01 to 4.19, one RCT, 81 women,
I2 = n/a, low quality evidence) (Analysis 2.17), febrile episodes
or unspecified infection (OR 0.14, 95% 0.01 to 2.72, one RCT,
81 women, I2 = n/a, low quality evidence) (Analysis 2.20). Other
infections (vaginal cuff, urinary tract or chest infection) were not
evaluated for this comparison. No evidence of a difference was
found for wound dehiscence (OR 3.15, 95% CI 0.12 to 79.69,
one RCT, 81 women, I2 = n/a, low quality evidence) (Analysis
2.22). Thromboembolism and perioperative mortality were not
evaluated for this comparison.
Also the occurrence of wound dehiscence showed no evidence of a
difference (OR 3.15, 95%CI 0.12 to 79.69, one RCT, 81 women,
I2 = n/a, low quality evidence) (Analysis 2.22).
There were no reports on perioperative mortality for this compar-
ison.
2.8 Cost
There was no evidence of a difference in the overall cost, but
only six RCTs examined comparative cost in any detail (Ellstrom
1998; Garry 2004 (as published in Sculpher 2004); Falcone 1999;
Lumsden 2000; Raju 1994; Summitt 1998).
3 Laparoscopic hysterectomy (LH) versus vaginal
hysterectomy (VH)
Primary outcomes
3.1 Return to normal activities
Women undergoing laparoscopic hysterectomy returned to work
one day earlier thanwomenundergoingVH, but the time to return
to normal activities showed no evidence of a difference (MD -
1.07, 95% CI -4.21 to 2.06, two RCTs, 140 women, I2 = 0%,
low quality evidence) (Figure 6; Analysis 3.1).
Figure 6. Forest plot of comparison: 3 LH versus VH, outcome: 3.1 Return to normal activities (days).
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Data from three RCTs could not be included in the meta-analysis
because of their descriptive nature (Richardson 1995; Roy 2011;
Roy 2012). These three trials did not show evidence of a difference
in return to normal activities between LH and VH either (Analysis
3.21).
3.2 Satisfaction and quality of life
Roy 2011 showed that sixmonths after surgery, patients weremore
satisfied after total laparoscopic hysterectomy and vaginal hysterec-
tomy than those who underwent laparoscopic-assisted vaginal hys-
terectomy (P value = 0.003). The satisfaction rate was similar be-
tween patients undergoing total laparoscopic hysterectomy and
non-descent vaginal hysterectomy (Analysis 3.22). The descriptive
character of these data means that these could not be included in
the meta-analysis.
3.3 Intra-operative visceral injury
There was no evidence of a difference in bladder injury (OR 0.91,
95% CI 0.32 to 2.56, seven RCTs, 895 women, I2 = 0%, low
quality evidence) (Analysis 3.3), ureter injury (OR 1.51, 95% CI
0.06 to 37.18, two RCTs, 594 women, I2 = n/a, low quality ev-
idence) (Analysis 3.2), urinary tract injury (OR 1.00, 95% CI
0.36 to 2.75, seven RCTs, 895 women, I2 = 0%, low quality evi-
dence) (Analysis 3.4), and vascular injury (OR 1.58, 95% CI 0.48
to 5.27, four RCTs, 685 women, I2 = 0%, low quality evidence)
(Analysis 3.6), but the power to detect a difference is low due to
the numbers and low event rates. In the studies from Garry 2004
and Roy 2011 bowel injury did not occur.
3.4 Major long-term complications
Also, there was no evidence of a difference in the following long-
term complications: fistula formation (OR 0.30, 95% CI 0.01
to 7.67, one RCT, 56 women, I2 = n/a, low quality evidence)
(Analysis 3.7), and urinary dysfunction (OR 3.08, 95% CI 0.12
to 77.80, one RCT, 80 women, I2 = n/a, low quality evidence)
(Analysis 3.8). Pelvi-abdominal pain, bowel dysfunction, pelvic
floor condition (prolapse) and sexual dysfunction were not studied
for this comparison.
Secondary outcomes
3.5 Operation time
All subcategories of laparoscopic hysterectomy showed a longer
operation time than vaginal hysterectomy. For LAVH versus VH:
MD 33.60, 95% CI 20.13 to 47.07, 5 RCTs, 377 women, I2 =
98%. For LH(a) versus VH: MD 53.58, 95% CI 43.67 to 63.49,
3 RCTs, 213 women, I2 = 0%. For TLH versus VH: MD 17.30,
95% CI 3.34 to 31.26, 1 RCT, 60 women. These analyses used a
random effects model. We considered clinical and methodological
differences between the studies that might account for the high
heterogeneity in the LAVH versus VH subgroup only; training
and experience of surgeons may play a role but we were unable
to explain why heterogeneity was not present in the LH(a) versus
VH subgroup. (Analysis 3.9)
In the operation time analysis, four studies could not be pooled
(Hwang 2002; Ribeiro 2003; Richardson 1995; Roy 2012). These
studies all found longer operation times in laparoscopic hysterec-
tomy with a statistical test result reported in two studies, of which
one showed evidence of a difference (Hwang 2002) and one did
not (Roy 2012) (Analysis 3.23).
3.6 Intra-operative complications (other than visceral injury)
There was no evidence of a difference in other intra-operative com-
plications between laparoscopic and vaginal hysterectomy: sub-
stantial bleeding (OR 1.55, 95% CI 0.24 to 10.09, three RCTs,
614 women, I2 = 0%, low quality evidence) (Analysis 3.10), , the
number of transfusions (OR 1.60, 95% CI 0.80 to 3.18, eight
RCTs, 1039 women, I2 = 0%, low quality evidence) (Analysis
3.11), pelvic haematoma (OR 1.21, 95% CI 0.36 to 4.03, four
RCTs, 308 women, I2 = 0%, moderate quality evidence) (Analysis
3.12) and unintended laparotomies (OR 1.55, 95% CI 0.76 to
3.15, 10 RCTs, 1160 women, I2 = 5%,moderate quality evidence)
(Analysis 3.13).
3.7 Short-term outcomes and complications
Hospital stay was one day shorter after vaginal hysterectomy (MD
0.99 days, 95% CI 0.94 to 1.03, seven RCTs, 525 women, I2
= 67%, moderate quality evidence) (Analysis 3.20). There was
no evidence of a difference in short-term outcomes between la-
paroscopic and vaginal hysterectomy, i.e. occurrence of pelvic
haematoma (OR 1.21, 95% CI 0.36 to 4.03, four RCTs, 308
women, I2 = 0%, low quality evidence) (Analysis 3.12), vaginal
cuff infection (OR 0.98, 95% CI 0.22 to 4.39, four RCTs, 276
women, I2 = 0%, low quality evidence) (Analysis 3.14), wound/
abdominal wall infection (OR 2.88, 95% CI 0.31 to 27.06, two
RCTs, 170women, I2 = 0%, lowquality evidence) (Analysis 3.15),
urinary tract infection (OR 1.66, 95% CI 0.40 to 6.82, three
RCTs, 230women, I2 = 0%, lowquality evidence) (Analysis 3.16),
chest infection (OR 0.19, 95% CI 0.01 to 4.06, one RCT, 60
women, low quality evidence) (Analysis 3.17), febrile episodes or
unspecified infection (OR 0.80, 95%CI 0.51 to 1.24, nine RCTs,
1074 women, I2 = 0%, low quality evidence) (Analysis 3.18), and
thromboembolic events (OR 1.00, 95% CI 0.15 to 6.67, two
RCTs, 564women, I2 = 0%, lowquality evidence) (Analysis 3.19),
but again confidence intervals were wide.
Four studies reported on differences in hospital stay, which could
not be pooled in the meta-analysis because of the descriptive for-
mat of the presented data (Hwang 2002; Richardson 1995; Roy
2011; Roy 2012). Two studies performed statistical testing but did
not find evidence of a difference (Roy 2011; Roy 2012).
3.8 Cost
Laparoscopic hysterectomy costs an average of GBP 401 more
than vaginal hysterectomy (95% CI GBP 271 to GBP 542; Garry
2004 as published in Sculpher 2004). Themean total hospital cost
was higher for LH than for VH (Summitt 1992).
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4 Robotic-assisted hysterectomy (RH) versus
laparoscopic hysterectomy (LH)
Primary outcomes
4.1 Return to normal activities
One small RCT evaluated return to normal activities between
robotic-assisted and laparoscopic hysterectomy. It showed a differ-
ence of two days favouring the robotic-assisted hysterectomy, but
there was no conclusive evidence of a difference (MD 2.4 days,
95% CI -8.5 to 3.7 days, one RCT, 100 women, I2 = n/a, mod-
erate quality evidence) (Figure 7; Analysis 4.1).
Figure 7. Forest plot of comparison: 4 RH versus LH, outcome: 4.1 Return to normal activities (days).
Data on return to normal baseline activities from the Paraiso 2013
study could not be pooled in the meta-analysis, but there was no
evidence of a difference between robotic-assisted and laparoscopic
hysterectomy.
4.2 Satisfaction and quality of life
These outcomes were not reported in studies comparing robotic-
assisted and laparoscopic hysterectomy.
4.3 Intra-operative visceral injury
The one RCT comparing these interventions was underpowered
regarding ureter injury (OR 0.33, 95% CI 0.0 to 8.21, one RCT,
100 women, I2 = n/a, low quality evidence) (Analysis 4.2) and
vascular injury (OR 1.00, 95% CI 0.06 to 16.44, one RCT, 100
women, I2 = n/a, low quality evidence) (Analysis 4.2).
4.4 Major long-term complications
Fistula formation, pelvi-abdominal pain, urinary dysfunction,
bowel dysfunction, pelvic floor condition (prolapse) and sexual
dysfunction were not reported in studies comparing robotic-as-
sisted and laparoscopic hysterectomy.
Secondary outcomes
4.5 Operation time
Robotic-assisted hysterectomy took 32 minutes longer than la-
paroscopic hysterectomy, which showed evidence of a difference
(MD 32.42 minutes, 95% CI 22.67 to 42.18, two RCTs, 152
women, I2 = 58%, moderate quality evidence) (Analysis 4.3).
4.6 Intra-operative complications (other than visceral injury)
No evidence of a difference was found between robotic-assisted
and laparoscopic hysterectomy regarding the need for transfusion
(OR 2.08, 95% CI 0.18 to 24.51, one RCT, 52 women, I2 = n/
a, low quality evidence) (Analysis 4.4). Sequelae of bleeding, drop
in haemoglobin/haematocrit, pelvic haematoma or unintended
laparotomy were not studied for this comparison.
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4.7 Short-term outcomes and complications
No evidence of a difference between robotic-assisted and laparo-
scopic hysterectomy was found for wound/abdominal wall infec-
tion (OR 0.33, 95% CI 0.01 to 8.21, one RCT, 100 women, I2
= n/a, low quality evidence) (Analysis 4.2) and wound dehiscence
(OR 0.33, 95% CI 0.01 to 8.21, one RCT, 100 women, I2 = n/a,
low quality evidence) (Analysis 4.2). Length of hospital stay, other
infections (urinary tract infection, chest infection, febrile episodes
or unspecified infections), thromboembolism, perioperative mor-
tality were not studied for this comparison.
4.8 Cost
Cost was not studied in studies comparing robotic-assisted and
laparoscopic hysterectomy.
5. Single-port laparoscopic hysterectomy subcategory
(SP-LH) versus laparoscopic hysterectomy (LH)
subcategories
Primary outcomes
5.1 Return to normal activities
No studies compared this outcome for this comparison.
5.2 Satisfaction and quality of life
No studies compared this outcome for this comparison.
5.3 Intra-operative visceral injury
No evidence of a difference was found between total laparoscopic
hysterectomy and single-port total laparoscopic hysterectomy for
bladder injury (OR 3.51, 95% CI 0.14 to 89.42, one RCT, 64
women, I2 =n/a,moderate quality evidence) (Analysis 5.1).Ureter,
urinary tract, bowel and vascular injury were not reported in stud-
ies comparing SP-LH and LH.
5.4 Major long-term complications
No studies compared this outcome for this comparison.
Secondary outcomes
5.5 Operation time
No evidence of a difference in operation time between SP-LH
and LH was found (MD 1.95 minutes, 95% CI -7.03 to 10.93,
two RCTs, 164 women, I2 = 57%, moderate quality evidence)
(Analysis 5.2).
Data from Song 2013 on operation time could not be pooled,
but also did not show evidence of a difference (LAVH median
= 92 minutes; SP-LAVH median = 95 minutes, P value = 0.47)
(Analysis 5.9).
5.6 Intra-operative complications (other than visceral injury)
No evidence of a difference between the groups was found for the
following outcomes: , transfusion (OR1.37, 95%CI 0.30 to 6.26,
three RCTs, 203 women, I2 = 0%, low quality evidence) (Analysis
5.3), pelvic haematoma (OR 3.06, 95% CI 0.12 to 76.95, one
RCT, 100 women, I2 = n/a, low quality evidence) (Analysis 5.4).
Numbers of bleeding and unintended laparotomy were not eval-
uated for this comparison.
5.7 Short-term outcomes and complications
No evidence of a difference in hospital stay was found between
TLH and SP-TLH (MD -0.20, 95% CI -0.49 to 0.09, one RCT,
100 women, I2 = n/a, low quality evidence) (Analysis 5.8).
Further data on hospital stay from two RCTs on SP-TLH versus
TLH could not be pooled, but both did not show evidence of a
difference (Song 2013: median TLH 3 days versus median SP-
TLH 3 days, P value = 0.95 and Jung 2011: TLH median 3 days
versus SP-TLH 3.4 days, P value = 0.075, Analysis 5.10).
No evidence of a difference was found for wound/abdominal wall
infection between TLH and SP-TLH (OR 0.33, 95% CI 0.01
to 8.21, one RCT, 100 women, I2 = n/a, low quality evidence)
(Analysis 5.5). More febrile episodes or unspecified infections oc-
curred in the SP-TLH group than in the TLH group (OR 4.87,
95% CI 0.93 to 25.62, one RCT, 64 women, I2 = n/a, moderate
quality evidence) (Analysis 5.6).
No evidence of a difference in postoperative ileus occurrence was
found (OR 2.36, 95% CI 0.20 to 27.39, one RCT, 64 women, I
2 = n/a, moderate quality evidence) (Analysis 5.7).
Other infections, i.e. vaginal cuff, urinary tract or chest infection,
were not reported.
Thromboembolism, perioperative mortality or wound dehiscence
were not studied.
5.8 Cost
Cost was not studied for this comparison.
6. Total laparoscopic hysterectomy (TLH) versus
laparoscopic-assisted vaginal hysterectomy (LAVH)
Primary outcomes
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6.1 Return to normal activities
No studies compared TLH and LAVH for this outcome.
6.2 Satisfaction and quality of life
No studies compared TLH and LAVH for this outcome.
6.3 Intra-operative visceral injury
There was no evidence of a difference in injury to bladder (OR
0.72, 95% CI 0.06 to 8.27, two RCTs, 161 women, I2 = n/a, low
quality evidence) (Analysis 6.1), ureter (OR 3.03, 95% CI 0.27
to 34.52, two RCTs, 161 women, I2 = n/a, low quality evidence)
(Analysis 6.1), urinary tract (OR 1.50, 95% CI 0.29 to 7.83, two
RCTs, 161 women, I2 = n/a, low quality evidence) (Analysis 6.1),
or vascular injury (OR 1.48, 95% CI 0.09 to 24.27, one RCT,
101 women, I2 = n/a, low quality evidence) (Analysis 6.1) for the
comparison TLH versus LAVH. No bowel injuries occurred in
either group.
6.4 Major long-term complications
No evidence of a difference was found in the following long-term
complications: dyspareunia (OR 2.64, 95% CI 0.59 to 11.72,
one RCT, 101 women, I2 = n/a, low quality evidence) (Analysis
6.2) or failure to orgasm (OR 0.84, 95% CI 0.38 to 1.86, one
RCT, 101 women, I2 = n/a, low quality evidence, Analysis 6.2).
Othermajor long-term complications (i.e. fistula formation, pelvi-
abdominal pain, urinary dysfunction, bowel dysfunction, pelvic
floor condition) were not studied for this comparison.
Secondary outcomes
6.5 Operation time
LAVH had a shorter operation time than TLH (MD -23.3 min-
utes, 95% CI -10.0 to -40.6; one RCT, 101 women, I2 = n/a, low
quality evidence) (Analysis 6.3).
6.6 Intra-operative complications (other than visceral injury)
There was no evidence of a difference in the number of unintended
laparotomies (OR 1.28, 95% CI 0.21 to 7.85, two RCTs, 104
women, I2 = 0%, low quality evidence) (Analysis 6.1).
6.7 Short-term outcomes and complications
There was no evidence of a difference in hospital stay for TLH
versus LAVH (MD 0.00, 95% CI -0.45 to 0.45, one RCT, 101
women, I2 =n/a, low quality evidence) (Analysis 6.5).No evidence
of difference was found between TLH and LAVH for vaginal cuff
infection (OR 0.28, 95% CI 0.03 to 2.45, one RCT, 101 women,
I2 = n/a, low quality evidence) (Analysis 6.4), abdominal wall/
wound infection (OR 0.19, 95% CI 0.01 to 4.06, one RCT, 60
women, I2 =n/a, low quality evidence) (Analysis 6.4), urinary tract
infection (OR 1.00, 95% CI 0.13 to 7.60, one RCT, 60 women,
I2 = n/a, low quality evidence) (Analysis 6.4) and febrile episodes
(OR 0.50, 95% CI 0.17 to 1.48, two RCTs, 161 women, I2 =
66%, low quality evidence) (Analysis 6.4). There was no evidence
of a difference in the number of patients that needed transfusion
between TLH and LAVH (OR 1.04, 95% CI 0.24 to 4.43, two
RCTs, 161 women, I2 = 0%, low quality evidence) (Analysis 6.4).
Other short-term outcomes (thromboembolism, perioperative
mortality, postoperative ileus or wound dehiscence) were not re-
ported in the studies included in this review.
6.8 Cost
Cost was not studied for this comparison.
7. Mini-laparoscopic hysterectomy (mini-LH) versus
total laparoscopic hysterectomy (TLH)
Primary outcomes
7.1 Return to normal activities
No studies compared mini-laparoscopic hysterectomy and total
laparoscopic hysterectomy for this outcome.
7.2 Satisfaction and quality of life
No studies compared mini-laparoscopic hysterectomy and total
laparoscopic hysterectomy for these outcomes.
7.3 Intra-operative visceral injury
No studies compared mini-laparoscopic hysterectomy and total
laparoscopic hysterectomy for these outcomes.
7.4 Major long-term complications
No studies compared mini-laparoscopic hysterectomy and total
laparoscopic hysterectomy for these outcomes.
Secondary outcomes
7.5 Operation time
Data on operation time could not be included in themeta-analysis,
but showed no evidence of a difference betweenmini-laparoscopic
hysterectomy and total laparoscopic hysterectomy (median mini-
LH 58 minutes; median TLH 60 minutes; one RCT, 66 women,
low quality evidence) (Analysis 7.1).
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7.6 Intra-operative complications (other than visceral injury)
. Bleeding, transfusion, pelvic haematoma or unintended laparo-
tomy were not studied for this comparison.
7.7 Short-term outcomes and complications
Women undergoing mini-laparoscopic hysterectomy and total la-
paroscopic hysterectomy both had a median hospital stay of one
day (one RCT, 66 women) (Analysis 7.2). The effect of these pro-
cedures on vaginal cuff, abdominal wall/wound, urinary tract or
chest infections, or febrile episodes, were not studied.
7.8 Cost
Cost was not studied for this comparison.
Sensitivity analyses
Exclusion of trials susceptible to inadequate sequence
generation during the randomisation process
Exclusion of seven trials with unclear or detrimental sequence
generation (Ellstrom 1998; Kunz 1996; Long 2002; Olsson 1996;
Perino 1999; Ribeiro 2003; Silva Filho 2006) altered the results as
follows: bleeding and transfusion in LH versus VHwere no longer
significantly different; and transfusion in LH(a) versus AHwas no
longer significantly different.
Exclusion of trials susceptible to ’surgeon effect’
Exclusion of the four trials in which surgeons for one interven-
tion were unequivocally different to those performing the other
intervention did not alter the statistical significance of any meta-
analysis results (Kluivers 2007; Langebrekke 1996; Olsson 1996;
Raju 1994).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Laparoscopic hysterectomy versus abdominal hysterectomy for benign gynaecological disease
Patient or population: pat ients with benign gynaecological disease
Settings: hospital
Intervention: laparoscopic versus abdominal hysterectomy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Abdominal hysterec-
tomy
Laparoscopic
hysterectomy
Return to normal activ-
ities (days)
The mean return to nor-
mal act ivit ies (days) in
the AH group was
36.3 days
The mean return to nor-
mal act ivit ies (days) in
the LH group was
13.6 lower
(15.4 to 11.8 lower)
- 520
(6 studies)
⊕⊕©©
low1,2
-
Urinary tract (bladder
or ureter) injury
10 per 1000 24 per 1000
(12 to 46)
OR 2.44
(1.24 to 4.80)
2140
(13 studies)
⊕⊕©©
low1,3
-
Bowel injury 7 per 1000 1 per 1000
(0 to 11)
OR 0.21
(0.03 to 1.33)
1175
(4 studies)
⊕⊕⊕©
moderate3
-
Vascular injury 9 per 1000 16 per 1000
(5 to 51)
OR 1.76
(0.52 to 5.87)
956
(2 studies)
⊕⊕⊕©
moderate3
-
Bleeding 16 per 1000 6 per 1000
(2 to 19)
OR 0.45
(0.15 to 1.37)
1266
(5 studies)
⊕⊕©©
low3,4
-
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
AH: abdominal hysterectomy; CI: conf idence interval; LH: laparoscopic hysterectomy; OR: odds rat io
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1In some studies there was doubt about the method used for random sequence generat ion or allocat ion of pat ients.
Furthermore, one study did not perform an intent ion-to-treat analysis.
2There was a large dif ference in return to normal act ivit ies between the dif ferent studies; the analysis had moderate
heterogeneity (I2 = 48%) but consistent direct ion of ef fect.
3Wide conf idence intervals crossing the line of no ef fect.
4In some studies there was doubt about the method used for random sequence generat ion or allocat ion of part icipants.
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Laparoscopic hysterectomy versus vaginal hysterectomy for benign gynaecological disease
Patient or population: pat ients with benign gynaecological disease
Settings: hospital
Intervention: laparoscopic versus vaginal hysterectomy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Vaginal hysterectomy Laparoscopic
hysterectomy
Return to normal activ-
ities (days)
The mean return to nor-
mal act ivit ies (days) in
the VH group was
25.2 days
The mean return to nor-
mal act ivit ies (days) in
the LH group was
1.1 lower
(4.2 lower to 2.1 higher)
- 140
(2 studies)
⊕⊕⊕©
moderate1
-
Urinary tract (bladder
or ureter) injury
16 per 1000 16 per 1000
(6 to 42)
OR 1.0
(0.36 to 2.75)
865
(7 studies)
⊕⊕©©
low2,3
-
Vascular injury 12 per 1000 18 per 1000
(6 to 58)
OR 1.58
(0.48 to 5.27)
745
(5 studies)
⊕⊕©©
low3,4
-
Bleeding 29 per 1000 25 per 1000
(9 to 70)
OR 2.45
(0.38 to 15.78)
644
(3 studies)
⊕⊕©©
low3,5
-
Unintended
laparotomy
24 per 1000 37 per 1000
(19 to 73)
OR 1.55
(0.76 to 3.15)
1160
(10 studies)
⊕⊕©©
low2,3
-
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; LH: laparoscopic hysterectomy; OR: odds rat io; VH: vaginal hysterectomy
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Wide conf idence intervals crossing the line of no ef fect.
2In some studies there was doubt about the method used for random sequence generat ion or allocat ion of pat ients.
3Wide conf idence intervals crossing the line of no ef fect.
4In one study it was unclear how part icipants were allocated to their study group.
5In two studies it was unclear how part icipants were randomised and allocated.
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D I S C U S S I O N
Summary of main results
Regarding the primary outcomes of this review, vaginal hysterec-
tomy proved to be the superior procedure since it was associated
with the quickest return to normal activities and earliest discharge
from hospital. Furthermore, vaginal hysterectomy had the short-
est operation time compared to both laparoscopic and abdomi-
nal hysterectomy. Vaginal hysterectomy proved to be superior to
laparoscopic hysterectomy regarding substantial bleeding, use of
oral pain tablets on day two and hospital costs. Laparoscopic hys-
terectomy offered a number of statistically significant advantages
over abdominal hysterectomy; among these were quicker return
to normal activities, less postoperative pain, earlier discharge from
hospital and improved quality of life in the first months and at
four years after surgery; the cost was more urinary tract injuries
and longer operating time. Single-port laparoscopic hysterectomy
showed no significant advantages over conventional laparoscopic
hysterectomy, besides better cosmetic outcomes. Robotic-assisted
hysterectomy offered no significant advantages over laparoscopic
hysterectomy; however operation time was significantly longer. In
conclusion, it seems that whenever vaginal hysterectomy is possi-
ble, it should be the preferred route over other approaches. How-
ever, uncertainty remains about the safety of these procedures
based on the low number of adverse events in this review. LH
appeared to result in better long-term quality of life compared to
AH; this is an important finding for the counselling of patients.
Urinary tract damage, in particular ureteric injury, remains the
major concern related to the laparoscopic approach (Garry 2004;
Garry 1995; Mäkinen 2013). However, this meta-analysis of ran-
domised controlled trials (RCTs) was underpowered to detect a
clinically significant increase in the incidence of bladder and ureter
damage as separate entities from a laparoscopic approach. Many
of the data for an increased incidence of urinary tract injury have
come from non-randomised studies. Only large case series usu-
ally have the power to detect such rare complications, but RCTs
remain the least biased way to assess the benefits and harms of
an intervention. When we pooled bladder and ureter injuries in
our meta-analysis under a single category ’urinary tract injury’, we
detected a significant increase in urinary tract injury for LH versus
AH.
Overall completeness and applicability of
evidence
It is particularly difficult to address the issues surrounding effec-
tiveness and complications in surgical procedures where the skill
base of surgeons is not only variable, but differs also regarding sur-
geon experience of ’traditional’ operations and laparoscopic oper-
ations. This is likely to be especially relevant to the rates at which
complications, such as ureteric damage, occur. Hysterectomy out-
comes tend to improve the more experience a surgeon gains in
a particular technique (Mäkinen 2013). In contrast to exclusive
assessment of numbers of performed operations, others have put
emphasis on an intrinsic skills factor of each surgeon, which can
only be monitored over time and in relation to the surgical case
mix (Twijnstra 2012). There is no good way to assess the indi-
vidual risk of rare complications per surgeon beyond the learning
curve, but continuous monitoring of, for example, the CUSUM
score, a tool to assess physicians’ clinical competence, may help us
forward in this respect.
The number of studies in the review was too low and the descrip-
tion of surgical skills was not specific enough to assess learning
curve effects for the different routes of hysterectomy in a subgroup
analysis. This is not just a hysterectomy issue but pervades many
aspects of surgical therapy and surgical innovations. It does not
apply to the same extent where drug therapy interventions are
being studied, in which the efficacy is much less dependent on
the skill of the investigator providing the treatment. Much of the
Cochrane methodology has been developed based on the medical
model of intervention.
Regarding the overall applicability of the evidence, itmust be noted
that most studies in this review had specific inclusion criteria. For
example, studies including vaginal hysterectomy in one treatment
arm had different exclusion criteria, ranging from a uterine size
more than 14 or more than 16 weeks of gestational age, pelvic
organ prolapse, chronic pelvic pain and a (subjectively assessed)
narrow vagina. The same matter is relevant for laparoscopic and
abdominal hysterectomy. These specific inclusion and exclusion
criteria make it more or less difficult to extrapolate the findings
to everyday practice, where one is confronted with patients that
often have more than one problem or have a surgical history that
surpasses that of most included patients in the studies in this re-
view.
Until the 1990s, the vast majority of hysterectomies were per-
formed abdominally (Reich 2003; Vessey 1992), and routes of
hysterectomy still vary widely per centre and country. In some
countries there is a tendency to perform fewer abdominal hysterec-
tomies in favour of other routes (Brummer 2008; Mäkinen 2013;
Moen 2014a; Spilsbury 2006). In the current state of gynaeco-
logical practice and training, gynaecologists tend to become best
trained in abdominal hysterectomy techniques, but there is huge
variation in their learning curve position in relation to vaginal and
laparoscopic hysterectomy techniques (Moen 2014b). Numbers
of hysterectomies are overall decreasing with the introduction of
more uterus-preserving techniques in benign gynaecology (e.g. ab-
lation techniques, Mirena intrauterine device (IUD)). For exam-
ple, in the Netherlands, subspecialty has already been introduced
in gynaecology training, which implies that not all gynaecologists
will be able to self dependently perform a hysterectomy at the end
of their training. The expected advantage is that the trainees who
decide for a surgical profile will become better trained in hysterec-
tomy.
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In clinical practice as well as in the trials included in this review,
vaginal hysterectomy will be mostly performed under optimum
conditions only, whereas abdominal hysterectomy remains the de-
fault intervention for all more difficult cases. Each gynaecologist
(as has been the case since abdominal hysterectomy became the
alternative to vaginal hysterectomy, in 1863) will have his or her
own indications for the choice of approach to hysterectomy for
benign disease. These choices may be influenced to some extent
by the results from scientific evidence (for example this review)
but the decisions will also be largely based on their own array of
surgical skills and the patient characteristics. Whether there will
be more of a consensus in the future than there has been to date,
regarding these indications for route of hysterectomy, is less cer-
tain. To reach this consensus, however, should probably not be
the ultimate goal since the prudent decision for one approach to
hysterectomy over the other may be very justified and may lead to
better outcomes after all.
Patient-reported outcome measures (PROMs) are increasingly
recognised as important outcomes for medical interventions.
PROMs (e.g. quality of life, patient experiences) can show the
impact of surgery and complications on patients’ lives, and thus
can be a leading argument in the discussion about the best way to
perform a hysterectomy (Dawson 2010). For instance, speed of re-
covery is determined by the avoidance of an abdominal procedure:
abdominal hysterectomy is associated with lengthier recovery than
all other approaches to hysterectomy. Only a few studies in the
meta-analysis have used quality of life as an outcome measure and
only one study reported the long-term (four years) effect on qual-
ity of life. However, the quality of life data do not lend them-
selves easily to meta-analysis (due to the use of diverse tools, time
frames and statistical analysis). The available data indicate that the
laparoscopic and vaginal procedures performed better or equally
compared with abdominal hysterectomy as far as quality of life in
the first weeks after the procedure was concerned. Laparoscopic
hysterectomy performed better after four years. In the decision as
to the approach to hysterectomy, the advantage of better quality
of life should be offset against the disadvantages. Meta-analysis of
PROMs, such as quality of life, would benefit from the use of well-
validated instruments applied in a standardised manner in future
studies.
One concern is the statistical heterogeneity of the trials included
in this review. The heterogeneity in such outcomes as operating
time, even when the ’traditional’ hysterectomy vaginal versus ab-
dominal techniques are compared, directly relates to the fact that
some surgeons are better trained in and thus perform faster either
type of hysterectomy. This heterogeneity might be expected to be
even more apparent when laparoscopic hysterectomy is compared
with either abdominal or vaginal hysterectomy. Sculpher et al have
analysed learning curve in the eVALuate trial (Sculpher 2004).
The conclusion was that after completing the mandatory 25 cases
to qualify for participation in the study, there was no surgical learn-
ing curve demonstrated, neither in seniority and experience nor
related to the place in the timeline of the study.
Another point of discussion relates to the inclusion and exclusion
criteria in several studies. Particularly the studies including an ab-
dominal hysterectomy arm excluded women who were not eligi-
ble for the less invasive approaches to hysterectomy. This results
in an abdominal hysterectomy population that is not represent-
ing the entire abdominal hysterectomy population in our clinical
practice, but a population of only those women who were eligible
for vaginal or laparoscopic hysterectomy as well.
Furthermore, studies typically do not address the same outcomes.
This makes it difficult to draw clinically relevant conclusions.
Increasingly it has been recognised that a standardised collec-
tion of core outcomes is needed. This resulted in the CROWN
(CoRe Outcomes in WomeN’s health) initiative, in which the
CochraneMenstrual Disorders and Subfertility Group also partic-
ipates (Khan 2014).With respect to this review, it would be worth
the effort to develop a core set of outcomes for the evaluation of
hysterectomy.
Quality of the evidence
The quality of the evidence for the comparisons included in this re-
view is mainly graded as low or moderate, resulting in uncertainty
regarding the effects on primary and secondary outcomes between
the different approaches to hysterectomy (Summary of findings
for the main comparison; Summary of findings 2; Summary of
findings 3). Limitations in the evidence included imprecision of
results and inadequate reporting of study methods (e.g. randomi-
sation and allocation procedure, no predefined primary and sec-
ondary outcomes). The ’Summary of findings’ tables show the
quality of evidence for our primary outcomes for the three main
comparisons. With regard to abdominal versus vaginal hysterec-
tomy there was a large difference in return to normal activities
between the different studies, although all results were in favour
of vaginal hysterectomy. In two studies, studying urinary tract in-
jury, there was doubt about themethod used for random sequence
generation.
With regard to laparoscopic versus abdominal hysterectomy doubt
existed about the method used for random sequence generation
or allocation of patients. There was a large difference in return
to normal activities between the different studies, although all
results were in favour of laparoscopic hysterectomy. Furthermore,
there were wide confidence intervals crossing the line of no effect
present.
Also, with regard to the comparison between laparoscopic and
vaginal hysterectomy wide confidence intervals crossing the line
of no effect were present. In some studies, studying urinary tract
injury and unintended laparotomy, there was doubt about the
method used for random sequence generation or allocation of
patients. In some trials, studying complications, it was unclear how
participants were randomised and allocated to their study group.
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Themajority of trials had unblinded participants, mostly imputed
to the nature of the intervention (e.g. vaginal hysterectomy re-
sulting in no abdominal scar in contrast with abdominal hysterec-
tomy). However, as for example Miskry 2003 and Paraiso 2013
showed, sham abdominal dressings could be applied to blinded
participants. This is particularly beneficial for unbiased patient-re-
ported outcomes, such as postoperative pain, satisfaction or qual-
ity of life. Trials studying short-term outcomes in short follow-up
periods, had minimal missing data. However, importantly, some
of the trials evaluating long-term outcomes, such as quality of
life (e.g. Garry 2004), had significant numbers lost to follow-up.
Therefore, the outcomes of these studies have to be interpreted
with caution. An important reason for the low quality of evi-
dence was imprecision of results, particularly resulting from the
low number of adverse events in terms of intraoperative and major
long-term complications per study. This is important to take into
account when interpreting the results regarding the safety of each
type of hysterectomy.
Most outcomes for the comparisons between laparoscopic and ab-
dominal hysterectomy, as well as laparoscopic and vaginal hys-
terectomy, are based on the large trial by Garry 2004, with a mod-
erate risk of bias and most importantly a high rate of incomplete
outcome data. Garry 2004 performed the largest trial (n = 1380)
and used major complications as the primary outcome. The re-
cruitment target was met in the laparoscopic versus abdominal
hysterectomy arm but not in the laparoscopic versus vaginal hys-
terectomy arm. With regard to the comparison between vaginal
and abdominal hysterectomy, the conclusions are based on six tri-
als with comparable sample sizes and low risk of bias. The sensi-
tivity analysis has led to some changes in statistical significance in
various variables on bleeding and blood loss. Complication rates,
operation times and recovery times did not change with the ex-
clusion of trials with more detrimental trial quality.
In conclusion, further research is at least likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate.
Potential biases in the review process
We used a rigorous process to identify all relevant studies, but
we excluded grey literature. Some attempts to contact authors of
studies lacking sufficient data to include them in this review were
not successful. Four so-called multi-arm trials have been included
in the review (Hwang 2002; Ottosen 2000; Ribeiro 2003; Sesti
2008a), where data have been used twice in different comparisons.
There is not an agreed approach to this problem. Since no large
effects of correlation and non-independence of data are expected
on the resulting conclusions, we took no special measures in the
review to address this issue. Similar correlation between the two
trials and inter-dependence of data might be present in the study
by Garry 2004, where the surgeon, and not randomisation, made
the decision in which trial a patient was included. We followed
procedures to reduce other potential bias in the review process.
Agreements and disagreements with other
studies or reviews
Several other reviews and studies have evaluated different ap-
proaches to hysterectomy. Kovac 2014 reported that the evidence
demonstrated that, in general, vaginal hysterectomy is associated
with better outcomes and has fewer complications than laparo-
scopic or abdominal hysterectomy.This is also the conclusion from
the Committee on Gynecologic Practice of the American Col-
lege of Obstetrics & Gynecology (ACOG 2009). Furthermore,
it is mentioned that laparoscopic hysterectomy is an alternative
to abdominal hysterectomy for those women for whom a vaginal
hysterectomy is not indicated or feasible. Overall, this is in ac-
cordance with the conclusions from this review. Pynnä 2014 per-
formed a systematic review of studies that have investigated the
cost-effectiveness of hysterectomy for benign gynaecological dis-
ease. They concluded that the cost-effectiveness of hysterectomy
has been surprisingly poorly studied and that conclusions are dif-
ficult to draw due to the different study designs, indications, fol-
low-up times and quality of life instruments used. Laparoscopic
hysterectomy seemed to be the least cost-effective in their review,
although further data fromoriginal patient cohorts with long-term
follow-up are needed. However, they did not include any studies
with robot-assisted hysterectomy and not all studies included cost
derived from sick leave. Smorgick 2014 studied he benefits and
challenges of robotic-assisted hysterectomy. Conforming with our
review, they found that recent studies comparing robotic and la-
paroscopic hysterectomy for benign indications have not demon-
strated a clear advantage for either approach in terms of compli-
cations, blood loss and hospital stay. The higher cost of robotic
hysterectomy remains a significant disadvantage of this approach,
although the total cost may decrease with increasing surgeon ex-
perience (via shorter operative time) and may be offset in some
circumstances by reduced hospital stay and cost of complications
compared with abdominal hysterectomy. It is expected that when
more robotic consoles enter the market, prices will drop and cost-
effectiveness may move into the direction of that in laparoscopic
hysterectomy. Furthermore, better ergonomic circumstances in
robotic-assisted hysterectomy will likely have the benefit of fewer
physical complaints in laparoscopic surgeons and, consequently,
less cost regarding surgeons absenteeism.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Among women undergoing hysterectomy for benign disease, vagi-
nal hysterectomy appears to be superior to laparoscopic and ab-
36Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
dominal hysterectomy, as it is associated with a speedier return to
normal activities. When technically feasible, vaginal hysterectomy
should be performed in preference to abdominal hysterectomy be-
cause of more rapid recovery and fewer febrile episodes postoper-
atively. Where vaginal hysterectomy is not possible, laparoscopic
hysterectomy has some advantages over abdominal hysterectomy
(including less operative blood loss, more rapid recovery, fewer
febrile episodes, and fewer wound or abdominal wall infections)
but these are offset by a longer operating time. No advantages of
laparoscopic over vaginal hysterectomy could be found; laparo-
scopic hysterectomy had a longer operation time, and total la-
paroscopic hysterectomy had more urinary tract injuries. Of the
three subcategories of laparoscopic hysterectomy, there are more
randomised controlled trial (RCT) data for laparoscopic-assisted
vaginal hysterectomy and LH(a) than for total laparoscopic hys-
terectomy. The surgical approach to hysterectomy should be de-
cided by the woman in discussion with her surgeon in light of
the relative benefits and hazards. These benefits and hazards seem
to be dependent on surgical expertise and this may influence the
decision. Single-port laparoscopic and robotic-assisted hysterec-
tomy should be either abandoned or further evaluated since there
is a lack of evidence of any benefit over conventional laparoscopic
hysterectomy. However, this has to be interpreted with caution
as adverse event rates were low, resulting in low power for these
outcomes.
Implications for research
The concept of evidence-based gynaecological surgery has been
challenged based on the many pitfalls in being able to successfully
undertake RCTs to assess surgical interventions (Johnson 2009),
however our extensive systematic review of surgical approaches to
hysterectomy shows the concept of evidence-based gynaecologi-
cal surgery to be alive and well. When the quality of RCTs of
surgical interventions is sufficiently good, this yields information
unrivalled in its quality compared to studies of other designs that
assess surgical interventions. There is no longer any excuse not to
undertake high quality trials of surgical interventions.
The enhanced evidence on short-term outcomes and adverse
events generated by this meta-analysis would benefit from large
study populations, with surgeons well beyond their learning curve.
Since laparoscopic hysterectomy was introduced 20 years ago and
adequate training programmes are available, studies undertaken
during the learning curve will not be helpful for making choices
in current clinical practice. We also recommend that future trials
should stratify allocation by surgeon, so that there is a balance of
procedures performed by each surgeon in both arms. It should,
however, be noted that outcomes for patients treated by the same
surgeon will be correlated, and that failure to account for this will
lead to incorrect inferences in the individual studies.
More high quality research would be welcome regarding the long-
term effects of the different approaches to hysterectomy, such as
pelvic organ dysfunction.
The various subcategories of laparoscopic hysterectomy may be
further evaluated against each other. For example, whether total
laparoscopic hysterectomy has any benefits or harms in compari-
son to other forms of laparoscopic hysterectomy (including LH(a)
and laparoscopic-assisted vaginal hysterectomy). The increase in
the rate of ureteric injury resulting from laparoscopic hysterec-
tomy, suggested by very large observational studies, remains to
be conclusively proven by RCT data. We strongly encourage trial
authors to report their laparoscopic approach to hysterectomy ac-
cording to our defined subcategories: laparoscopic-assisted vagi-
nal, LH(a), total laparoscopic and subtotal laparoscopic hysterec-
tomy (Table 1). This should minimise the confusion that has pre-
vailed in the first published literature on laparoscopic hysterec-
tomy. Single-port laparoscopic and robotic-assisted hysterectomy
should be performed in clinical trials only, since there is lack of
evidence of any benefit over conventional laparoscopic hysterec-
tomy. The claimed superior ergonomics of robotic hysterectomy
has not been shown to give rise to enhanced patients outcomes.
Although it is important that RCTs should have the same surgeon
(or group of surgeons) carrying out each of the approaches being
compared, different levels of expertise with each approach means
that such RCTs are always likely to be statistically heterogeneous
when considered for pooling in meta-analyses.
There is an absence of data for long-term outcomes in RCTs com-
paring surgical approaches to hysterectomy. RCTs should aim to
report long-term outcomes, including urinary, bowel and sexual
function, along with occurrence of fistulae. Quality of life or other
PROMs may be regarded as key outcomes in trials on approaches
to hysterectomy for benign disease to capture the patient’s perspec-
tive. To enable meta-analysis of quality of life data, well-validated
instruments should be applied in a standardised manner.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agostini 2006
Methods Single-centre study, parallel-group design
Duration: April 2002 to February 2004 (1 year, 10 months)
Randomisation: computer-generated allocation list
Allocation concealment: numbered, sealed, opaque envelopes
Blinding: no
Number of women eligible and randomised = 48
Dropouts: there were no dropouts or conversions
Follow-up: women were followed up until 1 month after surgery. No loss to follow-up
Power calculation for sample size: yes. 24 patients per group were necessary to detect
a difference in complications between the 2 groups of 35% or more (25% versus 60%
in VHO and LAVHO respectively) with 80% power and a significance level of 0.05
Analysis by intention-to-treat: yes (no conversions)
Participants 48 women with a mean age of 55 years in the VHO group and 53 years in the LAVHO
group
Inclusion criteria: women with benign disease, older than 45 years, uterine size below
halfway pubis and umbilicus
Exclusion criteria: virgin patient, contraindication pneumoperitoneum, adnexal mass
Interventions VHO versus LAVHO
VHO: standard VH technique with removal of ovaries and tubes as described by Ballard,
or an endo loop in case needed
LAVHO: laparoscopic dissection of suspensory ligaments and round ligaments, followed
by vaginal hysterectomy. Laparoscopy at the end of the procedure
Both groups received prophylactic antibiotic treatment (Cefoxitin IV)
GA for both VHO and LAVHO
Surgeons: 5 different surgeons carried out both procedures
Surgeon experience: surgeons experienced in vaginal surgery
Outcomes Primary outcome: complications (blood loss more than 500 ml, blood transfusion,
haematoma, postoperative fever)
Secondary outcomes: operative time; hospital stay
Notes France
University Hospital of Marseille
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation list
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Agostini 2006 (Continued)
Allocation concealment (selection bias) Low risk Numbered, sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no losses to follow-up
Selective reporting (reporting bias) Unclear risk No clear primary outcome was defined
Other bias Unclear risk Surgeons’ experience with laparoscopic
procedures not reported
Benassi 2002
Methods Single-centre study, parallel-group design
Duration: June 1997 to December 2000 (2 years, 6 months)
Randomisation: computer-selected randomisation
Allocation concealment: not clearly described
Blinding: no
Number of women randomised = 119. No dropouts reported
Follow-up: no loss to follow-up
No power calculation reported
Participants 119 women with a mean age of 47 years for the AH group and 48 years for the VH
group
Inclusion criteria: women with symptomatic enlarged uteri (200 ml to 1300 ml)
Exclusion criteria: prolapse, uterine or adnexal neoplasia, pelvic inflammation, vaginal
stenosis, previous pelvic or vaginal procedures, hormonal treatment in the 6 months
prior to surgery
Interventions AH versus VH
AH and VH performed according to Novak technique
Peri-menopausal patients also underwent bilateral oophorectomy
Antibiotic treatment: both groups received prophylactic antibiotic treatment (cefo-
taxime 2 g IV) and anticoagulant therapy with enoxaparin 2000 IU
General anaesthetic for AH; spinal anaesthetic for VH
Surgeons: the same surgeons carried out the surgery. Experience not reported
Outcomes Operative time; operative complications (injury to major vessel, ureter, bladder and
bowel); drop in haemoglobin; postoperative complications; hospital stay
No clear primary or secondary outcomes
Notes Italy
University Hospital of Parma
Funding not reported
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Benassi 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-selected randomisation
Allocation concealment (selection bias) Unclear risk Patients were randomly allocated, not
clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not (pre)defined
Other bias Unclear risk No other bias identified. Surgeons’ experi-
ence not reported
Candiani 2009
Methods Single-centre study, parallel-group design
Duration: April 2004 to April 2006 (2 years)
Randomisation: computer-generated
Allocation concealment: sealed, opaque envelopes
Blinding: no
Number of women eligible = 95. Number of patients randomised = 60
Follow-up: in the 12-month follow-up, 7 patients in LH and 6 in VH were lost to
follow-up. There were no conversions
Power calculation was performed for sample size: 30 patients per group were necessary
to detect a difference of more than 25% in discharge at day 2 (less than 5% versus more
than 30% in VH and LH, respectively) with 80% power and a significance level of 0.05
Analysis by intention-to-treat: yes (no conversions)
Participants 60 women with a mean age of 49 years in the LH group and 51 in the VH group
Inclusion criteria: women with an indication for vaginal hysterectomy for benign
pathology
Exclusion criteria: uterine volume greater than 300 ml, previous surgery for pelvic
inflammatory disease or endometriosis, suspicion of malignancy, the presence of an
ovarian cyst greater than 4 cm and a vaginal prolapse higher than first degree
Interventions LH versus VH
LH: total laparoscopic hysterectomy including the laparoscopic closure of the vaginal
cuff and its suspension to the uterosacral ligaments
VH: following Heaney’s technique
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Candiani 2009 (Continued)
Antibiotic treatment: prophylactic antibiotic treatment (type not mentioned) at the
beginning of the surgery and repeated 12 hours later
Type of anaesthesia (in VH): not mentioned
Surgeons’ experience: all the procedures were performed by 2 skilled surgeons for each
group; only surgeons who had performed at least 50 procedures were involved
Outcomes Primary outcome: hospital stay (with fixed parameters to discharge patients)
Secondary outcomes: pain (as measured by VAS and analgesic request), blood loss and
execution of adnexectomy if preoperatively planned
Notes Italy
San Paolo Hospital, University School of Medicine (Milan)
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation list
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes based on a com-
puter-generated allocation list
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout and loss to follow-up mentioned;
no conversions. 10% lost to follow-up
Selective reporting (reporting bias) Low risk Primary endpoint was clearly stated
Other bias Low risk No other bias identified
48Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chakraborty 2011
Methods Single-centre study, parallel-group design
Duration: June 2006 to May 2008 (2 years)
Randomisation: computer-generated random numbers
Allocation concealment: envelopes
Blinding: no
Number of women randomised = 200. No dropouts reported. No conversions men-
tioned
Follow-up: duration of follow-up not mentioned. No loss to follow-up
Power calculation for sample size: not reported
Analysis by intention-to-treat: not reported
Participants 200 women; age only mentioned in groups and not in means
Inclusion criteria: women scheduled for hysterectomy for benigndiseasewithout uterine
decent and a uterine size < 14 weeks gestational age
Exclusion criteria: primary diagnosis related to cancer, pelvic endometriosis, adnexal
pathology, multiple abdominal scar from previous surgery and prolapse
Interventions VH versus AH
VH: non-descent vaginal hysterectomy. The surgical technique is not described either
for VH or for AH
Use of prophylactic antibiotic treatment not reported
Surgeons’ experience not mentioned
Outcomes Length of hospital stay, operating time, intra and postoperative blood transfusion, minor
and major complications
Notes India
Hospital New Raipur (Dabur Park)
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Computer-generated random numbers
were used for randomisation. While assign-
ing groups to envelopes, if the computer-
generated random number was odd, the as-
signed group was A (non-descent vaginal
hysterectomy). If the random number was
even, the envelope was assigned to group
B: abdominal hysterectomy
Allocation concealment (selection bias) Low risk Simple random allocation of study partic-
ipants to 2 surgical procedure groups was
done by using envelopes numbered from
001 to 200. While assigning groups to en-
velopes, if the computer-generated random
number was odd, the assigned group was
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Chakraborty 2011 (Continued)
A (non-descent vaginal hysterectomy) for
the first (001 numbered) envelope. A card
withGroup-A: ND vaginal hysterectomy
written over it was put inside the envelope.
The next envelope was then taken and next
random number was checked. If the ran-
dom number was even, the envelope was
assigned to group B: abdominal hysterec-
tomy. A card with Group-B: abdominal
hysterectomy written over it was put in-
side the envelope no 002. Similarly cards
with group-A/Bwritten over themwere put
inside sequentially numbered envelopes by
matching with odd/even random numbers
as generated by computer. 1st patient for
the clinical trial was allocated to the group
assigned to the envelope no-001, 2nd pa-
tient was allotted to the group assigned to
the envelope no.002. In this way 200 par-
ticipants were allocated into 2 intervention
groups and eventually the numbers in 2
groups were 100 in group A and 100 in
group B
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Unclear risk The distribution in age and parity between
the groups is somewhat skewed. Surgeon’s
experience not reported
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Chen 2011
Methods Single-centre study
Duration: September 2009 to June 2010
Randomisation: computerised balanced method (1:1). Random numbers were com-
puter-generated
Allocation concealment: random numbers were inserted in numbered, sealed and
opaque envelopes. A single envelope was opened by the surgeon when the patient was
hospitalised
Blinding: no
Number of women: assessed for eligibility = 118, randomised = 102
Follow-up: single-port LAVH - no loss to follow-up or dropout; multiple-port LAVH -
2 excluded from analysis, 0 lost to follow-up - 2 discontinued intervention
Power calculation for sample size: yes, based on previous study of 24-hour pain scores,
they used 2.5 +/- 0.7 compared with 3.5 +/- 0.8 (mean and SD) and 1.9 +/- 1.4 compared
with 2.8 +/- 1.4 for single-port LAVH and multi-port LAVH, as the primary criterion
to calculate a minimum sample size of 45 patients for each group
Participants n = 102
Inclusion criteria: women, age 30 to 79 years, and an ASA classification of I or II
Exclusion criteria: if disease was malignant, if they needed additional adnexal surgery
(n = 13) or unwilling to participate (n = 3)
Interventions Single-port LAVH versus multi-port LAVH
Single-port LAVH:
A 1.5 cm horizontal intra-umbilical skin incision, a 1.5 cm to 2 cm rectus fasciotomy to
open the peritoneal cavity, insertion small wound extractor. The wrist of surgical glove
fixed to outer ring of wound extractor. A 12 mm trocar was inserted through a small hole
made in one of the fingertip areas of the glove and advanced into the abdominal cavity.
An additional hole for the accessory channel was made in another fingertip of the glove
and one 5 mm trocar was inserted
Multi-port LAVH:
4 ports, one 12 mm port inserted umbilically, the other 5 mm ports in lateral abdominal
wall and suprapubic. 0 degree rigid 10 mm scope
Surgeons: all procedureswere performedby a single surgeon, assisted by another surgeon,
at a single institute
Antibiotics: perioperative antibiotic treatment not reported
Postoperative assessment performed by 2 independent investigators
Outcomes Postoperative pain (at 12, 24 and 48 hours, VAS)
Operative time, additional procedures, blood loss, transfusion requirements, postopera-
tive hospital stay
Notes Taiwan
Taipei Veterans General Hospital, Taipei
Funding reported, i.e. Taipei Veterans General Hospital, Taipei and Yen-Tjing-Ling
Medical Foundation, Taiwan
Risk of bias
Bias Authors’ judgement Support for judgement
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Chen 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated numbers
Allocation concealment (selection bias) Low risk Numbered, sealed and opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts and loss to follow-up reported.
No loss to follow-up. 2 discontinuedmulti-
port LAVH
Selective reporting (reporting bias) Unclear risk No primary outcome defined. Insufficient
information available
Other bias Unclear risk Surgeons reported, but experience unclear.
Analysis according to intention-to-treat
not mentioned
Darai 2001
Methods Multicentre study (n = 2), parallel-group design
Duration: January to December 1999 (1 year)
Randomisation: pre-determined computer-generated randomisation code
Allocation concealment: not reported
Blinding: no
Number of women randomised = 80. No dropouts reported. 3 LAVH converted to AH
Follow-up: 6 to 8 weeks after surgery. No loss to follow-up reported
Power calculation to estimate sample size: yes, 35 women required for each surgery
arm (assuming that the incidence of complications in women who had LH(a) was 10%
and there was an increase of complication rate to 40%), with an alpha (type I error) of
0.05 and a beta (type II error) of 0.2
Participants 80 women with a mean age of 50 years for the LH(a) group and 49 years for the VH
group
Inclusion criteria: women scheduled for abdominal hysterectomy for benign disease
with traditional contraindications for VH, including uterine size larger than 280 g and
one or more of the following: previous pelvic surgery, history of pelvic inflammatory
disease (PID),moderate or severe endometriosis, concomitant adnexalmasses, indication
for adnexectomy and nulliparity without uterine descent
Exclusion criteria: anaesthetic contraindications for laparoscopic surgery; suspicious
adnexal mass on ultrasound; ovarian blood flow and tumour markers; vaginal narrowed
to less than 2 fingers wide; immobile uterus with no descent and no lateral mobilisation
Interventions VH versus LH (LH(a))
LH(a) arm (considered LH type IV): included coagulation and sectioning of the round
ligament, utero-ovarian ligaments with fallopian tubes when ovaries were conserved, and
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Darai 2001 (Continued)
the infundibulopelvic ligaments when ovaries were removed; opening of the bladder
flap and bladder dissection, uterosacral ligaments, base of cardinal ligaments and uterine
vessels. Vaginal phases included circular incision of the vagina and,whennecessary, wedge
morcellation, coring or bivalving. Peritoneal closure and closure of the vaginal vault
concluded the vaginal phase, at which time the pelvis and abdomen were re-evaluated
through the laparoscope to be sure of haemostasis and for pelvic lavage
VH arm: according to modified Heaney technique
Antibiotics: both groups received prophylactic antibiotic treatment (cefazolin 2 g IV) at
the beginning and anticoagulant therapy with low molecular weight heparin the evening
before the operation
Surgeons: surgeons experienced in laparoscopic and vaginal surgery completed all the
operations
Outcomes Intra-operative and postoperative complications; febrile morbidity; analgesia require-
ment; postoperative hospital stay; conversion to laparotomy; uterine size and weight
Notes France
2 hospitals in Paris
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pre-determined computer-generated ran-
domisation code
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts, 3 procedures converted. No
loss to follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information available. Primary
outcome not clearly defined in paper
Other bias Low risk No other bias identified
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Ellstrom 1998
Methods Single-centre study, parallel-group design
Duration: not reported
Randomisation: method not stated
Allocation concealment not reported
Blinding: no
Number of women randomised = 40. No dropouts reported
Follow-up: assessment of pain, nausea and vomiting, 8 pm day of surgery, 10 am and
6 pm first day and 10 am second postoperative day. Pulmonary function assessed pre-
operatively and 10 am, first and second day. Time of anaesthesia, surgery, per and post-
operative complications and difference in erythrocyte volume fraction (EVF) before and
2 days after surgery. No loss to follow-up
Power calculation for sample size: not reported
Participants 40 women with a mean age of 46 years (LH(a) group) and 48 years (AH group)
Inclusion criteria: scheduled for abdominal hysterectomy for benign disorders; maxi-
mum width of uterus, measured by transvaginal ultrasound, less than 11 cm. American
Society of Anaesthesiologists (ASA) Grade 1
Exclusion criteria: not reported
Interventions AH versus LH (LH(a)). Both groups stratified to total and subtotal hysterectomies
LH(a) arm: total hysterectomy (n = 14) and laparoscopic subtotal hysterectomy (n = 6).
The laparoscopic part of the total hysterectomy was finished when the uterine artery and
parts of the sacrouterine ligaments were transected. The operation was then continued
vaginally
Second-generation cephalosporin and metronidazole were given intravenously during
the operation and by oral administration for 2 days after surgery. With the subtotal
hysterectomy, morcellation was carried out after transection of the uterine arteries using
a mechanical or an electrical morcellator. The cervical canal was desiccated with bipolar
cautery
AH arm: total hysterectomy (n = 14) and subtotal hysterectomy (n = 6). With the
abdominal hysterectomies, standard surgical techniques were used. A lower midline or
Pfannenstiel incision was made. The type of incision was left to the individual surgeon
and patient to decide
Anaesthesia: both groups received standardised anaesthesia; flunitrazepam (1 mg) was
given as pre-medication approximately 2 hours before surgery. Anaesthesia was induced
with propofol (1.5 to 2.5 mg per kg body weight). Morphine (100 uG per kg body
weight) was given for perioperative analgesia. Neuromuscular block was achieved with
vecuronium (0.1 mg per kg body weight). Suxamethonium (1.0 mg per kg body weight)
was administrated for optimal intubation. Anaesthesia was maintained with isoflurane
in oxygen/air. Morphine was postoperatively self administered by the patients by pro-
grammable infusion pump containing morphine 1.0 mg/ml. Additional analgesic med-
ication was restricted to paracetamol. Patients with nausea were given 10 mg metoclo-
pramide
Surgeon experience: not reported
Outcomes Primary: postoperative pain, pulmonary function
Secondary: time of anaesthesia, time of surgery, per and postoperative complications,
difference in erythrocyte volume fraction (EVF)
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Ellstrom 1998 (Continued)
Notes Sweden
University Hospital of Sahlgrenska
Funding: Goteborg Medical Society Fund, Swedish Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Low risk Primary outcome clearly defined
Other bias High risk Analysis according to intention-to-treat
unclear; no exclusion criteria reported. No
sample size calculation performed. Sur-
geon’s experience not reported
Falcone 1999
Methods Single-centre study, parallel-group design
Duration: September 1995 to February 1997 (1 year, 6 months)
Randomisation: assigned according to a computer-generated randomisation schedule
with random block sizes
Allocation concealment: All patients were told of their assignment before surgery
Blinding: no
Number of women randomised = 48, number analysed = 44
Dropout: 4 withdrew before surgery (3 AH group and 1 LH group)
Follow-up: daily diary for 6 weeks, recording symptoms, lifestyle impact, life events,
medication. In each arm, 1 patient refused to keep a diary
Power calculation for sample size: yes, 22 patients per group were necessary to detect a
difference of 30 minutes or more in surgical time between the 2 groups with 90% power
and a significance level of 0.05
Analysis by intention-to-treat: yes
Participants 44 women with a mean age of 42.8 years (LH group) and 43.8 years (AH group)
Inclusion criteria: scheduled for abdominal hysterectomy for benign disease
Exclusion criteria: pelvic mass size greater than 2 cm below the umbilicus; concomitant
incontinence or pelvic reconstructive procedures required
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Falcone 1999 (Continued)
Interventions AH versus LH
LH arm:
3 10 mm trocar sites - 1 umbilical and 1 in each lower quadrant lateral to inferior epi-
gastric artery 6 cm to 8 cm above pubic rami. Uterine arteries occluded laparoscopically
with electrocautery. Cardinal ligaments cut laparoscopically. If the uterus had minimal
descent, uterosacral ligaments were also cut laparoscopically. Vagina incised either laparo-
scopically or vaginally, depending on the ease that this could be achieved. Either anterior
or posterior fornix, depending on access. Surgery then completed vaginally. Vaginal cuff
closed vaginally
Surgeons: performed by senior author with assistance from pelvic surgery fellow or
resident
Postoperative pain relief was given to patients intravenously
AH arm: procedure not reported
Outcomes Operative time; blood loss; length of hospital stay; uterine weight; intra-operative com-
plications; postoperative pain; return to work/normal activities and hospital costs per
patient
Notes USA
Cleveland Clinic Foundation, Ohio
Funding by Ethicon Endosurgery and the Minimally Invasive Center of the Cleveland
Clinic Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
schedule with random block sizes
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4patientswithdrewbefore surgery anddata
were included where possible. In each arm
1 patient was lost to follow-up
Selective reporting (reporting bias) Low risk No reporting bias identified
Other bias Unclear risk Funding from pharmaceutical or surgical
instrumentation company. Surgeon’s expe-
rience unclear
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Ferrari 2000
Methods Single-centre study, parallel-group design
Duration: 24 months
Randomisation: computer-generated randomisation numbers
Allocation concealment: sealed opaque envelopes
Blinding: no
Number of women randomised = 62. No dropouts reported. With 3 women in the
LAVH group, the procedure was converted to a AH. In all cases the decision was made
during the laparoscopic part of the procedure
Follow-up: women were followed up until discharge from hospital. Postoperatively,
temperature and analgesic requirement were recorded daily. No loss to follow-up
Power calculation for sample size: no
Participants 62 women aged from 43 to 50 years
Inclusion criteria: symptomatic uterine fibroids
Exclusion criteria: history of severe pelvic disease; lack of uterine accessibility and mo-
bility or a sonographically estimated uterine volume > 1500 ml (abdominal hysterec-
tomy). Women without a history of severe pelvic disease, with an accessible and mobile
uterus and a sonographically estimated uterine volume < 500 ml, underwent a vaginal
hysterectomy
Interventions AH versus LH (LAVH)
LAVH arm: visualisation of the pelvis and upper abdomen, the treatment of adhesions
or endometriosis when present, and the completion of the upper part of the hysterec-
tomy. Round ligaments, tubes and utero-ovarian ligaments were desiccated and tran-
sected when the adnexa were to be preserved, while the round and infundibulopelvic
ligaments were desiccated and transected when the adnexa were to be removed. The
broad ligaments were dissected to their lower margin. When the bladder was stretched
over the anterior aspect of the uterus due to previous surgery, the bladder flap was devel-
oped laparoscopically. The vaginal part of the hysterectomy included colpoceliotomy an
bilateral ligation and transection of utero-sacral ligaments, uterine vessels and cardinal
ligaments; cervical amputation, corporal hemisection, myomectomy and uterine mor-
cellation were performed when necessary
AH arm: performed according to a standard technique
Surgeon experience: not reported
Outcomes Operating time; blood loss; complications; febrile morbidity; analgesic administration
and hospital stay
Notes Italy
San Paolo Biomedical Sciences Institute, University of Milan
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation num-
bers
57Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ferrari 2000 (Continued)
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not predefined
Other bias Unclear risk Surgeon’s experience unclear. Power calcu-
lation for sample size not performed
Garry 2004
Methods Multicentre study (n = 30), parallel-group design
Duration: November 1996 to September 2000 (4 years)
Randomisation: 2:1 imbalance randomisation method. Allocation to abdominal or
vaginal trial by surgeon. Randomisation to conventional or laparoscopic approach was
performed with a computer-generated program and allocation was advised by telephone
call to the central North Yorkshire Clinical Trials unit
Allocation concealment:
Blinding: no
Number of women randomised: 1380
- Abdominal trial: 876 (AH: 292, aLH: 584)
- Vaginal trial: 504 (VH: 168, vLH: 336)
- Number of patients that withdrew/dropped out pre-operatively: AH:6, aLH: 11,VH:
5, vLH: 12
Follow-up: 6 weeks, 4 months and 1 year. In the abdominal trial: AH arm - 6 weeks n
= 17, 4 months n = 104, 1 year n = 104; LH arm - 6 weeks n = 29, 4 months n = 166,
1 year n = 166. In the vaginal trial: VH arm - 6 weeks n = 10, 4 months n = 55, 1 year
n = 55; LH arm - 6 weeks n = 27, 4 months n = 110, 1 year n = 118
Power calculation to estimate sample size: yes. The sample size for the abdominal trial
was calculated on the basis of 9% of AH having major complications. In order to detect
a reduction in complication rate of 50%, a sample size of 450 in each arm was required
using 80% power and a 2-sided type 1 error rate of 5%
Results were confirmed using a per-protocol analysis
Participants 1380 women with a mean age of 41 years
Inclusion criteria: women who needed hysterectomy for non-malignant conditions
Exclusion criteria: confirmed or suspected malignant disease of any part of the genital
tract; 2nd or 3rd degree uterine prolapse; a uterine mass greater than the size of a 12-week
pregnancy; any associated medical illness precluding laparoscopic surgery; a requirement
for bladder or other pelvic support surgery and patient refusal of consent for the trial
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Interventions 4 arms: VH, LH in the vaginal trial (vLH); AH and LH in the abdominal trial(aLH)
Surgical procedures were not reported
Surgeons recruited had to have performed at least 25 of each type of procedure, however
cases could be used for teaching if themain assistant was the designated surgeon. Surgeons
of all grades and experience participated
Outcomes Primary outcomes: major complications (major haemorrhage, bowel injury, ureteric in-
jury, bladder injury, pulmonary embolus, anaesthesia problems, unintended laparotomy,
wound dehiscence, haematoma)
Secondary outcomes: minor complications (major haemorrhage, anaesthesia problems,
pyrexia, infection, haematoma, DVT); blood loss; pain; analgesia requirement; sexual
activity; body image; health status; length of surgery; length of hospital stay
Notes UK (28 centres) and South Africa (2 centres)
Funding: National Health Service Research and Development Health Technology As-
sessment Programme, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised with use of a computer-gen-
erated program
Allocation concealment (selection bias) Low risk Telephone inquiry
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 17 patients in each trial dropped out be-
fore surgery and sensitivity analysiswas per-
formed. Particularly in the AHarm andLH
arms loss to follow-up was high (> 15%)
Quality of life outcome at baseline reported
in 76% of women
Selective reporting (reporting bias) Low risk Primary and secondary outcomes well de-
fined
Other bias Unclear risk Surgical procedures not reported. Surgeons
of all grades and experience participated
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Ghezzi 2010
Methods Single-centre
Duration: February 2009 to September 2009 (7 months)
Randomisation: computer-generated list
Allocation concealment: treatment allocation was concealed until the day of surgery
Blinding: no
Number of women: 123 women eligible, of which 82 randomised: 41 randomised to
LH and 41 randomised to VH. No dropout
Follow-up: no loss to follow-up
Power calculation to estimate sample size: yes, based on mean VAS pain score after
VH reported by Candiani et al (2011). With an alpha error of 5% and a power of
95%, at least 40 patients in each group needed to detect a 50% decrease in the mean
postoperative pain on day 0 in patients with LH
Intention-to-treat analysis: not reported
Participants 82 women with a mean age of 48 years in both groups
Inclusion criteria: indication for hysterectomy for a supposed benign gynaecological
condition
Exclusion criteria: uterine volume > 14 weeks of gestation, suspicion of malignancy,
concomitant presence of large adnexalmasses (diameter > 4 cm) andpelvic organprolapse
> stage 1 according to POP-Q classification. Chronic pelvic pain and endometriosis or
PID were excluded
Interventions TLH versus VH
TLH: intrauterine manipulator inserted. 5 mm scope umbilical site. 3 5 mm ancillary
trocars inserted, 1 suprapubically and 2 laterally. Coagulation and dissection of round
ligaments and infundibulopelvic ligaments. Broad ligament opened to uterovesical fold,
caudal reflection of bladder. Uterine arteries, cardinal ligaments and uterosacral ligaments
coagulated and transected. Colpotomywithmonopolar hook.Uterus extracted vaginally.
Vaginal cuff closure with single layer sutures
VH: performed according to a standardised technique
Surgeons: surgical team and their experience were not reported
Antibiotic and antithrombotic prophylaxis administered postoperatively
Outcomes Primary outcome: postoperative pain (VAS at 1, 3, 8 and 24 hours after procedure)
Secondary outcome: operative time
Notes Varese, Italy
Del Ponte Hospital, University of Insubria
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation with use of a computer-
generated list
Allocation concealment (selection bias) Unclear risk Concealed until day of surgery. Method of
concealment not reported
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Ghezzi 2010 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout and loss to follow-up reported.
Low numbers
Selective reporting (reporting bias) Unclear risk Primary outcome not clearly defined in
methods of study
Other bias Low risk Surgical experience reported
Ghezzi 2011
Methods Single-centre
Duration: October 2009 to May 2010 (7 months)
Randomisation: block randomisation, computer-generated list, with block size of 28
Allocation concealment: the surgeon was notified of the allocation on the day of the
procedure
Blinding: patients and research assistants were blinded to group randomisation
Number of women: 112 patients eligible of which 76 randomised. 38 allocated to each
group. Randomised = 76; analysed = 76. No dropouts
Follow-up: no loss to follow-up
Power calculation for sample size: yes, a reduction in pain intensity of 2 points on the
VAS would be regarded as clinically significant. With alpha = 0.05 and beta = 0.20, a
sample size of 38 women per group would be required to detect a reduction in the mean
pain score at 1 hour after surgery from 4.7 to 2.7
Intention-to-treat analysis: not reported
Participants 76 patients with a mean age of 46 and 47 years for each group
Inclusion criteria: women with benign gynaecological conditions requiring hysterec-
tomy
Exclusion criteria: pelvic organ prolapse > grade I. Severe cardiopulmonary disease if
anaesthesiology team decided that laparoscopy was contraindicated
Interventions LH versus mini-LH
Same surgical technique was used for both LH and mini-LH. LH was a standardised
technique. Only difference is that in mini- LH all ports were 3 mm or smaller
Surgeons: same surgical team skilled in advanced laparoscopy
Patients underwent a standardised anaesthesia protocol
Outcomes Primary outcome: postoperative pain (VAS 1, 3, 8 and 24 hours postoperative)
Secondary outcomes: operative parameters, volume in inflated CO2
Notes Varese, Italy
Del Ponte Hospital, University of Insubria
Funding: not reported
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Ghezzi 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation: block-randomisation,
computer-generated list
Allocation concealment (selection bias) Low risk Allocation concealment described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients and research assistants were
blinded to group randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout and loss to follow-up reported,
low numbers
Selective reporting (reporting bias) Low risk Primary and secondary outcomes defined
Other bias Low risk No other bias identified
Harkki-Siren 2000
Methods Single-centre study, parallel-group design with no blinding
Duration: March to September 1997 (6 months)
Randomisation: patients were randomly allocated
Allocation concealment: sequentially numbered, opaque and sealed envelopes
Blinding: no
Number of women randomised = 50. No dropouts reported. Tissue trauma analysis for
18 uncomplicated hysterectomies in both groups were included
Follow-up: first follow-up visit was scheduled 4 weeks after the operation and then
followed up until complete recovery. No loss to follow-up
Power calculation for sample size: yes, 21 women in each group would be needed for
90% study power and for differentiation of 10 mg/L (standard deviation) between the
means of C-reactive protein (CRP) concentration when type I error is 5%. For 80%
study power, 15 women in each group needed
Participants 50 women with a mean age of 47 years (LH(a) group) and 48 years (AH group)
Inclusion criteria: scheduled for AH for benign reasons
Exclusion criteria: major medical diseases; BMI above 32 kg/m2; size of uterus larger
than of 14 weeks of pregnancy or uterine width greater than 10 cm by transvaginal ultra-
sonography; severe adhesions or endometriosis; prolapse and any other contraindications
for laparoscopy
Interventions AH versus LH (LH(a))
LH(a) arm: a 5 mm trocar was inserted suprapubically. Pelvis was inspected and ureters
located. The uterosacral ligaments were coagulated with bipolar electrocoagulation and
cut with unipolar scissors, as were the infundibulopelvic vessels and ligaments (if adnexa
were to be removed) or the round ligaments, fallopian tubes and utero-ovarian ligaments
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Harkki-Siren 2000 (Continued)
(adnexa not removed). The vesical peritoneum was opened with scissors and the bladder
pulled down. Uterine vessels were prepared free and divided. The anterior fornix of the
vagina was opened laparoscopically with monopolar scissors, the uterus was removed
vaginally and the vagina was closed with resorbable suture
AH arm: operated on in a standard manner through a lower midline or Pfannenstiel
incision. Diathermy was used only for haemostasis and peritoneal closure was performed
All women received 500 mgmetronidazole intravenously at the beginning of anaesthesia
and operations were performed under GA with endotracheal intubation in both groups.
The bladder was drained with a Foley catheter in all women. A drain was left from the
perineal cavity in both groups
Surgeon experience: not reported
Outcomes Operating time; anaesthetic time; blood loss; haemoglobin change; hospital stay; sick
leave and complications
Notes Finland
Jorvi Hospital, Espoo
Funding: The Clinical Research Institution of Helsinki University Central Hospital and
Jorvi Hospital, The Finnish Medical Foundation and The Research Foundation of Orion
Corporation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly allocated. Method
not clearly described
Allocation concealment (selection bias) Low risk Sequentially numbered and sealed, opaque
envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Unclear risk Tissue trauma reported in uncomplicated
surgeries only
Funding from pharmaceutical or surgical
instrumentation company
63Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hwang 2002
Methods Single-centre study, parallel-group design
Duration: June 1999 to May 2001 (2 years)
Randomisation: sealed envelopes containing computer-generated block randomisation
numbers, block size of 10
Blinding: no
Number of women randomised = 90. No dropouts reported
Follow-up: 6 weeks after surgery
Power calculation to estimate sample size: yes. Power of analysis was 80% at alpha =
0.05. Result of power calculation not reported
Participants 90 women with a mean age of 45.1 years
Inclusion criteria: scheduled for hysterectomy for uterine fibroids; myoma diameter
larger than 8 cm and second myoma less than 5 cm or 2 myomata, both at least 6 cm in
diameter but less than 8 cm (maximum number of fibroids was 3)
Exclusion criteria: indications of adenomyosis; uterine prolapse; chronic pelvic pain;
dysfunctional uterine bleeding; cervical dysplasia; pelvic inflammatory disease
Interventions AH versus VH versus LH (LH(a))
AH arm: abdomen opened by vertical midline or Pfannenstiel skin incision. Uterus
removed by extrafascial technique and vaginal cuff closed with continuous interrupted
suture followed by re-peritonealisation
VHarm: patients inTrendelenburg tilt position and given vasopressin injection. Anterior
circumferential incision of the cervix and posterior V-shape incision. Anterior peritoneal
cavity opened and cul-de-sac of Douglas entered. After uterine artery ligation, volume
reducing techniques were performed vaginally. Peritoneum closed and uterosacral liga-
ments and vaginal vault sutured.
LH(a) arm: 10mmtrocar inserted intoumbilical position, one 5mm trocar in each lower
quadrant and another inserted suprapubically. Uterosacral ligament incision and round
and broad ligaments were excised. Anterior colpotomy was performed after ligation of
the bilateral uterine artery. The rest of the hysterectomy was completed vaginally. The
uterus was removed vaginally by volume reducing techniques and the vaginal cuff was
closed
All operations performed under general anaesthesia by second author, with the assistance
of the other authors. Standardised postoperative protocol of 2 doses of IV meperidine
50 mg every 4 hours for pain control followed by acetaminophen 325 mg every 6 hours
Prophylactic antibiotics (cephalosporin 1.0 g every 8 hours (3 doses/day) combined with
aminoglycoside 80 mg every 12 hours (2 doses/day), were administered to all for 1 day
after surgery
Surgeons’ experience: 1 surgeon performed all procedures and had much experience
Outcomes Operating time; hospital stay; intra-operative blood loss; complications; postoperative
tenderness score; return to work; antibiotics used
Notes Taiwan
Shin Kong Wu Ho-Su Memorial Medical Centre, Taipei
Funding not reported
Risk of bias
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Hwang 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
numbers
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts. No loss to follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information
Other bias Unclear risk Uterine weight in AH group was signifi-
cantly higher than in VH and LAVHgroup
Jung 2011
Methods Single-centre
Duration: October 2009 to March 2010 (5 months)
Randomisation: based on computer-generated random sampling numbers
Allocation concealment: not described
Blinding: no
Number of women randomised = 68. 34 in TLH arm analysed. 30 in SP-LH arm
analysed: 4 converted procedures excluded from analysis
Follow-up: no loss to follow-up
Power calculation for sample size: yes, a difference of 0.8 in the VAS score was con-
sidered clinically relevant. The number of cases needed per group was 34
Intention-to-treat analysis not applied
Participants Mean age was 48 years
Inclusion criteria: age >/ = 20 years, no evidence of gynaecologic malignancy, normal
cervical cytology or histology, appropriate medical status for laparoscopic surgery (ASA
1 or 2), adequate uterus size for vaginal removal (</ = 12 weeks)
Exclusion criteria: uterine size larger than 12 weeks, history of pelvic radiation therapy,
suspicion of gynaecologic cancer, more than 3 prior laparotomies, treated for gastroin-
testinal or gynaecologic malignancy
Interventions SP-TLH versus 4-port/conventional TLH
Conventional TLH:
4 5 mm trocars were placed. A 5 mm port for the laparoscope inserted through the
umbilicus. 2 5 mm ports were placed in the left lower quadrant of the abdomen and one
in the right lower quadrant
SP-TLH: a 1.2 cm vertical intra-umbilical skin incision was made and a 1.5 cm rectus
fasciotomy was performed for entrance to the peritoneal cavity. A single 3-channel port
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Jung 2011 (Continued)
was used. After introduction in both arms the procedure was performed similarly. Utero-
ovarian ligaments and round ligaments and broad ligaments were sequentially ligated
and dissected. The vesico-uterine peritoneal fold was opened and the bladder mobilised.
The uterine vessels were sealed and dissected. The uterus was removed vaginally; some
had to be morcellated. The vaginal vault was sutured laparoscopically or transvaginally,
depending on the surgeon’s decision
Surgeons’ experience: all procedures performed by 3 skilled surgeons. Surgical experi-
ence: at least 100 LH and 30 SP-LH
Outcomes Primary: postoperative pain (VAS) and need of analgesics
Secondary: operative time, intra and postoperative complications, postoperative hospital
stay, haemoglobin
Notes Korea
Gangnam Medical Center, Seoul
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation: based on computer-gener-
ated random sampling numbers
Allocation concealment (selection bias) High risk Allocation concealment not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No loss to follow-up, 4 converted proce-
dures in SP arm excluded from analysis
Selective reporting (reporting bias) Unclear risk Converted procedures not analysed; pri-
mary and secondary outcomes predefined
Other bias Low risk No other bias identified
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Kluivers 2007
Methods Single-centre study, parallel-group design
Duration: August 2002 to January 2005 (2 years, 6 months)
Randomisation: randomly allocated
Allocation concealment: sealed, opaque envelopes
Blinding: no
Number of women eligible = 88, and randomised = 59
Dropouts: in the LH group, 1 woman refused the allocated procedure and an AH was
performed. There were 2 intra-operative conversions to AH. There were 2 patients with
re interventions (laparotomy) in the AH group
Follow-up: women were followed up until 3 months after surgery. At 12 weeks the
follow-up was complete in 81% of the LH group and 94% of the AH group
Power calculation for sample size: yes, 28 patients per group were necessary to detect a
difference between the 2 groups of 15 units or more on each of the 8 RAND-36 subscales
with standard deviation 20 units and 80% power with a significance level of 0.05
Analysis was by intention-to-treat
Participants 59 women with a mean age of 46 years in both groups
Inclusion criteria: women with benign disease in whom VH was not possible and LH
was feasible
Exclusion criteria: suspicion of malignancy, a previous lower midline incision, the need
for simultaneous procedures like prolapse repair, inability to speak Dutch
Interventions TAH versus TLH
AH: was performed according to the extrafascial technique (clamps and suture ligation)
LH: intentional TLH procedures, using the Storz uterine manipulator type Clemont
Ferrand, and a 4-port technique with bipolar coagulation and scissors. Opening the
bladder flap and colpotomy (with the use of monopolar coagulation) were performed
laparoscopically, as well as laparoscopic extracorporeal suturing of the vagina
Antibiotic treatment: both groups received prophylactic antibiotic treatment (amoxi-
cillin clavulanate 2.2 g IV) and anticoagulant therapy
Anaesthesia: general anaesthesia for both AH and LH
Surgeons: 10 different surgeons carried out AH, of whom 3 surgeons also carried out
LH; (supervising) surgeons had performed at least 100 procedures
Outcomes Primary: quality of life (questionnaire RAND-36)
Secondary: operative time; blood loss; operative complications (injury to adjacent or-
gans, haemorrhage, anaesthesia problems); conversions to AH, LAVH, LH(a) or subtotal
hysterectomy; haemoglobin decrease; postoperative complications; hospital stay; use of
opioids and antiemetics
Notes The Netherlands
Maxima Medical Centre, Veldhoven
No funding
Risk of bias
Bias Authors’ judgement Support for judgement
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Kluivers 2007 (Continued)
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes shuffled and se-
quentially numbered
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 1 refused assigned procedure and was anal-
ysed in assigned treatment group. Loss to
follow-up was almost 20% in LH group; in
AH group 6%
Selective reporting (reporting bias) Low risk Primary outcomes predefined and accord-
ingly reported
Other bias Unclear risk Different group of surgeons for different
procedures. More residents as first surgeon
in AH
Kongwattanakul 2012
Methods Single-centre. Stratified, open, randomised, controlled, parallel-group trial
Duration: April 2010 to March 2011 (1 year)
Randomisation: computer-generated list. Stratified random sampling. Group 1: uterus
</ = 12 weeks of gestation (n = 32); Group 2: uterus > 12 to 16 weeks of gestation (n =
11); Group 3: history of abdominal surgery (n = 7)
Allocation concealment: sealed, opaque, numbered envelopes
Blinding: researcher blinded; patients not blinded
Number of women: after randomisation: LAVH 25 (group 1 = 16; group 2 = 6; group
3 = 3); AH 25 (group 1 = 16; group 2 = 5; group 3 = 4)
Follow-up: until discharge from the hospital. No loss to follow-up
Power calculation for sample size: yes, it was calculated from the population mean
from a sample size determination as per WHO Health Studies. A power calculation
verified that no more that 24 patients were needed in each group
Analysis by intention-to-treat: not reported
Participants 50 women
Inclusion criteria: indication for hysterectomy because of benign disease. Uterus </ =
16 weeks
Exclusion criteria: cardiopulmonary disease, cardiac arrhythmias, history of ischaemic
heart disease, other medical risks
Interventions LAVH versus AH
Surgical techniques not reported
Surgeons: 2 surgeons who performed both procedures at least 30 times
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Kongwattanakul 2012 (Continued)
Preoperatively antibiotic prophylaxis cefotaxime 1 g
Outcomes Intraoperative blood loss, duration of operation, intraoperative and early postoperative
complications, conversion rate, pain, duration of hospital stay
Notes Thailand
Srinagarind Hospital, Khon Kaen
Funding: grant support by the Faculty of Medicine of Khon Kaen University
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by means of a computer-
generated list of random numbers
Allocation concealment (selection bias) Low risk Sealed, opaque, numbered envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of researcher; patients not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported, conversion
rate reported
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Unclear risk Not reported if 3 groups are comparable
on basic characteristics; power calculation
unclear
Kunz 1996
Methods Single-centre study, parallel-group design
Duration: November 1993 to February 1995 (1 year, 4 months)
Randomisation: method not reported
Allocation concealment: not reported
Blinding: no
Number of women randomised = 70, number analysed = 70. No dropouts
Follow-up: until discharge from the hospital. No loss to follow-up
No power calculation for sample size was reported
Participants 70 women with a mean age of 43 (LAVH group) and 48 years (AH group)
Inclusion criteria: scheduled for hysterectomy for non-malignant diseases
Exclusion criteria: not reported
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Interventions AH versus LH (LAVH)
LAVH arm: a curette was inserted into the uterus and the laparoscopic video camera
was introduced. 2 5 mm trocars were inserted. Division of the adnexopexy from the
uterus or the infundibulopelvic ligaments and round ligaments was accomplished with
tissue tension, bipolar coagulation and the use of hook scissors. Transverse incision on
the anterior fold of the broad ligaments bilaterally and transection of the visceral peri-
toneum at the bladder resection. Separation of the posterior fold of the broad ligaments,
uterine arteries are skeletonised and demonstrated close to the uterus (2 cm). The hys-
terectomy was continued vaginally. The cervix was circumcised and the vaginal skin is
reflected. Reflection of the bladder and the anterior peritoneum is demonstrated. The
pouch of Douglas is entered and the sacrouterine ligaments are clamped and ligated.
Uterine arteries are clamped and ligated bilaterally and the uterus extracted vaginally.
The sacrouterine ligaments are fixed together and the vagina is closed in interrupted
sutures
AH arm: the abdominal hysterectomies followed a common technique (Ober andMein-
renken 1964)
Antibiotics: both groups received peri-operative antibiotic prophylaxis with 2 g of
cephalosporin (Ceftriaxon), 15 minutes prior to the operation
Both groups had a pre and postoperative vaginal ultrasound scan. Pre and postoperative
blood tests and measured CRP postoperatively (day 1 and 3)
Postoperative analgesia was piritramid (22 mg ampoule), pentazocin (30 mg ampoule)
and tramadol hydrochloride (100 mg orally)
Outcomes Operating time, pain relief, size of uterus, haemoglobin change, stay in hospital and
complications
Notes Germany
Hospital in Stuttgart
Funding not reported
Paper in German language. Translation was commissioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not defined
70Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kunz 1996 (Continued)
Other bias High risk No exclusion criteria; no power calculation
for sample size. Surgeons’ experience un-
clear
Langebrekke 1996
Methods Multicentre study (n = 2), parallel-group design
Duration: not reported
Randomisation: a table of random digits, numbered 1 to 100
Allocation concealment: sealed envelopes
Blinding: no
Number of women randomised = 100, number analysed = 100. No dropouts or con-
versions
Follow-up: until women returned to work/normal activities. No loss to follow-up
No power calculation for sample size was reported
Participants 100 women. The age of the women was not reported
Inclusion criteria: women with indications for elective hysterectomy
Exclusion criteria: proven or suspected malignancies in the pelvic area, suspected intra-
abdominal adhesions; uterus enlarged beyond the size of a 12-week size pregnancy;
serious cardiopulmonary disease; previous colporrhapy
Interventions AH versus LH (LH(a))
LH(a) arm: a 10 mm laparoscope was inserted through the umbilicus and a general
inspection of the entire pelvic cavity was performed. 2 5 mm trocars were introduced
into the iliac fossae. A 12 mm trocar was placed in the midline 4 cm below the umbilicus
in cases where the automatic stapler endo-GIA was used. Bipolar diathermy or GIA
were used to divide the ligaments. With unipolar scissors, the vesicouterine perineal fold
was cut and the bladder mobilised. The uterine arteries were coagulated with bipolar
diathermy. The vagina was opened laparoscopically with unipolar scissors and the uterus
removed vaginally. The vagina was closed with resorbable sutures from below, the sutures
including the cardinal ligaments. All operations performed exclusively by 2 of the authors
AH arm: according to standard techniques. Abdomen was entered via a Pfannenstiel
incision. The entire abdominal cavity was palpated and the pelvis inspected. The uterine
ligamentswere clamped and ligated.The bladder peritoneumwas opened and the bladder
was mobilised away from the cervix and upper anterior vaginal wall. Uterine vessels were
clamped, cut and ligated. The vagina was closed with resorbable sutures. Performed by
any skilled gynaecologist in the department
Antibiotics: cephalosporin (2 g IV) and lowmolecular heparin (injected subcutaneously)
was given to both groups postoperatively
Surgeons: different group of surgeons for different procedures
Outcomes Operation time; hospital stay; time elapsed before resuming work; postoperative pain;
complications and blood loss
Notes Norway (2 centres)
Aker University Hospital, Oslo, and Akershus central Hospital, Oslo
Funding not reported
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Langebrekke 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random digits
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not defined
Other bias Unclear risk Different group of surgeons for different
procedures
Long 2002
Methods Duration: November 1999 to December 2000 (1 year, 1 month)
Randomisation: randomly assigned to treatment groups. Method not stated
Allocation concealment not reported
Single-centre study, parallel-group design with no blinding
Number of women randomised = 167. Number of dropouts = 13. Number of women
analysed = 101 (women excluded if hysterectomy performed for reasons other than
uterine fibroids of adenomyosis)
Follow-up: until discharged from hospital. No loss to follow-up reported
Power calculation for sample size: no
Intention-to-treat analysis: no
Participants 101 women with a mean age of 45.9 (LAVH group) and 45.5 (TLH group)
Inclusion criteria: indications of uterine fibroids of adenomyosis and contraindications
for VH - uterine weight > 280 g, previous pelvic surgery, history of PID, need for
adnexectomy, lack of uterine descent and limited vaginal access
Criteria for choosing laparoscopic hysterectomy was based on the uterine volume, less
than that of a 16-week pregnancy (700 g)
Exclusion criteria: suitable for a vaginal hysterectomy and the uterine volumewas greater
than a 16-week pregnancy
Interventions LAVH versus TLH (a comparison of 2 LH techniques)
LAVH arm: if the ovaries were to be conserved, the fallopian tubes, round and utero-
ovarian ligament was resected with bipolar forceps and scissors. For adnexectomy, mesos-
alpinx, round and infundibulopelvic ligament were resected. Laparoscopic dissection of
the bladder flap, resection of the broad ligaments, anterior and posterior colpotomies
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were performed. Proceeded vaginally - clamping, transecting and suture ligating of uter-
ine vessels, cardinal and uterosacral ligaments. Closure of peritoneum and vaginal vault
anchored to the cardinal-uterosacral ligament complex after removing uterus
TLH arm: same manner as the LAVH procedure above the uterine artery level. After
dissection of the bladder flap and resection of the broad ligament, the uterine artery
was coagulated by bipolar electrocoagulator and separated from the uterine sidewall
by scissors. Bilateral desiccation and transection of the cardinal-uterosacral ligament
complex. Circular colpotomy was performed close to the cervix and uterus was removed
through the vagina
All operations performed under GA
Surgeons: by the same gynaecologist for each procedure (LAVH by one surgeon and
TLH by another)
Postoperative analgesia included lysine aspirin which was administered intravenously
Antibiotic prophylaxis IV cefazolin 1 g administered pre and postoperatively
Outcomes Operation time, blood loss, hospital stay, cost, complications and sexual symptoms
Notes Taiwan
Kaohsiung Municipal Hsiao Kang Hospital
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 13 dropouts (excluded from analysis after
randomisation because of conversions to
AH (n = 3), incomplete records (n = 7) or
combined surgical procedures (n = 3)). No
further loss to follow-up reported
Selective reporting (reporting bias) Unclear risk Primary outcome not defined
Other bias High risk Analysis not according to intention-to-
treat. Different surgeons for different pro-
cedures
Women were randomised to treatment
groups before a large number (i.e. 66) of
the women were excluded. Therefore, the
women in each treatment group may not
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have been a true representation of the orig-
inal randomised groups
Lumsden 2000
Methods Multicentre (n = 3) study, parallel-group design
Duration: 2 years
Randomisation: performed by the research nurse using a computer-generated schedule
Allocation concealment: by third party (research nurse)
Number of women randomised = 200, number analysed = 190. Dropouts: 7 did not
attend for operation and the case records were not available for a further 3 women
Follow-up: women asked to keep a diary of recovery ’milestones’ and reviewed by the
research nurse 4 weeks after surgery. EuroQol Health Questionnaire completed at 1, 6
and 12 months after surgery. The response rate for the patient questionnaire was 87%
and that for EuroQol was 78%, 64% and 47% at 1, 6 and 12 months, respectively
Power calculation for sample size: yes; 120 patients per arm allowed an 80% chance
of detecting a 15% difference in complication rates at a 5% level using a 2-sided test
Analysis was stated as by intention-to-treat (8women did not have LAVHas randomised
but were analysed in the LAVH group)
Participants 190 women with a mean age of 42.7 years (AH group) and 41.1 (LH group)
Inclusion criteria: scheduled for AH for benign gynaecological disease and they were
not suitable for VH because of a uterine size in excess of 14 weeks or a requirement for
oophorectomy
Exclusion criteria: suitable for VH
Interventions AH versus LH. Operation procedures not reported
Surgeons: performed by 5 consultant gynaecologists who have undertaken a minimum
of 50 LH procedures
Outcomes Length of operation; length of hospital stay; admission to ITU; readmissions; women
requiring additional surgery; blood transfusions; complications (major and minor); pa-
tient-reported outcomes; costs and change in health status
Notes Scotland
3 hospitals in Glasgow
Funding: Scottish Home and Health Department, Scotland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk By third party (research nurse)
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Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 10 dropouts were not analysed. 7 women
did not attend surgery and 3 records were
not available (< 10%) Loss to follow-up: at
12 months only 47% of patients filled out
the questionnaire
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Low risk No other bias identified
Marana 1999
Methods Multicentre study (n = 4), parallel-group design
Duration: October 1995 to November 1996 (1 year, 1 month)
Randomisation: computer-generated sequence
Allocation concealment: not reported
Blinding: no
Number of women randomised 116, number analysed 116. No dropouts
Follow-up: until patient left hospital. Postoperative follow-up included evaluation of
pain on postoperative days 1, 2 and 3, length of postoperative hospital stay and evaluation
of postoperative complications. No loss to follow-up
Power calculation for sample size: yes. The sample sizewas selected todetect a difference
of 25% in total complication rates with a power of 80% at the 5% level of significance,
given a complication rate in the control group of 42%
Participants 116 women with a mean age of 49 years
Inclusion criteria: scheduled for AH for benign disease and had one or more of the
following contraindications to VH: uterine size > 280 g and an upper limit of 16 weeks
gestation (700 g); previous pelvic surgery; history of pelvic inflammatory disease; mod-
erate or severe endometriosis; concomitant adnexal mass or indication for adnexectomy;
and nulliparity with lack of uterine descent and limited vaginal access
Exclusion criteria: suitable for VH
Interventions AH versus LH (LAVH)
LAVH arm: 10 mm laparoscope introduced through the umbilicus, and 3 accessory 5
mm reusable trocars were introduced suprapubically. The pelvis and upper abdomen
were then accurately evaluated, and endometriotic lesions, adhesions or ovarian cysts,
when present, were treated appropriately.When the ovaries were to be conserved, bipolar
forceps and scissors were used to resect the round and uteroovarian ligaments with the
fallopian tubes
For adnexectomy, bipolar forceps and scissors were used to resect the round and in-
fundibulopelvic ligaments, mesosalpinx, and mesovarium. Opening of the bladder flap
was performed at the laparoscopic phase, whereas bladder dissection was performed dur-
ing the vaginal phase. Laparoscopic haemostasis was achieved using exclusively bipolar
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electrocoagulation. The vaginal phase included circular incision of the vagina; bladder
dissection to the laparoscopically opened bladder flap; entry in the posterior cul-de-sac;
and clamping, transecting, and suture ligating of uterosacral ligaments, base of cardinal
ligaments, and uterine vessels. Where necessary, wedge morcellation, coring or bivalving
was performed. Peritoneal closure with pedicles exteriorised and closure of vaginal vault
anchored to the uterosacral and cardinal ligaments concluded the vaginal phase
AH arm: performed according to the technique described by Mattingly and Thompson
Surgeon experience: not reported
Antibiotic prophylaxis: all received intravenous piperacillin 2 g administered 30 min-
utes before surgery
Postoperative medication consisted of the administration of ketorolac by intramuscular
injection or by mouth every 6 hours for the first 24 hours
Outcomes Blood loss; postoperative fever; postoperative pain; length of postoperative hospital stay;
postoperative complications; haemoglobin reduction and intra-operative conversion to
abdominal surgery
Notes Italy
4 university hospitals
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Low risk No other bias identified
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Miskry 2003
Methods 2-centre study, parallel-group design
Duration of trial not stated
Randomisation: computer-generated in blocks of 10
Allocation concealment: sequentially numbered, sealed, opaque envelopes, opened by
nursing staff immediately prior to surgery
Blinding: double-blind until discharge from hospital, maintained by a sham opaque
lower abdominal dressing (unless pyrexia or other complication necessitated direct in-
spection of the abdomen) and vaginal staining with methylene blue in cases undergoing
VH
Number of women randomised = 36, number analysed = 36. No dropouts
Follow-up: follow-up at 6 weeks and 6 months with completion of SF-6 Short Form
general health survey. Loss to follow-up not clearly described
Power calculation for sample size: yes; 36 women required for 80% power to show a
2-day difference in hospital stay at P = 0.05
Participants 36 women with a mean age of 42 years
Inclusion criteria: scheduled for elective hysterectomy
Exclusion criteria: genital tract malignancy; adnexal pathology; uterine size > 14 weeks;
need for concurrent procedure (e.g. vaginal repair, colposuspension); reduced uterine
mobility on VE; inadequate vaginal access
Interventions AH versus VH
Total hysterectomy performed by standard technique for each route. Low transverse
incision, closed with subcuticular absorbable suture, for AH; Heaney technique for VH.
In all cases, concurrent oophorectomy performed if indicated; peritoneal and vaginal
vault closed
Surgeons: performed by most senior surgeon available
All GA plus caudal block for one VH case
Antibiotic prophylaxis co-amoxiclav 1.2 g at induction of anaesthesia. Thrombopro-
phylaxis heparin 5000 units at induction and twice daily until mobile
Outcomes Primary outcome: duration of hospital stay
Secondary outcomes: analgesic requirements; complications; return to normal function
Notes UK
Royal Free and North Middlesex Hospitals
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by computer
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
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Blinding (performance bias and detection
bias)
All outcomes
Low risk Sham abdominal dressing until discharge
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts; loss to follow-up not clearly
described
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were ad-
equately reported
Other bias Low risk No other bias identified
Muzii 2007
Methods Multicentre study, parallel-group design
Duration: January 2005 to December 2005 (1 year)
Randomisation: computer-generated allocation list; in operating room
Allocation concealment: numbered, sealed opaque envelopes
Blinding: no
Number of women eligible: 86. Number of women randomised = 81. There were no
dropouts. Conversions to AH: 2 in LAVH group and 4 in minilaparotomy group
Follow-up: women were followed up until discharge. No loss to follow-up
Power calculation was performed for sample size. Actual sample size was necessary to
detect a difference in complications between the 2 groups of 30% (complication rate
42% in control group) with 80% power with a significance level of 0.05
Intention-to-treat analysis was possible from data but not performed by authors on all
outcomes
Participants 81 women with a mean age of 49 years in the LAVH group and 48 years in the minila-
parotomy group
Inclusion criteria: benign disease: myoma and/or abnormal uterine bleeding with and
without adnexal masses. Contraindication for vaginal hysterectomy
Exclusion criteria: uterine size greater than 700 g on ultrasound, previous midline
incision, absolute contraindication to laparoscopy
Interventions LAVH versus minilaparotomy
LAVH: 4-port technique, laparoscopic dissection with bipolar forceps and scissors of
either round and utero-ovarian ligaments or infundibulo-pelvic ligaments. Opening
bladder flap, followed by vaginal hysterectomy. Uterosacral/cardinal ligament complex
was anchored vaginally to vaginal vault. Laparoscopy at the end of the procedure
Minilaparotomy: Trendelenburg position, 4 cm to 9 cm transverse incision, moving
operative window with 3 retractors. Ligaments cut after electrocoagulation, whereas
vascular pedicles clamped, ligated and cut. Vaginal vault abdominally closedwith running
suture and suspension to uterosacral/cardinal ligament complex
Surgeons: experience not reported
Prophylactic antibiotic treatment: first or second-generation cephalosporin IV
GA for both LAVH and mini-laparotomy
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Outcomes Primary outcome: overall complications
Secondary outcomes: operative time; conversions; haemoglobin drop (day 1); VAS pain
(day 1 and 2); time to return bowel function; hospital stay
Notes Italy
3 university hospitals in Rome
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk Numbered, sealed, opaque envelopes in op-
erating room
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Low risk No other bias identified
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Methods Single-centre, parallel-group design
Duration: not reported
Randomisation: 1:1 ratio. Method not reported
Allocation concealment: sealed, opaque envelopes
Blinding: no
Number of women randomised = 143, number analysed = 143. No dropouts
Follow-up: 4 to 6 weeks after surgery, all patients returned for a gynaecological exam-
ination including vaginal ultrasound. 6 to 8 weeks after surgery patients were asked to
complete an anonymous questionnaire if they considered the duration of their postoper-
ative hospital stay and sick leave to have been adequate. In a subgroup of patients (TLH:
n = 38; AH: n = 38), postoperative health status and quality of life were self assessed
prospectively 1, 3 and 12 weeks after surgery using “The Medical Outcome Trust 36-
item Short-Form Health Survey questionnaire”. Loss to follow-up not described
Power calculation for sample size: yes; assuming a complication probability of 40%
for AH, the power of predicting a difference in complication rate was at least 80% at
the 5% level, 2-sided test, provided that the probability of complications following LH
(a) is at most 18% and at least 64% when 70 patients are included in each group
Participants 143 women with median age 48 years
Inclusion criteria: scheduled for AH for benign disorders, with a maximum uterine
width of less than 11 cm and not considered suitable for VH
Exclusion criteria: suitable for VH (adnexa are not to be removed; no suspicion of
endometriosis or post-inflammatory disorders, when uterine size is normal, or in the case
of uterovaginal prolapse, less than the size of an 8-week pregnancy)
Interventions AH versus LH (LH(a))
LH(a) arm: all patients were prescribed a second-generation cephalosporin as well as
metronidazole intravenously during the operation and by oral administration for 2 days
after surgery. Ureters were identified, where this was difficult, the ureters were dissected
free down to the level of the uterine arteries. If the adnexa were to be removed, the
infundibulopelvic ligaments were transected by diathermal cautery and monopolar scis-
sors. If the adnexa were to be conserved the utero-ovarian pedicles were transected on
both sides, using the same instruments. The round ligaments and the upper portion of
the broad ligaments were divided using monopolar scissors and the bladder was dissected
to the level just below the vaginal cuff. The posterior part of the broad ligaments were di-
vided by scissors close to the uterus, down to the upper part of the uterosacral ligaments,
which were then transected. The uterine arteries were transected close to the uterus after
bipolar coagulation. The upper portion of the cardinal ligaments were divided close to
the uterus, after which an incision was made into the anterior fornix of the vagina. The
vaginal phase: vaginal epithelium surrounding the cervix was transected as well as any
residual tissue from the cardinal and uterosacral ligaments. The transected ligaments
were ligated together and incorporated into the vaginal wall
AH arm: antibiotics were not routinely prescribed in this group of patients. They under-
went either a lower midline or Pfannenstiel incision. If the adnexa were to be removed,
the infundibulopelvic ligaments were clamped, transected and ligated. In cases where the
adnexa were not to be removed, the utero-ovarian pedicles were transected and ligated.
The anterior broad ligaments were divided down to the vesico-vaginal junction and the
bladder reflected to just below the vaginal cuff. The uterine vessels were divided close to
the uterus. Following division of the cardinal and uterosacral ligaments, the uterus was
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excised. The vaginal cuff was closed with interrupted sutures and the peritoneal layers
closed and attached to the top of vagina
Surgeons: 2 out of 5 surgeons of senior registrar grade and specifically trained in LH(a)
. 2 out of 10 surgeons of senior registrar grade trained in AH
Outcomes Operating time (minutes); complications; postoperative pain relief; convalescence (sick
leave); hospital stay; quality of life; economic analysis (cost)
Notes Sweden
University Hospital of Sahlgrenska
Funding: Goteborg Medical Society Fund, Swedish Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts; loss to follow-up unknown
Selective reporting (reporting bias) Low risk Primary outcomes clearly defined and re-
ported
Other bias Low risk No other bias identified
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Methods Single-centre study, parallel-group design
Duration: January 1996 to May 1998 (2 years, 5 months)
Randomisation: computer-generated numbers. Randomly allocated to one of 3 oper-
ating methods in 4 blocks of 30 to ensure a balanced number of patients throughout
study period. Interim analysis done after 25 patients were randomised to each group
Allocation concealment: sealed, opaque envelopes prepared by and successively opened
by the research nurse
Blinding: no
Number of women randomised = 120, number analysed = 120. No dropouts
Follow-up: 2 weeks postoperatively in outpatient clinic for examination to detect com-
plications and evaluate need for further sick leave. No loss to follow-up
Power calculation for sample size: yes; sample size based on reported hospital stay for
vaginal and abdominal hysterectomy of 2.3 and 4 days, respectively. If 1.5 is the SD for
hospital stay, 40 women were randomised to achieve a power of 80% at alpha = 0.05
Intention-to-treat analysis: yes
Participants 120 women with a mean age of 47 years (AH group), 49 years (VH group) and 48 years
(LAVH group)
Inclusion criteria: scheduled for hysterectomy for anticipated benign causes. Inclusion:
menorrhagia, leiomyomas < 15 cm in diameter, dysplasia, endometrial atypia and pain
Exclusion criteria: ovarian pathology, uterus larger than 16 weeks of gestational size,
previously known dense adhesions, narrow vagina or obvious inaccessible uterus
Interventions AH versus VH versus LH (LAVH) - 3 treatment arms
LAVH arm: the laparoscopic part was minimised. Trocars were left in place and after
closing the vaginal wall the surgeon returned to laparoscopic view to confirmhaemostasis.
The surgery was performed under GA in 109/120 cases, spinal block in 3/120 or in
combination with epidural block in 8/120 cases
AH arm: the abdomen was opened and closed in different ways according to surgeon
preference. The uterus was removed by extrafascial technique and the vagina closed and
covered by peritoneum
VH arm: the vault was injected with 20 ml of mepivacain/adrenalin before incision in
order to minimise bleeding. The peritoneal folds were opened and ligaments and uterine
vessels were divided. If at this time the uterine size did not allow easy exteriorisation,
bisecting, coring, morcellation, enucleation or combinations of these volume-reducing
techniques were performed. The peritoneum was closed, followed by suturing of the
sacrouterine ligaments and vaginal vault
Surgeons: 1 of 15 gynaecological surgeons, experience varied and in some cases residents
performed under supervision
Antibiotics: all patients had at least 1 dose of prophylactic antibiotic peri-operatively:
cefuroxime 1.5 g intravenously and metronidazole 1 g rectally. A daily dose of exoxaparin
20 mg subcutaneously was given as thrombotic prophylaxis through the hospital stay
Outcomes Duration of surgery, duration of anaesthesia, stay in hospital, recovery time, peri-oper-
ative blood loss and complications
Notes Sweden
Hospital of Helsingborg
Funding: Thelma Zoegas Foundation and the Stig and Ragna Gorthons Foundation,
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Sweden
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by computer
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Low risk Primary outcome defined
Other bias Low risk No other bias; no differences between the
3 groups regarding patients’ characteristics.
Surgeons’ experience varied
Paraiso 2013
Methods Multicentre study (2 institutions)
Duration: June 2007 to March 2011 (45 months)
Randomisation: stratified by surgeon and uterine size (> or </= 12 weeks). Participants
were assigned randomly according to a computer-generated randomisation schedule with
random block sizes
Allocation concealment: not described
Blinding: yes; patients were blinded to their assessment
Number of women: randomised = 75 women. In both arms 6 cases dropped out before
the intervention was performed
Follow-up: no loss to follow-up
Power calculation for sample size: yes, 23 participants per arm were needed to detect
a difference of >/= 30 minutes in operating time between conventional versus robotic-
assisted TLH with 90% power and a significance level of 0.05
Intention-to-treat analysis applied (converted procedures analysed in original allocated
arm)
Participants 53 women with a mean age of 45.6 and 43.8 respectively
Inclusion criteria: >/= 18 years old, hysterectomy for benign conditions
Exclusion criteria: suspected malignancy, medical illness that precluded laparoscopy,
inability to give informed consent, morbid obesity (BMI > 44), or need for concomitant
bowel resection
83Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Paraiso 2013 (Continued)
Interventions TLH and robotic-assisted TLH
Conventional: 4 ports
Robotic-assisted: performed with the Da Vinci Surgical System with an umbilical port
for laparoscopic camera, one 10/12 mm port placed in the right of left subcostal area
lateral to the rectus for suture introduction, 2 8 mm robotic ports placed in the bilateral
lower quadrants and one 5 mm port 8 cm inferior to right or left subcostal margin
The technique to perform the hysterectomy was performed in both arms in a standard
fashion, with the entirety of the hysterectomy performed laparoscopically
Surgeons: 5 experienced laparoscopists: 75 to 400 LH and at least 20 RH
Outcomes Primary outcomes: total case time from incision to closure
Secondary outcomes: intra- and postoperative complications, the impact of surgery on
daily living and narcotic use for 6 weeks
Notes USA
Cleveland Clinic
Supported by a grant from theClevelandClinicCenter for Surgical Innovation, Teaching
and Education
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by surgeon
and uterine size (> or </= 12 weeks). Par-
ticipants were assigned randomly accord-
ing to a computer-generated randomisa-
tion schedule with random block sizes
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients blinded to their assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up. In both arms 6 cases
dropped out before the intervention was
performed
Selective reporting (reporting bias) Low risk No reporting bias identified
Other bias Low risk No other bias. Stratified by surgeon and
uterine size
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Methods Single-centre study, parallel-group design
Duration: January 1997 to 30 September 1998 (1 year, 9 months)
Randomisation: method not stated and allocation concealment not reported
Allocation concealment: not reported
Blinding: no
Number of women randomised = 102, number analysed = 102. No dropouts
Follow-up: until women were discharged from hospital. Postoperative pain was assessed
3 days after surgery. No loss to follow-up
Power calculation for sample size: no
Participants 102 women with a mean age of 48 years
Inclusion criteria: scheduled for hysterectomy for benign diseases
Exclusion criteria: not stated
Interventions AH versus LH (TLH)
TLH arm: after a CO2 pneumoperitoneum was created, a 10 mm trocar was placed in
the umbilical site to introduce the laparoscope and the camera. 3 ancillary 5 m trocars
were placed suprapubically. After an abdominal inspection, lysis of any adhesions was
performed, the uterus was thenmobilised. After bipolar coagulation, the round ligament
was sectioned at 3 cm from the uterus. The areolar tissue of the broad ligament was
then dissected and its posterior fold fenestrated at an avascular area above the uterine
vessels. The infundibulo-pelvic ligament vessels were coagulated and cut using bipolar
forceps and scissors under direct visualisation of the pelvic ureter. Once the uterine lig-
aments were sectioned, the operation continued centrally in a downward direction. If
the adnexae were not to be removed, the utero-ovarian ligament was coagulated and sec-
tioned proximal to the ovaries. The vesico-uterine peritoneal fold was opened by scissors
and a bladder dissection from the low uterine segment down to the upper part of the
vagina was performed. The utero-sacral ligaments were then coagulated and sectioned.
The uterine artery was skeletonised and then coagulated with bipolar forceps and cut
with scissors. Incision and coagulation of the cardinal ligaments to expose the vaginal
fornices, separated from the stump of the uterine artery. Circular colpotomy was then
performed and the uterus was removed from the vagina. The vaginal vault was then
sutured laparoscopically or vaginally
AH arm: performed according to the technique described for benign disease (Mattingly
and Thompson)
Intravenous pain relief was given postoperatively
Surgeons: all operations performed by the same team of 3 surgeons with experience of
100+ TLH procedures
Outcomes Operating time; blood loss; postoperative pain; postoperative decrease in haemoglobin;
complications and duration of postoperative hospital stay
Notes Italy
Gynaecologic University Hospital of Palermo
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not defined
Other bias Low risk No power calculation reported, no other
bias identified
Persson 2006
Methods Multicentre study, parallel-group design
Duration: October 1996 to May 2003 (5 years, 6 months)
Randomisation: block randomisation (according random table)
Allocation concealment: sealed, opaque envelopes
Number of women eligible = 1360, and randomised = 125. 1 dropout: withdrew before
consent. In the LH group, there were 3 intra-operative conversions to AH
Follow-up: women were followed up until 6 months after surgery. 5 lost to follow-up: in
the LH group 1 woman withdrew consent before the 5 weeks follow-up, and 4 women
withdrew consent before the 5 weeks follow-up
Power calculation for sample size: 60 patients per group were necessary to detect a
difference between the 2 groups of 10 units or more on the PGWB with 90% power, a
significance level of 0.05 and a dropout rate of 20%
Analysis was byintention-to-treat
Participants 119 women with a mean age of 44 years in both groups
Inclusion criteria: women with benign disease, LH was feasible, fluent in Swedish
Exclusion criteria: genital tract malignancy, pre-operative GnRH analogues, post-
menopausal women without HRT, psychiatric disorders
Interventions AH versus LH(a)
AH: performed by Pfannenstiel incision and according to the extrafascial technique
LH were LH(a) procedures: with a 3-port technique. Parametrium and uterine
artery were sealed laparoscopically with bipolar coagulation or stapling. Cardinal and
uterosacral ligaments as well as suturing of vaginal cuff vaginally. In both procedures the
vaginal cuff was anchored to the uterosacral ligaments without peritonealisation
Antibiotics: both groups received prophylactic antibiotic treatment (cefuroxime 1.5 g
and metronidazole 1 g IV)
Surgeon experience: (supervising) surgeons were skilled and experienced
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Outcomes Primary outcome: psychological well being (questionnaires PGWB)
Secondary outcomes: questionnairesWHQ, STAI, BDI; operative time; complications,
conversions to AH; hospital stay; return to normal activities
Notes Sweden
2 county hospitals, 2 central hospitals and 1 university hospital in the southeast
Funding: grants from the Medical Research Council of South East Sweden
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk According to random table
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 dropout after randomisation and 5 lost
to follow-up were not analysed (1 LH and
5 AH group), i.e. < 5%. It is not clear how
many women were lost to follow-up after
6 months
Selective reporting (reporting bias) Low risk Primary outcome predefined
Other bias Unclear risk Only 9% of eligible patients were ran-
domised
Raju 1994
Methods Single-centre study, parallel-group design
Duration: March 1992 to October 1993 (1 year, 8 months)
Randomisation: containing computer-generated block randomisation numbers. Block
size of 10
Allocation concealment: sealed envelopes
Blinding: no
Number of women randomised = 80, number analysed = 80. No dropouts
Follow-up: 6 weeks after surgery and until women return to work. No loss to follow-up
Power calculation for sample size: yes, 40 patients in each armwere estimated to detect
a 25% difference in morbidity between the groups, with a power of 90% at the 5% level
Participants 80 women with a mean age of 46 years
Inclusion criteria: scheduled for hysterectomy and bilateral oophorectomy for benign
conditions
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Exclusion criteria: morbid obesity, uterus larger than 14 weeks gestation size or
uterovaginal prolapse
Interventions AH + BSO versus LH (LAVH) + BSO
LAVH + BSO arm: 5.5 mm flap-valved trocars were inserted enabling the insertion of
laparoscopic instruments. 12 mm trocar and cannula were introduced suprapubically
in the midline 3 cm above the upper border of the symphysis pubis as a port for the
use of the Autosuture Multifire Endo GIA 30 stapling device.The cervix was grasped
with a vulsellum and a broad-ended blunt uterine curette was inserted to manipulate the
uterus from the perineal end. Any adhesions between the uterus or adnexae to adjacent
structures were divided with scissors after diathermy coagulation. Both round ligaments
were treated with diathermy and cut with scissors approximately 3 cm from the internal
inguinal ring whilst holding the ligament with a grasping forceps. The peritoneum of
the anterior leaf of the broad ligament was dissected from the divided round ligament
back towards the infundibulo-pelvic ligament thus opening the tissue space between the
2 folds of broad ligament. The posterior leaf of the broad ligament was then pierced
with endoshears to make a window, a safe distance above the ureter which had been
previously identified. The ovarian pedicle was then sized for thickness of tissue by means
of a GIA endo gauge inserted through the midline suprapubic incision. The correct
size of endo stapling clamp was selected. The ovarian pedicle was clamped and cut
with the appropriate GIA endo stapling device, placed from the upper border of the
infundibulo-pelvic ligament and with the jaws of the stapler passing well through the
peritoneal window in the broad ligament. By using this technique each ovarian pedicle
required only one firing of the GIA stapler to divide it. Finally the uterovesical fold
of the peritoneum was divided with scissors and sometimes the uterosacral ligaments
were divided after diathermy coagulation. The uterus, tubes and both ovaries were then
removed vaginally after circumcising the cervix and opening the pouch of Douglas to
allow ligation and division of the cardinal ligaments and uterine vessels as in a traditional
vaginal hysterectomy. The vaginal vault was anchored to the cardinal ligaments and
closed with interrupted sutures
AH+BSO arm: procedures were performed using a standard technique
Operationswere performed by one of the authors or by another surgeon of senior registrar
grade
Surgeons: operations performed by one of the authors. Experience unknown
Premedication: temazepam20mg, 2 hours before operation. GA induced with thiopen-
tone and maintained with enflurane and nitrous oxide. Under anaesthesia a bolus in-
travenous injection of amoxicillin clavulanate (Augmentin) 1.2 g was given. Antibiotic
therapy continued for 7 days postoperatively
Outcomes Operating time, blood loss, haemoglobin change, hospital stay, postoperative analgesia,
complications, recovery time (subjective assessment of patient’s general well being and
return to normal activity) and cost
Notes UK
St Thomas’s Hospital, London
Funding not reported
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by computer
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Insufficient information available
Other bias Low risk No other bias reported. Surgeon’s experi-
ence unknown, but all surgeries performed
by 1 surgeon
Ribeiro 2003
Methods Single-centre study, parallel-group design
Duration: not reported
Randomisation: method not stated
Allocation concealment: not reported
Blinding: no
Number of women randomised = 60, number analysed = 60. No dropouts
Follow-up: routinely up to 6 days. No loss to follow-up
Power calculation for sample size: no
Participants 60 women with an overall mean age of 42.3 years (range 34 to 76 years)
Inclusion criteria: benign uterine disease: myoma n = 41; adenomyosis n = 19
Exclusion criteria: uterine volume greater than 400 ml; use of any anti-inflammatory
medication during preceding 3 months; diabetes mellitus; coagulation disorders; au-
toimmune diseases
Interventions AH versus VH versus LH (TLH)
AH: by Thompson and Warshaw technique
VH: by Heaney’s technique
LH (TLH): 10 mm laparoscope inserted at umbilicus, 2 5 mm secondary ports for
laparoscopic instruments. Uterine mobiliser with blunt tip used to antevert uterus and
delineate vaginal fornices. Round ligaments divided with monopolar forceps and vesico-
uterine fold divided with scissors and bladder mobilised until anterior vagina identified.
Utero-ovarian ligament and fallopian tube pedicles desiccated with bipolar forceps, then
scissors division of broad ligament peritoneum. Uterine artery grasped, elevated and
bipolar coagulated. Cardinal and uterosacral ligaments divided with monopolar forceps.
Vagina entered posteriorly near cervico-vaginal junction. 4 cm vaginal delineator out-
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lined circumferentially the cervico-vaginal junction and prevented loss of pneumoperi-
toneum. Monopolar forceps completed the circumferential culdotomy. Uterus removed
vaginally (after morcellation if necessary). Laparoscopic vaginal vault interrupted sutur-
ing and suspended by suture attachment to uterosacral/cardinal pedicles, sutures being
tied extracorporally
Surgeon experience: not reported
Antibiotic and thrombo prophylaxis not specified
Outcomes Operative time; pre and postoperative haemoglobin; complications
Notes Brazil
Sao Paulo University School of Medicine Hospital
Funding: Foundation of Research Support from Sao Paulo State
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not clearly defined
Other bias Low risk No other bias identified
Richardson 1995
Methods Single-centre study, parallel-group design
Duration: not reported
Randomisation: random numbers table
Allocation concealment: not reported
Blinding: no
Number of women randomised = 45, number analysed = 45. No dropouts
Follow-up: 6 to 8 weeks after surgery, women completed a questionnaire on their re-
covery. All kept a prospective diary of their recovery for 6 weeks. No loss to follow-up
Power calculation for sample size: no
Participants 45 women with a mean age of 41 years (LH group) and 45 years (VH group)
Inclusion criteria: contraindications for vaginal surgery according to traditional criteria
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(absence of vaginal prolapse, nulliparity, uterine enlargement, previous pelvic surgery
endometriosis and need for oophorectomy)
Exclusion criteria: uterine size greater than the equivalent of 16 weeks’ gestation, en-
dometrial carcinoma, adnexal masses, known dense pelvic adhesions, or moderate/severe
endometriosis
Interventions VH versus LH
LH arm: the laparoscope was inserted sub-umbilical incision, and usually 2 5 mm sec-
ondary portals were used for the laparoscopic instruments. Surgery was performed under
the guidance of the image generated by a Supercam 9050 PB video chip camera at-
tached to a 30 degree forward oblique laparoscope. The principal method of haemostasis
was bipolar electrosurgical desiccation but Endo-GIA 30 linear staplers were used in 8
women. In 1 woman VH was done after diagnostic laparoscopy (stage 0 VH) and in
2 VH was carried out after laparoscopic adhesiolysis had made this possible (stage 1
LH). When the ovaries were conserved, bipolar diathermy was used medially to des-
iccate the round and ovarian ligaments, and the fallopian tube. The approach to the
ovarian pedicle during oophorectomy depended on whether the uterine vessels were to
be divided laparoscopically or vaginally. If divided vaginally, the ovarian vessels were
coagulated and divided but not the round ligaments. Dissection then proceeded towards
the uterine origin of the round ligament, after which the hysterectomy was completed
vaginally (stage 2 LH) or after laparoscopic mobilisation of the bladder (stage 3 LH). If
the uterine vessels were treated laparoscopically (stage 4 LH), the round ligaments were
always divided, together with the ovarian vessels and fallopian tubes, and the dissection
continued to the level of the uterine arteries which were then desiccated and cut close to
the uterus. Laparoscopic dissection only continued further than the uterine artery in 3
cases (stage 5 LH), all other procedures being completed vaginally
VH arm: modified Heaney approach
Surgeon experience: not reported
Outcomes Operating time; analgesia required; hospital stay; recovery time and postoperative com-
plications
Notes UK
Royal Free Hospital, London
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not defined; insufficient
information available
Other bias Low risk No other bias identified
Roy 2011
Methods Duration: April 2007 to June 2009 (2 years, 1 month)
Randomisation and allocation: not reported
Blinding: no. Randomisationwas revealed to the surgeon before induction of anaesthesia
Follow-up: at 1, 3 and 6 months. 9 patients were lost to follow-up and were not analysed
and reported because they needed adenectomy or did not return for follow-up
Power calculation for sample size: yes was calculated using operative time as a primary
outcome. With a type I error of 0.05 and a power of 80%, a sample size of 30 women
in each arm was required
No intention-to-treat analysis
Participants 90 women with a mean age of 41.9 in the TLH group, 43.4 in the LAVH group and
43.7 in the NDVH group
Inclusion: benign pathology of uterus and not amenable to or failed medical therapy
Exclusion: malignancy, PID, uterovaginal descent greater that first degree. Patients with
contraindication for laparoscopy
Interventions TLH versus LAVH versus non-descent VH (NDVH)
TLH: 4 ports were made. A 10 mm umbilical port for laparoscope, 2 ports of 5 mm, 1
extra 10 mm port. All pedicles were coagulated and transected laparoscopically. Adnexa
were preserved. The uterus was cut at the vault laparoscopically. Uterus was delivered
vaginally and vault was sutured laparoscopically
LAVH: the laparoscopic part included coagulation and transection of round ligament,
ovarian ligament and medial end of tube followed by dissection of bladder peritoneum.
The procedure was then completed vaginally: uterosacrale ligaments, cardinal ligaments
anduterine vesselswere ligated and transected.The uteruswas extracted vaginally. Vaginal
cuff sutured
NDVH: incision was made in cervico-vesical junction anteriorly. Bladder was pushed
anteriorly and pouch of Douglas opened posteriorly. Uterosacral ligaments, Macken-
rodt ligament, uterine vessels followed by round and ovarian ligament were clamped,
transected. In cases of large uteri, bisection of the specimen or myomectomy was done.
Vaginal cuff was sutured
Surgeons: all procedures were performed by the same surgeon. Experience not reported
Outcomes Intra- and postoperative parameters
Primary outcomes: total duration of surgery and blood loss
Secondary outcomes: postoperative pain, febrile morbidity, infection, total duration of
hospital stay, satisfaction (HRQOL and SF-12) and sexual dysfunction (self developed
questionnaire)
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Notes India
All India institute, New Delhi
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Randomisation was revealed to surgeon
just before induction of anaesthesia. Blind-
ing of patients or researchers not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Nodropouts. Loss to follow-up reported (n
= 9; i.e. 10%)
Selective reporting (reporting bias) Low risk Patients who also underwent adnexal re-
moval were excluded to minimise bias
Other bias Low risk No other bias identified
Roy 2012
Methods Single tertiary centre
Duration: April 2008 to June 2010 (2 years, 1 month)
Randomisation: computer-based
Allocation procedure: not reported
Number of patients randomised = 23, number of patients analysed = 20. 3 dropouts:
serum interleukin level could not be processed in 1 patient from each group; 1 patient
had conversion to mini-laparotomy
Blinding: not reported
Analysis by intention-to-treat: no; 1 conversion in the LAVH group was taken out of
analysis and was not further reported
Follow-up: no loss to follow-up
Power calculation for sample size: to detect a difference of 1 standard deviation between
interleukin level of the 2 groups of hysterectomy for a uterine size >/= 12 weeks, with
type 1 error of 0.01 and a power of 80%, we calculated that 10 women needed to be
operated in each group
Participants 20 women with a mean age of 41.6 years in the LAVH group and 43 years in the NDVH
group
Inclusion criteria: women with benign pathology of uterus who had estimated uterine
weight between 300 g and 1500 g and were planned for hysterectomy
Exclusion criteria: genital malignancy, acute pelvic inflammatory disease, utero-vaginal
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descent greater than first degree and any contraindications for laparoscopy
Interventions Laparoscopic-assisted vaginal hysterectomy (LAVH) versus non-descent vaginal hysterec-
tomy (NDVH)
LAVH: 4 ports weremade. A 10mmport was placed at umbilicus for laparoscope. 3 other
ports were placed in the lowed abdomen. The laparoscopic part included coagulation and
transectionof round ligament and transection of bladder peritoneum.Whenpreservation
of adnexa was needed, the fallopian tube and ovarian ligament were coagulated and
transected. In cases where salpingo-oophorectomy was needed, the infundibulopelvic
ligamentwas isolated, coagulated and transected.The procedurewas completed vaginally.
The anterior and posterior cul-de-sac were opened. The cardinal ligaments, uterosacral
ligaments and the uterine vessels were ligated and transected. The uterus was extracted
vaginally. Vaginal cuff was closed
NDVH: incision was made in cervico-vesical junction anteriorly. Bladder was pushed
anteriorly and pouch of Douglas opened posteriorly. The uterosacral ligaments, cardinal
ligaments, uterine vessels followed by round and ovarian ligaments were clamped, cut
and ligated. After clamping uterine arteries, uterus was bisected and myomectomy done
to reduce the bulk of the uterus. Vaginal cuff was closed
Surgeons: all procedures performed by the same surgeon. Experience not reported
Antibiotic and thrombo prophylaxis not specified
Outcomes Primary: venous blood levels of IL-6 preoperatively and 3, 24 and 72 hours after surgery
Secondary: blood loss, operating time, postoperative analgesia requirement, hospital
stay and morbidity
Notes India
All India institute, New Delhi
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation: computer-based, but not
further specified
Allocation concealment (selection bias) Unclear risk Allocation procedure not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts: n = 3, i.e. 15%. No loss to fol-
low-up
Selective reporting (reporting bias) Unclear risk Since the study focused mainly on tissue
trauma, 1 patient who underwent a con-
version to mini-laparotomy was excluded
from the final analysis
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Other bias Unclear risk Analysis by intention-to-treat: not reported
Sarlos 2012
Methods Single-centre
Duration: 2008 to 2011 (3 years)
Randomisation: the randomisation scheme was generated by using the website www.
randomization.com
Allocation concealment: not reported
Blinding: patients could not be blinded because the robot surgery took place in another
building
Number of women: 100 patients randomised; 95 completed the study
Follow-up: loss to follow-up not described
Power calculation for sample size: not performed
Analysis by intention-to-treat
Participants 95 patients with a mean age of 45.8 years in the conventional group and 46.3 years in
the robot-assisted group
Inclusion criteria: indication for hysterectomy because of benign lesions if vaginal hys-
terectomy was expected to be difficult because of myomas or nulliparity. Uterus weight
less than 500 g
Exclusion criteria: not reported
Interventions Robot-assisted LH versus conventional LH
RALH: a 3-armed daVinci standard surgical robot was used
cLH: a 10 mm optical port and 3 5 mm working trocars were used
Both procedures performed according the same standard operating procedure
Antibiotic prophylaxis: cefazoline 2 g
Surgeons: 2 senior gynaecologists experienced in laparoscopic surgery, performing at
least 50 laparoscopic LH and 30 RH per year. The surgical team consisted of a console
surgeon, a bedside assistant and a surgical nurse
No conversions to laparotomy
Outcomes Primary outcomes: surgical outcome (time to hospital discharge) and quality of life
Notes Switzerland
Cantonal Hospital, Aarau
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation scheme was generated
by using the website www.randomization.
com
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Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Patients could not be blinded because the
robot surgery took place in another build-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropout. Follow-up not described
Selective reporting (reporting bias) Low risk Primary and secondary outcomes prede-
fined and reported as such
Other bias Low risk No other bias identified
Schutz 2002
Methods Single-centre study, parallel-group design
Duration: August 1995 to December 1997 (2 years, 4 months)
Randomisation: computer-generated randomisation list
Allocation concealment: concealment by telephone inquiry
Blinding: no
Number of women randomised = 48, number analysed = 48. No dropouts
Follow-up: following discharge from hospital the women received a self administered
questionnaire to evaluate their recuperation over a period of 12 months. 35 women (72.
9%) answered the questionnaire, 20 of 28 (71.4%) in the LAVH group and 15 of 20
(75%) in the AH group
Power calculation for sample size: yes
Participants 48 women with median age of 48 years
Inclusion criteria: sonographically estimated uterine weight > 200 g and patient has no
preference for either surgical technique
Exclusion criteria: not stated
Interventions AH versus LH (LH(a))
LH(a) arm: either type I or II procedure. Type I: the laparoscopic part included coagu-
lation and transection of the round ligament and transection of the bladder peritoneum.
If the adnexa was desired, the fallopian tube and the ovarian ligament were coagulated
and transected. Where salpingo-oophorectomy was needed, the infundibulo-pelvic liga-
ment was isolated, coagulated and transected following visualisation of the ureter. Type
II: the uterine artery was identified at its origin when branching off the internal iliac
artery. The identification was made coming from either the internal umbilical ligament
or the pararectal fossa. Prior to coagulation of the uterine artery, the ureter was identified
and pushed medially. After coagulation, it was left to the discretion of the surgeon to
transect the uterine artery. The uterus was mobilised by pulling on the transected round
ligaments and no intrauterine probes were applied for mobilisation of the uterus
71.4% operations performed by attending physician, 28.6% by resident assisted by
physician
AH arm: followed the standard extrafascial technique. A Balfour retractor was used and
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the skin incision was stapled
Surgeons: 40% performed by physician and 60% by resident assisted by physician
Outcomes Primary outcome: length of stay in hospital
Secondary outcomes: operating time; postoperative pain; blood loss and recovery time
until return to full work activity
Notes Germany
Friedrich Schiller University, Jena
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk Telephone inquiry
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk No dropouts; loss to follow-up: 75% and
78% (i.e. > 15% loss to follow-up), respec-
tively, answered the questionnaire after 12
months
Selective reporting (reporting bias) Low risk No reporting bias identified
Other bias Unclear risk Surgeons’ experience was not clear
Seracchioli 2002
Methods Single-centre study, parallel-group design
Duration: January 1997 to January 2001 (4 years)
Randomisation: computer-generated randomisation unknown to the surgeons
Allocation concealment: not mentioned
Blinding: no
Number of women randomised = 122, 122 analysed. No dropouts reported
Follow-up: telephone interviews 2 months after discharge to determine the number of
days before going back to normal activities. No loss to follow-up
Power calculation for sample size: no
Participants 122 women with a mean age of 46.3 (LH(a) group) and 47.3 (AH group)
Inclusion criteria: eligible for AH due to a large uterus (> 14 weeks) caused by my-
omas. Uterine weight > 300 g, determined by a pelvic examination and transvaginal
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ultrasonography
Exclusion criteria: uterus projecting above the transverse umbilical line and with other
pelvic pathologies (prolapse, pelvic floor relaxation, stress incontinence and adnexal
masses).Medical conditions that require hospital monitoring, e.g. diabetes, heart disease,
if they had undergone previous abdominal surgery requiring longitudinal laparotomy or
contraindications to operative laparoscopy
Interventions AH versus LH (LH(a))
LH(a) arm: 10 mm cannula placed in the umbilical site to introduce the laparoscope
and camera. 2 5 mm suprapubic access routes were inserted lateral to deep inferior
epigastric arteries. A third cannula was inserted between the umbilicus and xiphoid.
Round ligaments, fallopian tubes and utero-ovarian ligaments (or infundibulopelvic
ligaments if the ovaries were to be removed) were coagulated and sectioned. Uterine
peritoneal fold was opened with scissors, dissecting the bladder off the lower uterine
segment and cervix. Incision of the fornix, extended laterally, stopping close to uterine
vessels. Uterine pedicles skeletonised, coagulated and sectioned. Parametrial tissues were
coagulated and sectioned so the uterus is free to be removed vaginally. Vaginal vault was
sutured vaginally with the cardinal-uterosacral ligaments
Antibiotic prophylaxis: ampicillin 2 g
Surgeons: all surgical procedures were performed by the same investigators under GA.
Experience not reported
Outcomes Operating time, laparo-conversions, blood loss, haemoglobin drop, fever, transfusions,
hospital stay and convalescence
Notes Italy
S Orsola Hospital, University of Bologna
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Allocation reported as “unknown to sur-
geons”
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not defined
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Other bias Low risk No other bias identified
Sesti 2008a
Methods Single-centre study, 3 parallel-groups
Duration: May 2005 to September 2007 (2 years, 4 months)
Randomisation: computer-generated list
Allocation concealment: serially numbered, opaque, sealed envelopes
Blinding: patients were not blinded. Those performing the surgical procedures did not
know which patients had been included in the study and those assessing the outcomes
were blinded to the group assignment
Number of women eligible 189, number of women randomised 150. There were no
dropouts
Follow-up: no loss to follow-up
Power calculation for sample size: yes, 36 patients in each group were necessary to
detect a difference of more than 24 hours in discharge time with an alpha error level of
5% and a beta error of 80%
Analysis was by intention-to-treat (no conversions)
Participants 50 women in the VH group (mean age 47.8 years)
50 women in the LAVH group (mean age 49.0 years)
50 women in the mini-laparotomy (mini-LPT) group (mean age 47.7 years)
Inclusion criteria: symptomatic or rapidly growing myomas, age less than 55 years and
uterine size greater than or equal to 12 weeks of gestation
Exclusion criteria: nulliparous women, uterine size greater than or equal to 16 weeks,
previous uterine surgery and suspicion of malignant gynaecological disease
Interventions VH versus LAVH versus mini-LPT
VH: as described byDargent in 2004. If the uterine size did not allow easy exteriorisation,
bisecting, coring,morcellation, enucleation ofmyomas or combinations of these volume-
reducing techniques were performed
LAVH: type ID (dissection up to but not including uterine arteries plus anterior struc-
tures, and posterior culdotomy) according to the AAGL Classification System for La-
paroscopic Hysterectomy
Mini-LPT: performed using a 4 cm to 7 cm suprapubic incision. The subcutaneous
fat and the abdominal fascia were transversely opened 2 cm above the skin incision.
The abdominal muscle and the parietal peritoneum were longitudinally opened on the
midline
Antibiotics: all patients received intraoperative prophylactic antibiotic therapy (ampi-
cillin sodium/sulbactam sodium combination 2 g). Intravenous pain relief was given
postoperatively
Surgeons: all procedures were performed by 2 equally skilled and experienced surgeons
using identical techniques
Outcomes Primary outcome: difference in hospital discharge time (measured in hours) among the
3 procedures
Secondary outcomes: operating time, blood loss, paralytic ileus time, intraoperative
complications, febrile morbidity, intensity of postoperative pain and early postoperative
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complications
Notes Italy
Tor Vergata University Hospital, Rome
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Those assessing the outcomes were blinded
to the group assignment; patients were not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Low risk Primary and secondary outcomes (pre)de-
fined and accordingly reported
Other bias Low risk Procedures were performed by 2 equally
skilled and experienced surgeons using
identical techniques
Sesti 2008b
Methods Single-centre study, parallel-group design
Duration: April 2003 to June 2005 (2 years, 2 months)
Randomisation: numbered, sealed, opaque envelopes based on a computer-generated
list
Blinding: those who performed surgical procedures did not know which patients un-
dergoing surgery had been included in the study. Those assessing the outcomes were
blinded to the group assignments
Number of women eligible = 89; 9 women refused to participate and 80 patients were
included (40 in each group). There were no conversions or dropouts
Follow-up: women were followed up until 30 days after surgery. No loss to follow-up
Power calculation for sample size: yes, at least 26 patients in each group were necessary
to detect a difference of more than 24 hours in discharge time with a significance level
of 0.05% and a power of 80%
Participants 80 women with a mean age of 49 years in the VH group and 48 years in the LAVH
group
Inclusion criteria: symptomatic or rapidly growing myomas, age < 55 years, uterine size
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at least 12 weeks gestation
Exclusion criteria: nulliparous women, uterine size greater than 16 weeks gestation,
previous uterine surgery, suspicion of malignant gynaecological disease
Interventions VH versus LAVH
VH: as described byDargent in 2004. If the uterine size did not allow easy exteriorisation,
bisecting, coring,morcellation, enucleation ofmyomas or combinations of these volume-
reducing techniques were performed
LAVH: type ID (dissection up to but not including uterine arteries plus anterior struc-
tures and posterior culdotomy) according to the AAGL Classification System for La-
paroscopic Hysterectomy
Antibiotics: patients in both groups received prophylactic antibiotic therapy by an ampi-
cillin sodium/sulbactam sodium combination
Type of anaesthesia not mentioned for VH
Surgeons: all procedures performed by the same 2 surgeons using the same technique.
Surgeon experience not mentioned
Outcomes Primary outcomes: discharge time as measured in hours after surgery. The patients were
discharged from the hospital when they were tolerant of a normal diet, able to dress
themselves, fully mobile, apyrexial and not requiring analgesics
Secondary outcomes: differences in operation time, blood loss, paralytic ileus time,
febrilemorbidity (body temperature 38°C in 2 consecutive measurements 4 hours apart),
intensity of pain, early postoperative complications (any unfavourable episode occurring
within 30 days after surgery requiring readmission, blood transfusion or repeat surgery)
Notes Italy
Tor Vergata University Hospital
Research funds by the Italian Ministry of Education
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list
Allocation concealment (selection bias) Low risk Numbered, sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Those assessing the outcomes were blinded
to the group assignments; patients not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Low risk Primary and secondary outcomes (pre)de-
fined and accordingly reported
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Other bias Low risk No other bias identified
Silva Filho 2006
Methods Parallel-group design
Duration: July 2004 to January 2005 (6 months)
Randomisation: not reported
Blinding: not reported
Number of women randomised = 60. There were no dropouts. There were no conver-
sions to AH in the VH group
Follow-up: women were followed up until 1 month after surgery. The return rate of the
questionnaires at 1 month was 100%
Power calculation for sample size: no
Analysis was by intention-to-treat
Participants 60 women. Mean age 45 years in both groups
Inclusion criteria: women with myoma and uterine size < 300 cm3
Exclusion criteria: uterine prolapse, need for associated procedures, suspicion of ex-
trauterine disease
Interventions VH and TAH
Procedures were performed according to the modified Richardson’s and Heaney’s tech-
nique. Bisection and morcellation if needed in VH
Antibiotics: both groups received prophylactic antibiotic treatment (cefalotin 1 g IV)
and anticoagulant therapy
Epidural anaesthesia for both VH and TAH
Surgeon experience: surgeons reported as experienced in both procedures
Outcomes Primary outcome: quality of life (questionnaire SF-36)
Secondary outcomes: operative time; conversions to AH; hospital stay
Notes Brazil
It is unclear from which hospital(s) the women were recruited
Funding not reported
The subscales and score ranges of the questionnaire SF-36 are not in agreement with the
international standard
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
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Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding of patients not reported. The in-
terviewer at 1 month after surgery was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Low risk No reporting bias identified
Other bias Unclear risk The subscales and score ranges of the ques-
tionnaire SF-36were not in agreementwith
the international standard
Song 2013
Methods Single-centre
Duration: January 2010 to January 2011 (12 months)
Randomisation: patients were randomly assigned 1:1 with the use of a computer-gen-
erated schedule to undergo LESS LAVH or multi-port LAVH. Randomisation was per-
formed in permuted blocks of 4 with random variation of the blocking number
Allocation procedure: a research nurse prepared all numbered, opaque, sealed envelopes
Blinding: not reported
Number of women 40 women randomised, 39 women analysed. 1 SP-LH procedure
converted
Follow-up: 1 woman assigned to multi-port was lost to follow-up
Power calculation for sample size: yes, on the basis of the difference in primary outcome.
Assuming a standard deviation of 2 points for the BIS or CS score, allowing 5% dropout
rate, they estimated that 20 patients would be needed per group
Participants 39 women with a mean age of 44.6 and 43.5 respectively
Inclusion criteria: patients who had an indication for hysterectomy, no evidence of
gynaecologic malignancy, appropriate medical status for laparoscopic surgery (ASA 1 or
2)
Exclusion criteria: age </= 18 years, uterine size > 20 weeks, recent diagnosis of cancer,
inability to understand and provide written informed consent
Interventions SP-LH versus conventional multi-port LAVH
Multi-port: after the primary 12 mm trocar was placed at the umbilicus, a 5 mm trocar
was placed in each lower quadrant, lateral to the inferior epigastric artery
Surgeons: all procedures by a single surgeon with experience of more than 500 LH and
200 SP-LH
Outcomes Primary outcomes: cosmetic satisfaction 1, 4 and 24 weeks after surgery
Secondary outcomes: operative time, perioperative complications and postoperative
hospital stay
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Notes Korea
Samsung Medical Center, Seoul
Supported by grant CRS 110-09-1 from Samsung Medical Center
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned 1:1 with the use of a
computer-generated schedule to undergo
LESS LAVH or multi-port LAVH. Ran-
domisation was performed in permuted
blocks of 4 with random variation of the
blocking number
Allocation concealment (selection bias) Low risk A research nurse prepared all numbered,
opaque, sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up/conversions reported (<
5%)
Selective reporting (reporting bias) Low risk No reporting bias
Other bias Low risk No other bias identified
Soriano 2001
Methods Single-centre study, parallel-group design
Duration: January 1999 to December 1999 (1 year)
Randomisation: pre-determined computer-generated randomisation code
Blinding: no
Number of women randomised = 80, number analysed = 80. No reported dropouts
Follow-up: until women were discharged from hospital
Power calculation to estimate sample size: yes. Assumed that the incidence of com-
plications in patients undergoing LH(a) is 10% and there will be an increase of compli-
cation rate to 40%, with alpha (type I error) of 0.05 and beta (type II error) of 0.2. It
was planned to recruit at least 35 women to each arm
Participants 80 women with a mean age of 49 years
Inclusion criteria: women referred for hysterectomy due to benign pathology. Uterine
size larger than 280 g and one or more of the following: previous pelvic surgery, history
of pelvic inflammatory disease, moderate or severe endometriosis, concomitant adnexal
masses or indication for adnexectomy
Exclusion criteria: suspicious adnexal mass, anaesthetic contra-indications for laparo-
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scopic surgery. Women with contra-indications to acetaminophen, or to nonsteroidal
antiinflammatory drugs and those whose pain evaluation was judged unreliable due to
neurological disease, or treatment by steroids, NSAIDs or opioids prior to surgery
Interventions VH versus LH (LH(a))
LH(a) arm (LH type IV): after induction of pneumoperitoneum and insertion of the
video laparoscope, 3 suprapubic trocars were introduced for the ancillary instruments.
The pelvis and the upper abdomen were evaluated and endo metric lesions, adhesion
or ovarian cysts, when present, were treated. When the ovaries were to be conserved,
bipolar forceps and scissors were used to resect the round ligament and the uteroovarian
ligaments with the fallopian tubes. For adnexectomy, bipolar forceps and scissors were
used to resect the round and infundibulopelvic ligaments, mesosalpinx and mesovarium.
The laparoscopy included opening the bladder flap and bladder dissection, coagulating
and transecting the uterosacral ligaments, base of cardinal ligaments and uterine vessels.
Laparoscopic haemostasis was achieved using exclusively bipolar electrocoagulation. The
vaginal phases included only circular incision of the vagina and wedge morcellation,
coring or bivalving was performed. Peritoneal closure and closure of the vaginal vault
concluded the vaginal phase
VH arm: performed using the modified Heaney procedure. When necessary, wedge
morcellation, coring or bivalving was performed
Surgeon experience: not reported
Prophylactic antibiotic: cefazoline 2 g IV and lowmolecular heparin the evening before
the operation. Intravenous pain relief was given postoperatively
Outcomes Uterine weight; operative time; haemoglobin drop; postoperative complications; blood
loss; pain relief and hospital stay
Notes France
Hopital Hotel-Dieu, Paris
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation code
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts; no loss to follow-up
Selective reporting (reporting bias) Unclear risk Outcomes not clearly defined; insufficient
information available
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Other bias Low risk Surgeons’ experience not specified. No
other possible bias identified
Summitt 1992
Methods Single-centre study, parallel-group design
Duration: June 1991 to February 1992 (9 months)
Randomisation: computer-generated randomisation numbers
Blinding: no
Number of women randomised = 56, number analysed = 56. One operation was un-
successful therefore for certain outcomes only 55 were analysed
Follow-up: postoperative follow-up consisted of a telephone call by the attending surgeon
on the evening of surgery and the first 2 postoperative days. Patients were then seen 1
and 6 weeks postoperatively in the outpatient clinic
Power calculation for sample size: not reported
Analysis not by intention-to-treat (conversion excluded from analysis)
Participants 56 women with a mean age of 38 years
Inclusion criteria: 1) age 18 to 65 years; 2) no significant medical illness that required
prolonged postoperative monitoring or care; 3) a telephone in working order; 4) a sup-
port person who could assist the patient for the first 48 hours after surgery and 5) an
understanding of all postoperative instructions
Criteria for VH: 1) uterine size no larger than 16 gestational weeks; 2) the presence of
uterine mobility; 3) a pubic arch of at least 90 degrees. Factors that did not influence
the decision to proceed vaginally include: 1) a preoperative diagnosis of pelvic pain; 2)
the need for oophorectomy, or 3) a history of previous pelvic surgery
Exclusion criteria: 1) A concomitant anterior or posterior colporrhaphy was required;
2) cervical conisation was performed within the previous 48 hours; and 3) additional
antibiotic prophylaxis was required for valvular heart disease. They were also excluded if
they had absolute contraindications to laparoscopy, such as 1) any condition that could
not tolerate anaesthesia, 2) severe bleeding disorder, 3) acute peritonitis of the upper
abdomen and uterine myomata or 4) a pelvic mass larger than 16 gestational weeks in
size
Interventions VH versus LH (LH(a))
LH(a) arm: 3 12 mm trocars were used, one placed infra-umbilically and one placed
in each lower quadrant approximately 6 cm to 8 cm above the pubic rami, lateral to
the inferior epigastric arteries. A Hulka tenaculum was used to manipulate the uterus.
The bladder flap was developed by incising the vesicouterine fold of peritoneum and
dissecting the bladder below the cervix. The ureters were then identified and mobilised
using linear incisions in the medial leaf of the broad ligament, midway between the
uterosacral ligaments and infundibulopelvic vessels
The Multifire EndoGIA disposable surgical stapler was used to staple-ligate and cut all
uterine pedicles, each consisting of the round ligament, fallopian tubes and utero-ovarian
ligament, were cut. If the ovaries were to be removed, the stapler was instead placed
outside the tube and ovary, encompassing the infundibulopelvic ligament. The uterine
arteries were next staple-ligated and cut bilaterally. If possible, the stapling device was
also used to ligate and cut the cardinal ligaments. Otherwise, stapling of uterine pedicles
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ended and the anterior vaginal fornix was entered with unipolar cautery, incising over
a moistened sponge distending the anterior vagina. The remainder of the hysterectomy
was completed vaginally
Surgeons: performed by a team of 3 surgeons (2 attending faculty and a senior gynae-
cology resident)
VH arm: anaesthesiologist’s choice of general or regional anaesthesia. AmodifiedHeaney
technique was performed using O-coated polyglycolic acid suture for all pedicles. The
vaginal cuff was closed in all cases
Surgeons: performed by a gynaecology resident with attending faculty member
All received pre-operative antibiotic prophylaxis (cefazolin 2 g) intravenously. If allergic
to penicillin, 200 mg dose of doxycycline intravenously was used
Outcomes Operating time, blood loss, anaesthesia time, intra-operative complications, febrile mor-
bidity, pain relief and costs
Notes USA
Gynecology clinic, University of Tennessee, Memphis
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated numbers
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nodropouts, loss to follow-upnot reported
Selective reporting (reporting bias) Unclear risk Primary outcome not defined
Other bias Unclear risk No intention-to-treat analysis, no power
calculation. Procedures performed by dif-
ferent group of surgeons
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Methods Multicentre study (n = 3), parallel-group design
Duration: not reported
Randomisation: computer-generated randomisation list
Allocation procedure: each surgical assignment placed in consecutive sealed envelopes
and opened by an independent person (study secretary)
Blinding: no
Number of women randomised = 67, number analysed = 65. 2 women who were
randomised refused their assigned procedure and they were removed from the study and
their random numbers discarded
Follow-up: 2 and 6 weeks postoperatively in the outpatient office. No loss to follow-up
Power calculation to estimate sample size: not reported
Analysis said to be by intention-to-treat, but 2 randomised women were not analysed
Participants 65 women with a mean age of 38.3 (LH(a) group) and 41.5 (AH group)
Inclusion criteria: scheduled for AH for benign diseases. Indications for AH: 1) doc-
umented visual diagnosis of pelvic endometriosis; 2) documented pelvic adhesions; 3)
3 or more previous laparotomies; 4) uterine leiomyomata 12 to 18 gestational weeks in
size; 5) previous tuboovarian abscess or 2 documented episodes of pelvic inflammatory
disease requiring IV antibiotic therapy; 6) adnexal mass in the presence of an indication
for hysterectomy; and 7) indicated hysterectomy with lack of mobility and unfavourable
vaginal introitus. The following inclusion criteria were met: 1) age at least 18 years, 2) a
working telephone in the home, 3) an available support person in the home for 48 hours
after surgery, and 4) an understanding of the postoperative instructions
Exclusion criteria: concomitant colporrhaphy, urethropexy, vaginal vault suspension or
a non-gynaecologic major operation required. Medical conditions requiring in-hospital
monitoring or if they had known cervical or endometrial cancer. Candidates were also
excluded if they had absolute contraindications to operative laparoscopy, including:
1) uterine leiomyomas or pelvic masses greater than 18 gestational weeks in size, 2)
conditions making them intolerant to anaesthesia, 3) severe bleeding disorders, 4) acute
periodontitis of the upper abdomen with severe distension, or 5) a midline abdominal
hernia
Interventions AH versus LH (LH(a))
LH(a) arm: 3 12 mm trocars were used, one placed infra umbilically and one placed
in each lower quadrant approximately 6 cm to 8 cm above the pubic rami, lateral to
the inferior epigastric arteries. A Hulka tenaculum was used to manipulate the uterus.
The bladder flap was developed by incising the vesicouterine fold of peritoneum and
dissecting the bladder below the cervix. The ureters were then identified and mobilised
using linear incisions in the medial leaf of the broad ligament, midway between the
uterosacral ligaments and infundibulopelvic vessels
The Multifire EndoGIA disposable surgical stapler was used to staple-ligate and cut all
uterine pedicles, each consisting of the round ligament, fallopian tubes and utero-ovarian
ligament, were cut. If the ovaries were to be removed, the stapler was instead placed
outside the tube and ovary, encompassing the infundibulopelvic ligament. The uterine
arteries were next staple-ligated and cut bilaterally. If possible, the stapling device was
also used to ligate and cut the cardinal ligaments. Otherwise, stapling of uterine pedicles
ended and the anterior vaginal fornix was entered with unipolar cautery, incising over
a moistened sponge distending the anterior vagina. The remainder of the hysterectomy
was completed vaginally
AH arm: modified Richardson technique
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Surgeon experience: not reported
All received pre-operative antibiotic prophylaxis (cefazolin 2 g) intravenously. If allergic
to penicillin, 200 mg dose of doxycycline intravenously was used
Outcomes Operating time; blood loss; intra-operative and postoperative complications; hospital
stay; febrilemorbidity; requirement for analgesia; recovery time; conversion to abdominal
hysterectomy and costs
Notes USA
University of Tennessee, Memphis; Bowman Gray School of medicine, Winston-Salem,
North Carolina; University of North Carolina, Chapel Hill
Funding: US Surgical Corporation, Norwalk, Connecticut USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women refused assigned procedure and
were excluded from analysis
No loss to follow-up
Selective reporting (reporting bias) Unclear risk Primary outcome not defined
Other bias Unclear risk Analysis not according to intention-to-
treat
Surgeons’ experience not reported
Funding from pharmaceutical or surgical
instrumentation company
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Tsai 2003
Methods Single-centre study, parallel-group design
Duration: August 1997 to March 1999 (1 year, 6 months)
Randomisation: computer-generated random number sequence
Allocation procedure: not reported
Blinding: no
Number of women randomised = 200, number analysed = 200
Follow-up: duration not specified
Not analysed on intention-to-treat basis - 2 LAVHs converted to AH analysed as AH
No power calculation for sample size reported
Participants 200 women with a mean age of 46.9 years (AH) and 46.7 years (LAVH)
Inclusion criteria: good mobility of an enlarged uterus on bimanual pelvic examination
Exclusion criteria: upper uterinemargin higher thanmidpoint between symphysis pubis
and umbilicus; pre-existing cardiopulmonary dysfunction or poorly controlled systemic
disease; cervical malignancy on colposcopy; indication for conventional VH
Interventions AH versus LH (LAVH)
AH technique: not specified
LAVH: under GA. Uterine manipulator applied and pneumoperitoneum established.
2 trocar puncture sites, 12 mm umbilically and 2 mm right lower quadrant. 2 mm
minilaparoscope allowed inspection and treatment of endometriosis lesions or adhesions
through umbilical port. Multifire EndoGIA stapler resection of round and utero-ovar-
ian ligaments (or bipolar forceps applied to round ligaments if large myoma present).
Vaginal phase included insertion of 10 mm laparoscope after division of the vesicouter-
ine fold and peritoneal entry (the LETS technique). Then standard VH technique, in-
cluding clamping, transection and suture ligation of uterosacral, cardinal and uterine
pedicles, followed by peritoneal closure, then laparoscopic re-evaluation and lavage after
haemostasis if necessary
Antibiotic and thrombo prophylaxis not specified
Surgeons’ experience: 2 attending doctors performed all hysterectomies, each with an
experience of more than 50 laparoscopic procedures
Outcomes Operating time; complications; duration of hospital stay
Notes Taiwan
University and municipal hospital in Kaohsuing
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Not reported
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Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nodropouts, loss to follow-upunclear. Fol-
low-up period not specified
Selective reporting (reporting bias) Unclear risk Primary outcome not defined
Other bias High risk Analysis not according to intention-to-
treat (with 2 conversions from LH to AH)
. No power calculation reported. Surgeons’
experience not reported. AH technique not
reported
Yuen 1998
Methods Single-centre study, parallel-group design
Duration: January 1996 to June 1996 (6 months)
Randomisation: computer-generated sequence of random numbers
Blinding: no
Number of women randomised = 50, number analysed = 44. 4 declined the operation
Follow-up: until discharge from hospital. 2 refused to participate postoperatively
No power calculation for sample size
Analysis by intention-to-treat was reported
Participants 44 women with a median age of 44 (LH(a) group) and 43 (AH group)
Inclusion criteria: no major medical diseases requiring hysterectomy for benign disor-
ders
Exclusion criteria: suitable for VH or a uterus larger than 16 weeks’ gravid size
Interventions AH versus LH (LH(a))
LH(a) arm: performed with the use of 3 ports and bipolar desiccation for hemostasis.
The laparoscopic part of the operation stopped after securing the uterine arteries, and
the remainder of the operation was performed vaginally
AH arm: performed in the standard manner through a Pfannenstiel or lower midline
incision
Surgeon experience: not reported
Outcomes Operation time; blood loss; postoperative stay and postoperative complications
Notes Hong Kong
Chinese University
Funding: direct grant for research from the Chinese University of Hong Kong
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4 dropouts were not analysed (4 declined
the operation) and 2 lost to follow-up (re-
fused to participate postoperatively). This
is 5% to 10% of the sample
Selective reporting (reporting bias) Unclear risk Primary outcome not defined. Dropouts
were not analysed
Other bias Low risk No other bias identified
Zhu 2009
Methods Single-centre
Duration: 2004 to 2007 (3 years)
Randomisation: not reported
Allocation concealment: not reported
Blinding: not reported
Number of women: 101 women were randomised to 3 groups (34 LAVH, 35 TVH,
32 TAH). Dropouts not reported
Follow-up: duration not specified
Power calculation for sample size: not reported
Participants 69 women
Inclusion criteria: patients of reproductive age and who had delivered at least 1 child.
No adnexal disease, no gynaecological surgery history
Interventions TAH versus LAVH versus TVH
TAH: performed utilising a standard technique
LAVH: performed in a modified lithotomy position using a video-monitor to record the
laparoscopic part of the operation. A 10 mm scope was inserted subumbilically. Second
and third entries were made suprapubically and on both sides. Round ligaments, tubes
and utero-ovarian ligaments were diathermy and cut. In some cases the adnexa were also
removed and others were to be preserved. The uterovesical fold of the peritoneum was
divided by scissors. The uterine artery and the partial cardinal and uterosacral ligament
were diathermy and cut. The cervix was circumcised and the pouch of Douglas opened
to allow ligation and division of the partial cardinal and uterosacral ligament, as in a
traditional vaginal hysterectomy
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No conversions
Surgeons: 2 senior gynaecologists performed all operations
Outcomes Operation time, blood loss, pain score (VAS), bowel recovery time, fever, postoperative
morbidity, hospital stay
Notes China
Peking Union Medical College hospital, Beijing
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not mentioned. From tables it
seems that there was no loss to follow-up,
but follow-up procedure was not specified
Selective reporting (reporting bias) Unclear risk Primary and secondary outcomes not de-
fined
Other bias High risk Procedures really comparable as in 2 of the
3 groups salpingo-oophorectomy was also
performed. Pain score resultsmust be inter-
preted with caution as different analgesics
were used during the operation and post-
operatively
AAGL: American Association of Gynecologic Laparoscopists
AH: abdominal hysterectomy
aLH = laparoscopic cases in the abdominal arm of the eVALuate trial
ASA: American Society of Anaesthesiologists
BDI: Beck Depression Inventory
BIS: Body Image Scale
BMI: body mass index
BSO: bilateral oophorectomy
cLH: conventional laparoscopic hysterectomy
CRP: C-reactive protein
CS: Cosmetic Scale
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DVT: deep vein thrombosis
GA: general anaesthesia
GIA: not an abbreviation; refers to a registered trademark (stapler device)
HRQOL: health-related quality of life
HRT: hormone replacement therapy
IL-6: interleukin 6
ITU: intensive therapy unit
IV: intravenous
LAVH: laparoscopic-assisted vaginal hysterectomy
LAVHO: laparoscopy-assisted vaginal hysterectomy with bilateral oophorectomy
LH(a): hysterectomy where the procedure is done laparoscopically up to and including the uterine vessels and the remaining part
vaginally
NDVH: non-descent vaginal hysterectomy
NSAID: nonsteroidal anti-inflammatory drug
PGWB: Psychological General Well Being
PID: pelvic inflammatory disease
RALH: robot-assisted laparoscopic hysterectomy
SD: standard deviation
SP: single-port
STAI: State-Trait Anxiety Inventory
TAH: Total Abdominal Hysterectomy
TVH: Total Vaginal Hysterectomy
TLH: total laparoscopic hysterectomy
VAS: visual analogue scale
VE: vaginal examination
VH: vaginal hysterectomy
VHO: vaginal hysterectomy with bilateral oophorectomy
vLH: laparoscopic cases in the vaginal arm of the eVALuate trial
WHO: World Health Organization
WHQ: Women’s Health Questionnaire
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aka 2004 Randomised trial comparing AH without colporrhaphy versus VHwith colporrhaphy (n = 30). The complica-
tion profile for hysterectomy with colporrhaphy is different to hysterectomy without colporrhaphy. Inclusion
of this trial and pooling for meta-analysis would introduce undue clinical heterogeneity. Operation time was
longer and hospital stay shorter in VH with colporrhaphy, compared with AH
Apoola 1998 Non-randomised comparison of VH and AH for women with moderately enlarged uterus. Women undergoing
VH had less blood loss, a smaller haemoglobin drop and a shorter hospital stay
Atabekoglu 2004 Randomised trial of LAVH versus AH (n = 46), but no intention-to-treat analysis. Authors did not measure
any of our pre-specified outcomes, focusing on tissue trauma (laboratory findings). There was one conversion
to laparotomy in the laparoscopy group and a bladder lesions and a thrombophlebitis in the AH group. These
patients were excluded from analysis. Lower CRP and CPK were found after LAVH
114Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Cardone 2010 Although presented as a randomised study, this was a comparison between a first sample of 100 patients treated
with hysterectomy by laparotomy and a second sample of 100 patients treated with laparoscopic hysterectomy
Celik 2008 There was not sufficient information available to decide that this was a randomised controlled study. Although
in the discussion it was mentioned that this was a randomised study, this could not be confirmed in the
description of the design of the study
Chapron 1999 This study was not a randomised controlled study. Study assessed hysterectomy techniques and the rate of total
laparoscopic hysterectomy (TLH)
Cucinella 2000 Women included in another publication on the same outcome measures
Davies 1998 There was not sufficient information available to decide that this was a randomised controlled study. No further
data provided by author after request
Demir 2008 Randomised trial of LH(a) (n = 15) versus TLH (n = 15) versus AH (n = 15) mainly focusing on tissue trauma
by measuring IL-6 and CRP. Lower values for both tissue trauma parameters were observed in LH(a) and TLH
compared to AH 24 hours postoperatively
Drahonovsky 2006 It appeared that only part of the collected data (i.e. 2 instead of 3 intervention groups) were reported in the
study published in 2006, which was included in the 2009 update of this review. In a paper published in 2010,
3 intervention groups were reported, including the 2 described in the paper of 2006 and the missing third
group. However, the study design (e.g. randomisation procedure) was insufficiently described to clarify this
discrepancy. After requesting from the authors more information on the study design, we received too little
information to assess the study for inclusion and exclusion criteria. Therefore, we excluded both papers from
2006 and 2010 from this review
Drahonovsky 2010 See Drahonovsky 2006
Dua 2012 No comparison between routes of hysterectomy; women were randomised to have a drain or no drain after VH
Ellstrom 2003 Randomised trial of TLH versus AH (n = 74), but did not measure any of our pre-specified outcomes, focusing
on psychological well being. No differences were found
Fanfani 2013 This randomised controlled study was excluded because 40 out of 68 included patients had surgery for non-
benign indications. The data on the 28 patients with benign indications were not reported separately
Ghanbari 2009 No comparison between different routes of hysterectomy; this randomised, double-blind study compared 2
laparotomy techniques: transverse muscle-cutting Maylard incision and the Pfannenstiel incision for AH
Hahlin 1994 Women included in another publication on the same outcome measures
Holub 2000 Randomised controlled trial (n = 70) but compared 2 variants of LAVH (described in the study as LAVH and
VALH (vaginally assisted laparoscopic hysterectomy) respectively), rather than comparing LAVH with another
surgical approach. In LAVH, the round ligament, upper broad ligament, infundibulopelvic or uteroovarian
ligament, bladder pillars in preparation of the bladder flap were taken laparoscopically; the uterine vessels,
cardinal-uterosacral ligaments, anterior and posterior culdotomy and vaginal cuff closure were taken vaginally.
In VALH, all steps were performed laparoscopically, other than taking the uterine vessels and vaginal cuff
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closure, which were performed vaginally. Operation time shorter for VALH (mean 81.33 versus 89.47 minutes,
P value = 0.01), with no other significant differences in outcomes reported
Horng 2004 Randomised controlled trial (n = 541) but compared 2 variants of colpotomy in LAVH(vaginal and laparoscopic
approach), rather than comparing LAVH with another surgical approach. The vaginal approach was associated
with significantly fewer urinary tract injuries as compared with the laparoscopic approach (9/274 and 1/267
respectively)
Howard 1993 Not a randomised controlled study. Allocated to study groups based on the attending physician scheduled for
the case. Intervention: laparoscopic hysterectomy (LH) versus abdominal hysterectomy (AH)
Kim 2010 The study was excluded from the meta-analysis because the primary outcome was on laboratory results and
not on clinical data comparing routes of hysterectomy
Kucukozkan 2011 No comparison between routes of hysterectomy; patient with large symptomatic myomas were randomised for
an abdominal approach through minilaparotomy or midline incision
Lee 2011 This study is a prospective case-control study and not a RCT
Li 2012 Not a true randomised trial; patients were assigned to receive single-port TLH or conventional TLH according
to the sequence of their admission
Long 2005 Randomised controlled trial (n = 68) but compared 2 variants of LH(a) (with and without vaginal cuff sus-
pension), rather than comparing LH(a) with another surgical approach. Less mobility of the bladder neck was
found on ultrasound in LH(a) with suspension
Morelli 2007 Case of scientific felony at Magna Graecia University of Catanzaro (via http://www.ncbi.nlm.nih.gov/pubmed/
17923838)
Moustafa 2008 No comparison between routes of hysterectomy; this randomised prospective study among women undergoing
VH compared a closed vault technique with an open technique
Møller 2001 This study was excluded from the review and meta-analysis because this was not a randomised controlled
study. Patients were allocated to study groups by the attending gynaecologist in a non-randomised manner.
Intervention: laparoscopic hysterectomy (LH) versus abdominal hysterectomy (AH)
Nezhat 1992 Not a randomised controlled study, alternatively assigned to study groups. Intervention: laparoscopic hysterec-
tomy (LH) versus abdominal hysterectomy (AH)
Oscarsson 2006 Randomised trial comparing subtotal AH versus subtotal LH (n = 47). The complication profile for subtotal
hysterectomy is different to total hysterectomy. Inclusion of this trial and pooling for meta-analysis would
introduce undue clinical heterogeneity. ASHwas performed by Pfannenstiel incision and excision of the uterus
in the cervical isthmus region after dissection of the uterine arteries
LSH were performed by a 3-port technique. Adnexal pedicles were dissected with bipolar coagulation and
unipolar scissors. Uterine arteries were exposed prior to unipolar uterine dissection. Morcellation of the uterus
with 20mm automatic morcellator. Bipolar coagulation of the endocervical mucosa. Primary outcome: hospital
stay
Secondary outcomes: operation time, complications according to patient and physician, pain, pain medication,
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(Continued)
Foley catheter removal, return to fluid and food intake, return to normal activities and work, patient satisfaction
Operation time was longer for subtotal LH, intra-operative blood loss was higher for subtotal AH, VAS pain was
higher for subtotal AH at 6 hours after surgery, return to work was sooner after subtotal LH. Other comparisons
were not different
Pabuccu 1996 No further data provided by author
Pan 2008 Not a comparison of 2 different types of hysterectomy. In this study, 2 different techniques with regard to time
point of coagulation of uterine vessels during LH(a) were compared
Park 2003 This study was excluded in the review and meta-analysis because this was not a randomised controlled study.
Historical comparison of LAVH and TLH
Petrucco 1999 No further data provided by author
Phipps 1993 Not a truly randomised controlled study, allocated to study groups according to the last digit of their hospi-
tal record number by secretarial staff. Intervention: laparoscopic hysterectomy (LH) with bilateral salpingo-
oophorectomy (BSO) versus abdominal hysterectomy (AH) with BSO
Seow 2010 No comparison between routes of hysterectomy; this randomised controlled study compared wound bleeding
after injecting the colpotomy wound in LAVH with diluted vasopressin versus normal saline solution
Yue 2009 The study was excluded from the meta-analysis because the primary outcome was on laboratory results and
not on clinical data comparing routes of hysterectomy
AH: abdominal hysterectomy
ASH: subtotal abdominal hysterectomy
CPK: creatine phosphokinase
CRP: C-reactive protein
IL-6: interleukin 6
LAVH: laparoscopic-assisted vaginal hysterectomy
LH: laparoscopic hysterectomy
LSH: subtotal laparoscopic hysterectomy
RCT: randomised controlled trial
TLH: total laparoscopic hysterectomy
VALH: vaginally assisted laparoscopic hysterectomy
VAS: visual analogue scale
VH: vaginal hysterectomy
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Characteristics of studies awaiting assessment [ordered by study ID]
Sesti 2014
Methods Randomisation procedure was based on a computer-generated list
Participants 108 women requiring hysterectomy for enlarged myomatous uterus
Interventions 3 treatment arms: TLH (n = 36); LAVH (n = 36); VH (n = 36)
Outcomes The primary outcome was the discharge time comparison. The secondary outcomes were operating time, blood loss,
paralytic ileus time, intraoperative complications, postoperative pain and early postoperative complications
Notes Results: the mean discharge time was shorter after VH than after LAVH and TLH (P value = 0.001). Operating
time significantly influenced the discharge time, considered as a dependent variable in general linear model analysis
(P value = 0.006). In contrast, blood loss did not influence the discharge time (P value = 0.55). The mean operating
time was significantly shorter in VH than in TLH and LAVH groups (P value = 0.000). The intraoperative blood
loss was greater during LAVH than during TLH and VH (P value = 0.000). Paralytic ileus time was shorter after
VH than after TLH and LAVH (P value = 0.000). No intraoperative complications or conversions to laparotomy
occurred
LAVH: laparoscopic-assisted vaginal hysterectomy
TLH: total laparoscopic hysterectomy
VH: vaginal hysterectomy
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D A T A A N D A N A L Y S E S
Comparison 1. VH versus AH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Return to normal activities
(days)
3 176 Mean Difference (IV, Random, 95% CI) -12.33 [-19.89, -4.
77]
2 Long-term outcomes:
satisfaction (dichotomous)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Intraoperative visceral injury
(dichotomous)
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Bladder injury 4 439 Odds Ratio (M-H, Fixed, 95% CI) 3.09 [0.48, 19.97]
3.2 Ureter injury 1 119 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Urinary tract (bladder or
ureter) injury
4 439 Odds Ratio (M-H, Fixed, 95% CI) 3.09 [0.48, 19.97]
3.4 Bowel injury 2 319 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Vascular injury 1 119 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Long-term complications
(dichotomous)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Urinary dysfunction 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Operation time (mins) 4 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 VH versus standard AH 3 259 Mean Difference (IV, Random, 95% CI) -11.01 [-35.09, 13.
08]
5.2VHversusminilaparotomy
AH
1 100 Mean Difference (IV, Random, 95% CI) -63.0 [-65.11, -60.
89]
6 Short-term outcomes
(dichotomous)
6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Transfusion 5 495 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.34, 1.96]
6.2 Pelvic haematoma 5 535 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.34, 2.89]
6.3 Vaginal cuff infection 2 140 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
6.4 Wound/abdominal wall
infection
3 355 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.04, 1.00]
6.5 UTI 3 176 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.08, 4.61]
6.6 Chest infection 1 60 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.60]
6.7 Febrile episodes or
unspecified infection
5 495 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.36, 1.08]
6.8 Thromboembolism 1 119 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Length of hospital stay (days) 5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 VH versus standard AH 4 295 Mean Difference (IV, Fixed, 95% CI) -1.07 [-1.22, -0.92]
7.2VHversusminilaparotomy
AH
1 100 Mean Difference (IV, Fixed, 95% CI) -2.1 [-2.19, -2.01]
8 All outcomes, descriptive data Other data No numeric data
8.1 Quality of life (descriptive
data)
Other data No numeric data
8.2 Operation time
(descriptive data)
Other data No numeric data
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8.3 Length of hospital stay
(descriptive data)
Other data No numeric data
Comparison 2. LH versus AH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Return to normal activities
(days)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 LAVH versus AH 1 80 Mean Difference (IV, Fixed, 95% CI) -8.40 [-12.15, -4.65]
1.2 LH(a) versus AH 5 440 Mean Difference (IV, Fixed, 95% CI) -15.17 [-17.21, -13.
14]
2 Satisfaction 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 LH (method unspecified)
versus AH
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Bladder injury 12 2038 Odds Ratio (M-H, Fixed, 95% CI) 1.89 [0.91, 3.90]
3.1 LAVH versus AH 3 396 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 7.17]
3.2 LH(a) versus AH 4 427 Odds Ratio (M-H, Fixed, 95% CI) 2.02 [0.49, 8.24]
3.3 TLH versus AH 2 99 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.05, 6.73]
3.4 LH (method unspecified)
versus AH
3 1116 Odds Ratio (M-H, Fixed, 95% CI) 2.65 [0.88, 7.93]
4 Ureter injury 7 1417 Odds Ratio (M-H, Fixed, 95% CI) 3.46 [0.94, 12.71]
4.1 LH(a) versus AH 1 100 Odds Ratio (M-H, Fixed, 95% CI) 6.12 [0.29, 130.87]
4.2 TLH versus AH 3 201 Odds Ratio (M-H, Fixed, 95% CI) 3.35 [0.34, 32.97]
4.3 LH (method unspecified)
versus AH
3 1116 Odds Ratio (M-H, Fixed, 95% CI) 2.82 [0.44, 18.03]
5 Urinary tract (bladder or ureter)
injury
13 2140 Odds Ratio (M-H, Fixed, 95% CI) 2.44 [1.24, 4.80]
5.1 LAVH versus AH 3 396 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.14, 7.17]
5.2 LH(a) versus AH 4 427 Odds Ratio (M-H, Fixed, 95% CI) 2.79 [0.73, 10.68]
5.3 TLH versus AH 3 201 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [0.30, 8.63]
5.4 LH (method unspecified)
versus AH
3 1116 Odds Ratio (M-H, Fixed, 95% CI) 3.13 [1.12, 8.78]
6 Bowel injury 4 1175 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.03, 1.33]
6.1 LAVH versus AH 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.25]
6.2 TLH versus AH 1 59 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 LH (method unspecified)
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.60]
7 Vascular injury 2 956 Odds Ratio (M-H, Fixed, 95% CI) 1.76 [0.52, 5.87]
7.1 LAVH versus AH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 5.26 [0.24, 113.11]
7.2 LH (method unspecified)
versus AH
1 876 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.35, 5.08]
8 Fistula 2 245 Odds Ratio (M-H, Fixed, 95% CI) 3.07 [0.32, 29.96]
8.1 LH(a) versus AH 1 143 Odds Ratio (M-H, Fixed, 95% CI) 3.09 [0.12, 77.01]
8.2 TLH versus AH 1 102 Odds Ratio (M-H, Fixed, 95% CI) 3.06 [0.12, 76.88]
9 Urinary dysfunction 2 246 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.48, 1.84]
9.1 LAVH versus AH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
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9.2 LH (method unspecified)
versus AH
1 166 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.44, 1.76]
10 Operation time (mins) 12 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 LAVH versus AH 4 466 Mean Difference (IV, Random, 95% CI) 0.27 [-23.39, 23.93]
10.2 LH(A) versus AH 5 420 Mean Difference (IV, Random, 95% CI) 33.45 [14.82, 52.08]
10.3 TLH versus AH 2 161 Mean Difference (IV, Random, 95% CI) 28.74 [2.64, 54.85]
10.4 LAVH versus
minilaparotomy AH
1 100 Mean Difference (IV, Random, 95% CI) -8.0 [-10.56, -5.44]
11 Bleeding 5 1266 Odds Ratio (M-H, Fixed, 95% CI) 0.45 [0.15, 1.37]
11.1 LAVH versus AH 2 197 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.08, 4.64]
11.2 LH(a) versus AH 2 193 Odds Ratio (M-H, Fixed, 95% CI) 0.16 [0.02, 1.34]
11.3 LH (method unspecified)
versus AH
1 876 Odds Ratio (M-H, Fixed, 95% CI) 1.50 [0.16, 14.51]
12 Transfusion 19 2638 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.30, 1.10]
12.1 LAVH versus AH 5 539 Odds Ratio (M-H, Random, 95% CI) 0.38 [0.11, 1.34]
12.2 LH(a) versus AH 8 641 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.17, 1.35]
12.3 TLH versus AH 2 161 Odds Ratio (M-H, Random, 95% CI) 0.27 [0.03, 2.47]
12.4 LH (method unspecified)
versus AH
3 1116 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.08, 9.85]
12.5 LAVH versus
minilaparotomy AH
2 181 Odds Ratio (M-H, Random, 95% CI) 1.38 [0.09, 20.52]
13 Pelvic haematoma 8 782 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.38, 1.47]
13.1 LAVH versus AH 3 276 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.05, 2.10]
13.2 LH(a) versus AH 4 406 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.44, 1.97]
13.3 LAVH versus
minilaparotomy AH
1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.21]
14 Unintended laparotomy 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 LAVH versus
minilaparotomy AH
2 181 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.08, 2.82]
15 Length of hospital stay (days) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 LAVH versus AH 4 466 Mean Difference (IV, Random, 95% CI) -2.64 [-4.16, -1.12]
15.2 LH(a) versus AH 4 380 Mean Difference (IV, Random, 95% CI) -1.82 [-2.34, -1.31]
15.3 TLH versus AH 2 161 Mean Difference (IV, Random, 95% CI) -2.53 [-5.08, 0.01]
15.4 LAVH versus
minilaparotomy AH
1 100 Mean Difference (IV, Random, 95% CI) -1.1 [-1.20, -1.00]
16 Vaginal cuff infection 9 852 Odds Ratio (M-H, Fixed, 95% CI) 1.43 [0.67, 3.04]
16.1 LAVH versus AH 3 396 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.17, 3.37]
16.2 LH(a) versus AH 6 456 Odds Ratio (M-H, Fixed, 95% CI) 1.79 [0.73, 4.37]
17 Wound/abdominal wall
infection
6 611 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.12, 0.71]
17.1 LAVH versus AH 1 81 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.19]
17.2 LH(a) versus AH 4 259 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.12, 1.03]
17.3 LH (method unspecified)
versus AH
1 190 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 2.21]
17.4 LAVH versus
minilaparotomy AH
1 81 Odds Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.19]
18 Urinary tract infection 8 659 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.54, 2.00]
18.1 LAVH versus AH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
18.2 LH(a) versus AH 5 339 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.55, 2.95]
18.3 LH (method unspecified)
versus AH
2 240 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.26, 2.69]
19 Chest infection 3 294 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.07, 1.35]
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19.1 LH(a) versus AH 2 104 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.10, 3.93]
19.2 LH (method not
specified) versus AH
1 190 Odds Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.01]
20 Febrile episodes or unspecified
infection
16 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 LAVH versus AH 4 339 Odds Ratio (M-H, Fixed, 95% CI) 0.25 [0.09, 0.73]
20.2 LH(a) versus AH 7 572 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.33, 0.90]
20.3 TLH versus AH 2 161 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.11, 1.21]
20.4 LH (method unspecified)
versus AH
3 1116 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.65, 1.37]
20.5 LAVH versus
minilaparotomy AH
1 81 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.72]
21 Thromboembolism 3 1125 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.23, 3.39]
21.1 TLH versus AH 1 59 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.01, 9.76]
21.2 LH (method unspecified)
versus AH
2 1066 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.24, 5.13]
22 Wound dehiscence 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
22.1 LAVH versus
minilaparotomy AH
1 81 Odds Ratio (M-H, Fixed, 95% CI) 3.15 [0.12, 79.69]
23 Return to normal activities
(descriptive data)
Other data No numeric data
24 Long-term outcomes: quality
of life (descriptive data)
Other data No numeric data
25 Operation time (descriptive
data)
Other data No numeric data
26 Length of hospital stay
(descriptive data)
Other data No numeric data
27 Pain relief (descriptive data) Other data No numeric data
27.1 Pain scales Other data No numeric data
27.2 Postoperative analgesics Other data No numeric data
27.3 Recovery from pain
(days)
Other data No numeric data
28 Cost (descriptive data) Other data No numeric data
Comparison 3. LH versus VH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Return to normal activities
(days)
2 140 Mean Difference (IV, Fixed, 95% CI) -1.07 [-4.21, 2.06]
1.1 LAVH versus VH 1 80 Mean Difference (IV, Fixed, 95% CI) -1.60 [-5.11, 1.91]
1.2 LH(a) versus VH 1 60 Mean Difference (IV, Fixed, 95% CI) 1.0 [-5.95, 7.95]
2 Ureter injury 2 594 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
2.1 LAVH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 TLH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 LH (method unspecified)
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
3 Bladder injury 7 895 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.32, 2.56]
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3.1 LAVH versus VH 2 125 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
3.2 LH(a) versus VH 2 136 Odds Ratio (M-H, Fixed, 95% CI) 2.98 [0.30, 29.43]
3.3 TLH versus VH 2 85 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.26]
3.4 LH (method unspecified)
versus VH
2 549 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.18, 3.79]
4 Urinary tract (bladder or ureter)
injury
7 895 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.36, 2.75]
4.1 LAVH versus VH 2 125 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.22]
4.2 LH(a) versus VH 2 136 Odds Ratio (M-H, Fixed, 95% CI) 2.98 [0.30, 29.43]
4.3 TLH versus VH 2 85 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.26]
4.4 LH (method unspecified)
versus VH
2 549 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.23, 4.38]
5 Bowel injury 2 639 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.1 LAVH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 TLH versus VH 1 90 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 LH (method unspecified)
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Vascular injury 4 685 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.48, 5.27]
6.1 LH(a) versus VH 2 136 Odds Ratio (M-H, Fixed, 95% CI) 2.89 [0.11, 74.15]
6.2 LH (method unspecified)
versus VH
2 549 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.39, 5.22]
7 Fistula 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 LH(a) versus VH 1 56 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.01, 7.67]
8 Urinary dysfunction 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
9 Operation time (mins) 9 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 LAVH versus VH 5 377 Mean Difference (IV, Random, 95% CI) 33.60 [20.13, 47.07]
9.2 LH(a) versus VH 3 213 Mean Difference (IV, Random, 95% CI) 53.58 [43.67, 63.49]
9.3 TLH versus VH 1 60 Mean Difference (IV, Random, 95% CI) 17.30 [3.34, 31.26]
10 Bleeding 3 614 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.24, 10.09]
10.1 LAVH versus VH 2 65 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.06, 41.03]
10.2 TLH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.06, 41.03]
10.3 LH (method unspecified)
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.06, 37.18]
11 Transfusion 8 1039 Odds Ratio (M-H, Fixed, 95% CI) 1.60 [0.80, 3.18]
11.1 LAVH versus VH 4 273 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.16, 3.41]
11.2 LH(a) versus VH 3 217 Odds Ratio (M-H, Fixed, 95% CI) 2.49 [0.63, 9.86]
11.3 TLH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.06, 41.03]
11.4 LH (method unspecified)
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 1.74 [0.63, 4.79]
12 Pelvic haematoma 4 308 Odds Ratio (M-H, Fixed, 95% CI) 1.21 [0.36, 4.03]
12.1 LAVH versus VH 3 228 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [0.40, 7.26]
12.2 LH(a) versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.04, 5.60]
13 Unintended laparotomy 10 1160 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.76, 3.16]
13.1 LAVH versus VH 5 353 Odds Ratio (M-H, Fixed, 95% CI) 4.33 [0.46, 40.61]
13.2 LH(a) versus VH 3 213 Odds Ratio (M-H, Fixed, 95% CI) 6.11 [1.06, 35.21]
13.3 TLH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [0.06, 41.03]
13.4 LH (method unspecified)
versus VH
2 549 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.26, 1.74]
14 Vaginal cuff infection 4 276 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.22, 4.39]
14.1 LAVH versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.56]
14.2 LH(a) versus VH 3 196 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.16, 5.73]
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15 Wound/abdominal wall
infection
2 170 Odds Ratio (M-H, Fixed, 95% CI) 2.88 [0.31, 27.06]
15.1 LAVH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 2.72 [0.12, 60.29]
15.2 LH(a) versus VH 1 80 Odds Ratio (M-H, Fixed, 95% CI) 3.08 [0.12, 77.80]
15.3 TLH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Urinary tract infection 3 230 Odds Ratio (M-H, Fixed, 95% CI) 1.66 [0.40, 6.82]
16.1 LAVH versus VH 2 125 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.15, 6.89]
16.2 LH(a) versus VH 1 60 Odds Ratio (M-H, Fixed, 95% CI) 3.10 [0.12, 79.23]
16.3 TLH versus VH 1 45 Odds Ratio (M-H, Fixed, 95% CI) 2.72 [0.12, 60.29]
17 Chest infection 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 LH(a) versus VH 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.06]
18 Febrile episodes or unspecified
infection
9 1074 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.51, 1.24]
18.1 LAVH versus VH 4 253 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.49, 4.85]
18.2 LH(a) versus VH 3 196 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.28, 3.51]
18.3 TLH versus VH 2 121 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.06, 1.74]
18.4 LH (method unspecified)
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.41, 1.25]
19 Thromboembolism 2 564 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.15, 6.67]
19.1 TLH versus VH 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 8.24]
19.2 LH (method unspecified)
versus VH
1 504 Odds Ratio (M-H, Fixed, 95% CI) 2.52 [0.12, 52.76]
20 Length of hospital stay (days) 7 525 Mean Difference (IV, Random, 95% CI) 0.88 [0.73, 1.03]
20.1 LAVH versus VH 4 308 Mean Difference (IV, Random, 95% CI) 0.91 [0.76, 1.06]
20.2 LH(a) versus VH 2 157 Mean Difference (IV, Random, 95% CI) 0.40 [-0.42, 1.22]
20.3 TLH versus VH 1 60 Mean Difference (IV, Random, 95% CI) -0.5 [-2.41, 1.41]
21 Return to normal activities
(descriptive data)
Other data No numeric data
22 Long-term outcomes: quality
of life (descriptive data)
Other data No numeric data
23 Operation time (descriptive
data)
Other data No numeric data
24 Length of hospital stay
(descriptive data)
Other data No numeric data
25 Pain relief (descriptive data) Other data No numeric data
25.1 Pain scales Other data No numeric data
25.2 Postoperative analgesics Other data No numeric data
26 Cost (descriptive data) Other data No numeric data
Comparison 4. RH versus LH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Return to normal activities
(days)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 Intraoperative visceral injury
(dichotomous)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Ureter injury 1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.21]
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2.2 Vascular injury 1 100 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.44]
2.3 Wound/abdominal wall
infection
1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.21]
2.4 Wound dehiscence 1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.21]
3 Operation time 2 152 Mean Difference (IV, Random, 95% CI) 44.09 [5.31, 82.88]
4 Transfusion 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5 Return to normal activities
(descriptive data)
Other data No numeric data
Comparison 5. SP-LH versus LH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Bladder injury 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 SP-TLH versus TLH 1 64 Odds Ratio (M-H, Fixed, 95% CI) 3.51 [0.14, 89.42]
2 Operation time (mins) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 SP-LAVH versus LAVH 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 SP-TLH versus TLH 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Transfusion 3 203 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [0.30, 6.26]
3.1 SP-LAVH versus LAVH 2 139 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.16, 5.86]
3.2 SP-TLH versus TLH 1 64 Odds Ratio (M-H, Fixed, 95% CI) 3.51 [0.14, 89.42]
4 Pelvic haematoma 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 SP-LAVH versus LAVH 1 100 Odds Ratio (M-H, Fixed, 95% CI) 3.06 [0.12, 76.95]
5 Wound/abdominal wall
infection
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 SP-LAVH versus LAVH 1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.21]
6 Febrile episodes or unspecified
infection
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 SP-TLH versus TLH 1 64 Odds Ratio (M-H, Fixed, 95% CI) 4.87 [0.93, 25.62]
7 Postoperative ileus 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 SP-TLH versus TLH 1 64 Odds Ratio (M-H, Fixed, 95% CI) 2.36 [0.20, 27.39]
8 Length of hospital stay (days) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 SP-LAVH versus LAVH 1 100 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.49, 0.09]
9 Operation time (descriptive
data)
Other data No numeric data
10 Length of hospital stay
(descriptive data)
Other data No numeric data
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Comparison 6. TLH versus LAVH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Intraoperative visceral injury
(dich)
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Bladder injury 2 161 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.06, 8.27]
1.2 Ureter injury 2 161 Odds Ratio (M-H, Fixed, 95% CI) 3.03 [0.27, 34.52]
1.3 Urinary tract (bladder or
ureter) injury
2 161 Odds Ratio (M-H, Fixed, 95% CI) 1.5 [0.29, 7.83]
1.4 Bowel injury 2 161 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Vascular injury 1 101 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [0.09, 24.27]
1.6 Conversion to laparotomy 2 164 Odds Ratio (M-H, Fixed, 95% CI) 1.28 [0.21, 7.85]
2 Long-term complications (dich) 1 202 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.54, 2.17]
2.1 Dyspareunia 1 101 Odds Ratio (M-H, Fixed, 95% CI) 2.64 [0.59, 11.72]
2.2 Orgasm (< 1 of 3) 1 101 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.38, 1.86]
3 Operation time (mins) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Short-term outcomes (dich) 2 Odds Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Transfusion 2 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Vaginal cuff infection 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Abdominal wall/wound
infection
1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 UTI 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Febrile episodes or
unspecified infection
2 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Length of hospital stay (days) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Comparison 7. Mini-LH versus TLH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Operation time (descriptive
data)
Other data No numeric data
2 Length of hospital stay
(descriptive data)
Other data No numeric data
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Analysis 1.1. Comparison 1 VH versus AH, Outcome 1 Return to normal activities (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 1 VH versus AH
Outcome: 1 Return to normal activities (days)
Study or subgroup VH AH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hwang 2002 30 29 (11) 30 41 (10) 39.5 % -12.00 [ -17.32, -6.68 ]
Miskry 2003 18 32 (13) 18 59 (29) 17.2 % -27.00 [ -41.68, -12.32 ]
Ottosen 2000 40 21.3 (8.5) 40 28.1 (9.5) 43.3 % -6.80 [ -10.75, -2.85 ]
Total (95% CI) 88 88 100.0 % -12.33 [ -19.89, -4.77 ]
Heterogeneity: Tau2 = 30.31; Chi2 = 8.10, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours VH Favours AH
Analysis 1.2. Comparison 1 VH versus AH, Outcome 2 Long-term outcomes: satisfaction (dichotomous).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 1 VH versus AH
Outcome: 2 Long-term outcomes: satisfaction (dichotomous)
Study or subgroup VH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Benassi 2002 58/60 54/59 2.69 [ 0.50, 14.42 ]
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Increased with AH Increased with VH
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Analysis 1.3. Comparison 1 VH versus AH, Outcome 3 Intraoperative visceral injury (dichotomous).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 1 VH versus AH
Outcome: 3 Intraoperative visceral injury (dichotomous)
Study or subgroup VH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bladder injury
Benassi 2002 0/60 0/59 Not estimable
Chakraborty 2011 1/100 0/100 34.2 % 3.03 [ 0.12, 75.28 ]
Ottosen 2000 1/40 0/40 33.5 % 3.08 [ 0.12, 77.80 ]
Ribeiro 2003 1/20 0/20 32.3 % 3.15 [ 0.12, 82.16 ]
Subtotal (95% CI) 220 219 100.0 % 3.09 [ 0.48, 19.97 ]
Total events: 3 (VH), 0 (AH)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Ureter injury
Benassi 2002 0/60 0/59 Not estimable
Subtotal (95% CI) 60 59 Not estimable
Total events: 0 (VH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Urinary tract (bladder or ureter) injury
Benassi 2002 0/60 0/59 Not estimable
Chakraborty 2011 1/100 0/100 34.2 % 3.03 [ 0.12, 75.28 ]
Ottosen 2000 1/40 0/40 33.5 % 3.08 [ 0.12, 77.80 ]
Ribeiro 2003 1/20 0/20 32.3 % 3.15 [ 0.12, 82.16 ]
Subtotal (95% CI) 220 219 100.0 % 3.09 [ 0.48, 19.97 ]
Total events: 3 (VH), 0 (AH)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
4 Bowel injury
Benassi 2002 0/60 0/59 Not estimable
Chakraborty 2011 0/100 0/100 Not estimable
Subtotal (95% CI) 160 159 Not estimable
Total events: 0 (VH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.005 0.1 1 10 200
Favours VH Favours AH
(Continued . . . )
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(. . . Continued)
Study or subgroup VH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
5 Vascular injury
Benassi 2002 0/60 0/59 Not estimable
Subtotal (95% CI) 60 59 Not estimable
Total events: 0 (VH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
0.005 0.1 1 10 200
Favours VH Favours AH
Analysis 1.4. Comparison 1 VH versus AH, Outcome 4 Long-term complications (dichotomous).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 1 VH versus AH
Outcome: 4 Long-term complications (dichotomous)
Study or subgroup VH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Urinary dysfunction
Ottosen 2000 0/40 0/40 Not estimable
Subtotal (95% CI) 40 40 Not estimable
Total events: 0 (VH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Reduced with VH Reduced with AH
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Analysis 1.5. Comparison 1 VH versus AH, Outcome 5 Operation time (mins).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 1 VH versus AH
Outcome: 5 Operation time (mins)
Study or subgroup VH AH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 VH versus standard AH
Benassi 2002 60 86 (25.3) 59 102 (32) 33.2 % -16.00 [ -26.38, -5.62 ]
Ottosen 2000 40 81 (28) 40 68 (23) 32.9 % 13.00 [ 1.77, 24.23 ]
Silva Filho 2006 30 61.1 (3.8) 30 90.5 (23.7) 33.9 % -29.40 [ -37.99, -20.81 ]
Subtotal (95% CI) 130 129 100.0 % -11.01 [ -35.09, 13.08 ]
Heterogeneity: Tau2 = 426.27; Chi2 = 34.68, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 0.90 (P = 0.37)
2 VH versus minilaparotomy AH
Sesti 2008a (1) 50 70 (3) 50 133 (7) 100.0 % -63.00 [ -65.11, -60.89 ]
Subtotal (95% CI) 50 50 100.0 % -63.00 [ -65.11, -60.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 58.49 (P < 0.00001)
-50 -25 0 25 50
Favours VH Favours AH
(1) Used minilaparotomy approach. All other studies used standard approach.
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Analysis 1.6. Comparison 1 VH versus AH, Outcome 6 Short-term outcomes (dichotomous).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 1 VH versus AH
Outcome: 6 Short-term outcomes (dichotomous)
Study or subgroup VH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Transfusion
Benassi 2002 2/60 4/59 34.9 % 0.47 [ 0.08, 2.69 ]
Chakraborty 2011 1/100 5/100 44.3 % 0.19 [ 0.02, 1.67 ]
Hwang 2002 1/30 1/30 8.7 % 1.00 [ 0.06, 16.76 ]
Miskry 2003 3/18 0/18 3.7 % 8.35 [ 0.40, 174.50 ]
Ottosen 2000 2/40 1/40 8.5 % 2.05 [ 0.18, 23.59 ]
Subtotal (95% CI) 248 247 100.0 % 0.82 [ 0.34, 1.96 ]
Total events: 9 (VH), 11 (AH)
Heterogeneity: Chi2 = 4.91, df = 4 (P = 0.30); I2 =19%
Test for overall effect: Z = 0.45 (P = 0.65)
2 Pelvic haematoma
Benassi 2002 2/60 3/59 43.2 % 0.64 [ 0.10, 4.00 ]
Chakraborty 2011 1/100 0/100 7.3 % 3.03 [ 0.12, 75.28 ]
Miskry 2003 2/18 1/18 13.1 % 2.13 [ 0.18, 25.78 ]
Ottosen 2000 1/40 1/40 14.4 % 1.00 [ 0.06, 16.56 ]
Sesti 2008a (1) 0/50 1/50 22.0 % 0.33 [ 0.01, 8.21 ]
Subtotal (95% CI) 268 267 100.0 % 0.99 [ 0.34, 2.89 ]
Total events: 6 (VH), 6 (AH)
Heterogeneity: Chi2 = 1.49, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
3 Vaginal cuff infection
Hwang 2002 0/30 0/30 Not estimable
Ottosen 2000 1/40 0/40 100.0 % 3.08 [ 0.12, 77.80 ]
Subtotal (95% CI) 70 70 100.0 % 3.08 [ 0.12, 77.80 ]
Total events: 1 (VH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
4 Wound/abdominal wall infection
Benassi 2002 0/60 2/59 28.1 % 0.19 [ 0.01, 4.04 ]
Chakraborty 2011 1/100 5/100 55.6 % 0.19 [ 0.02, 1.67 ]
0.01 0.1 1 10 100
Favours VH Favours AH
(Continued . . . )
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(. . . Continued)
Study or subgroup VH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Miskry 2003 0/18 1/18 16.4 % 0.32 [ 0.01, 8.27 ]
Subtotal (95% CI) 178 177 100.0 % 0.21 [ 0.04, 1.00 ]
Total events: 1 (VH), 8 (AH)
Heterogeneity: Chi2 = 0.07, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.049)
5 UTI
Hwang 2002 0/30 0/30 Not estimable
Miskry 2003 0/18 1/18 60.0 % 0.32 [ 0.01, 8.27 ]
Ottosen 2000 1/40 1/40 40.0 % 1.00 [ 0.06, 16.56 ]
Subtotal (95% CI) 88 88 100.0 % 0.59 [ 0.08, 4.61 ]
Total events: 1 (VH), 2 (AH)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.61)
6 Chest infection
Hwang 2002 2/30 2/30 100.0 % 1.00 [ 0.13, 7.60 ]
Subtotal (95% CI) 30 30 100.0 % 1.00 [ 0.13, 7.60 ]
Total events: 2 (VH), 2 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Febrile episodes or unspecified infection
Benassi 2002 10/60 18/59 46.6 % 0.46 [ 0.19, 1.09 ]
Chakraborty 2011 10/100 7/100 19.4 % 1.48 [ 0.54, 4.05 ]
Hwang 2002 2/30 6/30 17.3 % 0.29 [ 0.05, 1.55 ]
Miskry 2003 2/18 5/18 13.7 % 0.33 [ 0.05, 1.96 ]
Ottosen 2000 1/40 1/40 3.0 % 1.00 [ 0.06, 16.56 ]
Subtotal (95% CI) 248 247 100.0 % 0.62 [ 0.36, 1.08 ]
Total events: 25 (VH), 37 (AH)
Heterogeneity: Chi2 = 4.73, df = 4 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.69 (P = 0.092)
8 Thromboembolism
Benassi 2002 0/60 0/59 Not estimable
Subtotal (95% CI) 60 59 Not estimable
Total events: 0 (VH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours VH Favours AH
(1) This study used a minilaparoscopic hysterectomy; all other studies used a standard hysterectomy approach
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Analysis 1.7. Comparison 1 VH versus AH, Outcome 7 Length of hospital stay (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 1 VH versus AH
Outcome: 7 Length of hospital stay (days)
Study or subgroup VH AH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 VH versus standard AH
Benassi 2002 60 3.4 (0.7) 59 4.3 (1.5) 12.8 % -0.90 [ -1.32, -0.48 ]
Miskry 2003 18 3.6 (1.42) 18 5 (1.49) 2.5 % -1.40 [ -2.35, -0.45 ]
Ottosen 2000 40 2.8 (1.1) 40 3.7 (1) 10.7 % -0.90 [ -1.36, -0.44 ]
Silva Filho 2006 30 1.03 (0.27) 30 2.14 (0.41) 73.9 % -1.11 [ -1.29, -0.93 ]
Subtotal (95% CI) 148 147 100.0 % -1.07 [ -1.22, -0.92 ]
Heterogeneity: Chi2 = 1.81, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 13.86 (P < 0.00001)
2 VH versus minilaparotomy AH
Sesti 2008a 50 1.9 (0.1) 50 4 (0.3) 100.0 % -2.10 [ -2.19, -2.01 ]
Subtotal (95% CI) 50 50 100.0 % -2.10 [ -2.19, -2.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 46.96 (P < 0.00001)
-2 -1 0 1 2
Favours VH Favours AH
Analysis 1.8. Comparison 1 VH versus AH, Outcome 8 All outcomes, descriptive data.
All outcomes, descriptive data
Study VH AH Comments
Quality of life (descriptive data)
Silva Filho 2006 Ques-
tionnaire SF-36.Only data
from functional capacity,
physical aspect and pain
are presented. A high score
is a better quality of life
n = 30
1 month after surgery, re-
sponse rate 100%
n = 30
1 month after surgery, re-
sponse rate 100%
Functional capacity: VH
mean = 95, IQ-range = 75
to 100. AH mean = 72.5,
IQ-range = 55 to 90
Physical aspect: VH mean
= 100, IQ-range = 25 to
100. AHmean = 37.5, IQ-
range = 0 to 100
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All outcomes, descriptive data (Continued)
Pain: VH mean = 84, IQ-
range = 59.2 to 100. AH
mean = 51, IQ-range = 41
to 65
A higher rate of patients
in VH would choose the
same therapeutic modality
(90 % versus 65.5 %, P
value = 0.021)
Operation time (descriptive data)
Hwang 2002 With 2nd procedure:
median = 93
range = 80 to 110
n = 3
Without 2nd procedure:
median = 74
range = 40 to 120
n = 27
With 2nd procedure:
median = 117
range = 90 to 190
n = 8
Without 2nd procedure:
median = 98
range = 85 to 150
n = 22
Not tested separately
Miskry 2003 Mean 68.8 (range 30 to
180) mins
n = 18
Mean 68.2 (range 45 to
174) mins
n = 18
-
Ribeiro 2003 Mean 78 mins
n = 20
Mean 109 mins
n = 20
No measure of spread
stated
Length of hospital stay (descriptive data)
Hwang 2002 n = 30
median = 4.7 days
range (3 to 7)
n = 30
median = 5 days
range (4 to 8)
Not tested separately
Ribeiro 2003 n = 20
All went home on second
postoperative day
n = 20
All went home on third
postoperative day
-
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Analysis 2.1. Comparison 2 LH versus AH, Outcome 1 Return to normal activities (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 1 Return to normal activities (days)
Study or subgroup LH AH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 LAVH versus AH
Ottosen 2000 40 19.7 (7.5) 40 28.1 (9.5) 100.0 % -8.40 [ -12.15, -4.65 ]
Subtotal (95% CI) 40 40 100.0 % -8.40 [ -12.15, -4.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.39 (P = 0.000011)
2 LH(a) versus AH
Harkki-Siren 2000 25 21.4 (6.7) 25 38.5 (5.7) 34.8 % -17.10 [ -20.55, -13.65 ]
Hwang 2002 30 30 (16) 30 41 (10) 9.1 % -11.00 [ -17.75, -4.25 ]
Olsson 1996 71 18 (11) 72 36.2 (16.2) 20.1 % -18.20 [ -22.73, -13.67 ]
Seracchioli 2002 60 22 (11.3) 62 36 (12.1) 24.0 % -14.00 [ -18.15, -9.85 ]
Summitt 1998 34 28 (13.3) 31 38 (10.8) 12.0 % -10.00 [ -15.87, -4.13 ]
Subtotal (95% CI) 220 220 100.0 % -15.17 [ -17.21, -13.14 ]
Heterogeneity: Chi2 = 7.67, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 14.62 (P < 0.00001)
-20 -10 0 10 20
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Analysis 2.2. Comparison 2 LH versus AH, Outcome 2 Satisfaction.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 2 Satisfaction
Study or subgroup LH AH Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LH (method unspecified) versus AH
Lumsden 2000 59/85 63/81 0.65 [ 0.32, 1.30 ]
0.1 0.2 0.5 1 2 5 10
Reduced with LH Reduced with AH
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Analysis 2.3. Comparison 2 LH versus AH, Outcome 3 Bladder injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 3 Bladder injury
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Marana 1999 1/58 0/58 4.2 % 3.05 [ 0.12, 76.48 ]
Ottosen 2000 0/40 0/40 Not estimable
Tsai 2003 0/100 1/100 13.0 % 0.33 [ 0.01, 8.20 ]
Subtotal (95% CI) 198 198 17.2 % 1.00 [ 0.14, 7.17 ]
Total events: 1 (LH), 1 (AH)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 LH(a) versus AH
Langebrekke 1996 1/46 1/54 7.8 % 1.18 [ 0.07, 19.37 ]
Olsson 1996 1/71 1/72 8.5 % 1.01 [ 0.06, 16.54 ]
Persson 2006 1/63 0/56 4.5 % 2.71 [ 0.11, 67.93 ]
Summitt 1998 2/34 0/31 4.2 % 4.85 [ 0.22, 104.99 ]
Subtotal (95% CI) 214 213 25.1 % 2.02 [ 0.49, 8.24 ]
Total events: 5 (LH), 2 (AH)
Heterogeneity: Chi2 = 0.72, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
3 TLH versus AH
Kluivers 2007 1/27 2/32 15.3 % 0.58 [ 0.05, 6.73 ]
Ribeiro 2003 0/20 0/20 Not estimable
Subtotal (95% CI) 47 52 15.3 % 0.58 [ 0.05, 6.73 ]
Total events: 1 (LH), 2 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
4 LH (method unspecified) versus AH
Garry 2004 15/584 3/292 33.9 % 2.54 [ 0.73, 8.84 ]
Kongwattanakul 2012 1/25 0/25 4.1 % 3.12 [ 0.12, 80.39 ]
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(. . . Continued)
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lumsden 2000 1/95 0/95 4.3 % 3.03 [ 0.12, 75.37 ]
Subtotal (95% CI) 704 412 42.3 % 2.65 [ 0.88, 7.93 ]
Total events: 17 (LH), 3 (AH)
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 1163 875 100.0 % 1.89 [ 0.91, 3.90 ]
Total events: 24 (LH), 8 (AH)
Heterogeneity: Chi2 = 3.21, df = 9 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Chi2 = 1.66, df = 3 (P = 0.65), I2 =0.0%
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Analysis 2.4. Comparison 2 LH versus AH, Outcome 4 Ureter injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 4 Ureter injury
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LH(a) versus AH
Langebrekke 1996 2/46 0/54 14.5 % 6.12 [ 0.29, 130.87 ]
Subtotal (95% CI) 46 54 14.5 % 6.12 [ 0.29, 130.87 ]
Total events: 2 (LH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
2 TLH versus AH
Kluivers 2007 1/27 0/32 14.5 % 3.68 [ 0.14, 94.08 ]
Perino 1999 1/51 0/51 16.2 % 3.06 [ 0.12, 76.88 ]
Ribeiro 2003 0/20 0/20 Not estimable
Subtotal (95% CI) 98 103 30.6 % 3.35 [ 0.34, 32.97 ]
Total events: 2 (LH), 0 (AH)
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(. . . Continued)
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
3 LH (method unspecified) versus AH
Garry 2004 5/584 0/292 22.0 % 5.55 [ 0.31, 100.75 ]
Kongwattanakul 2012 0/25 0/25 Not estimable
Lumsden 2000 1/95 1/95 32.9 % 1.00 [ 0.06, 16.22 ]
Subtotal (95% CI) 704 412 54.9 % 2.82 [ 0.44, 18.03 ]
Total events: 6 (LH), 1 (AH)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 848 569 100.0 % 3.46 [ 0.94, 12.71 ]
Total events: 10 (LH), 1 (AH)
Heterogeneity: Chi2 = 1.01, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 0.18, df = 2 (P = 0.91), I2 =0.0%
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Analysis 2.5. Comparison 2 LH versus AH, Outcome 5 Urinary tract (bladder or ureter) injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 5 Urinary tract (bladder or ureter) injury
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Marana 1999 1/58 0/58 4.0 % 3.05 [ 0.12, 76.48 ]
Ottosen 2000 0/40 0/40 Not estimable
Tsai 2003 0/100 1/100 12.1 % 0.33 [ 0.01, 8.20 ]
Subtotal (95% CI) 198 198 16.1 % 1.00 [ 0.14, 7.17 ]
Total events: 1 (LH), 1 (AH)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 LH(a) versus AH
Langebrekke 1996 3/46 1/54 7.0 % 3.70 [ 0.37, 36.83 ]
Olsson 1996 1/71 1/72 8.0 % 1.01 [ 0.06, 16.54 ]
Persson 2006 1/63 0/56 4.2 % 2.71 [ 0.11, 67.93 ]
Summitt 1998 2/34 0/31 3.9 % 4.85 [ 0.22, 104.99 ]
Subtotal (95% CI) 214 213 23.1 % 2.79 [ 0.73, 10.68 ]
Total events: 7 (LH), 2 (AH)
Heterogeneity: Chi2 = 0.69, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
3 TLH versus AH
Kluivers 2007 2/27 2/32 13.8 % 1.20 [ 0.16, 9.14 ]
Perino 1999 1/51 0/51 3.9 % 3.06 [ 0.12, 76.88 ]
Ribeiro 2003 0/20 0/20 Not estimable
Subtotal (95% CI) 98 103 17.7 % 1.61 [ 0.30, 8.63 ]
Total events: 3 (LH), 2 (AH)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
4 LH (method unspecified) versus AH
Garry 2004 20/584 3/292 31.4 % 3.42 [ 1.01, 11.59 ]
Kongwattanakul 2012 1/25 0/25 3.8 % 3.12 [ 0.12, 80.39 ]
Lumsden 2000 2/95 1/95 7.9 % 2.02 [ 0.18, 22.68 ]
Subtotal (95% CI) 704 412 43.1 % 3.13 [ 1.12, 8.78 ]
Total events: 23 (LH), 4 (AH)
Heterogeneity: Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
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(. . . Continued)
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 2.17 (P = 0.030)
Total (95% CI) 1214 926 100.0 % 2.44 [ 1.24, 4.80 ]
Total events: 34 (LH), 9 (AH)
Heterogeneity: Chi2 = 3.03, df = 10 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0096)
Test for subgroup differences: Chi2 = 1.28, df = 3 (P = 0.73), I2 =0.0%
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Analysis 2.6. Comparison 2 LH versus AH, Outcome 6 Bowel injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 6 Bowel injury
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Kongwattanakul 2012 0/25 1/25 26.9 % 0.32 [ 0.01, 8.25 ]
Subtotal (95% CI) 25 25 26.9 % 0.32 [ 0.01, 8.25 ]
Total events: 0 (LH), 1 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 TLH versus AH
Kluivers 2007 0/27 0/32 Not estimable
Subtotal (95% CI) 27 32 Not estimable
Total events: 0 (LH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LH (method unspecified) versus AH
Garry 2004 1/584 3/292 73.1 % 0.17 [ 0.02, 1.60 ]
Lumsden 2000 0/95 0/95 Not estimable
Subtotal (95% CI) 679 387 73.1 % 0.17 [ 0.02, 1.60 ]
Total events: 1 (LH), 3 (AH)
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(. . . Continued)
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI) 731 444 100.0 % 0.21 [ 0.03, 1.33 ]
Total events: 1 (LH), 4 (AH)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 2.7. Comparison 2 LH versus AH, Outcome 7 Vascular injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 7 Vascular injury
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Raju 1994 2/40 0/40 10.6 % 5.26 [ 0.24, 113.11 ]
Subtotal (95% CI) 40 40 10.6 % 5.26 [ 0.24, 113.11 ]
Total events: 2 (LH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 LH (method unspecified) versus AH
Garry 2004 8/584 3/292 89.4 % 1.34 [ 0.35, 5.08 ]
Subtotal (95% CI) 584 292 89.4 % 1.34 [ 0.35, 5.08 ]
Total events: 8 (LH), 3 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Total (95% CI) 624 332 100.0 % 1.76 [ 0.52, 5.87 ]
Total events: 10 (LH), 3 (AH)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.64, df = 1 (P = 0.42), I2 =0.0%
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Analysis 2.8. Comparison 2 LH versus AH, Outcome 8 Fistula.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 8 Fistula
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LH(a) versus AH
Olsson 1996 1/71 0/72 50.0 % 3.09 [ 0.12, 77.01 ]
Subtotal (95% CI) 71 72 50.0 % 3.09 [ 0.12, 77.01 ]
Total events: 1 (LH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 TLH versus AH
Perino 1999 1/51 0/51 50.0 % 3.06 [ 0.12, 76.88 ]
Subtotal (95% CI) 51 51 50.0 % 3.06 [ 0.12, 76.88 ]
Total events: 1 (LH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 122 123 100.0 % 3.07 [ 0.32, 29.96 ]
Total events: 2 (LH), 0 (AH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 2.9. Comparison 2 LH versus AH, Outcome 9 Urinary dysfunction.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 9 Urinary dysfunction
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Ottosen 2000 1/40 0/40 2.8 % 3.08 [ 0.12, 77.80 ]
Subtotal (95% CI) 40 40 2.8 % 3.08 [ 0.12, 77.80 ]
Total events: 1 (LH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 LH (method unspecified) versus AH
Lumsden 2000 21/85 22/81 97.2 % 0.88 [ 0.44, 1.76 ]
Subtotal (95% CI) 85 81 97.2 % 0.88 [ 0.44, 1.76 ]
Total events: 21 (LH), 22 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 125 121 100.0 % 0.94 [ 0.48, 1.84 ]
Total events: 22 (LH), 22 (AH)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 0.55, df = 1 (P = 0.46), I2 =0.0%
0.01 0.1 1 10 100
Favours LH Favours AH
143Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.10. Comparison 2 LH versus AH, Outcome 10 Operation time (mins).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 10 Operation time (mins)
Study or subgroup LH AH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LAVH versus AH
Kunz 1996 35 82 (18.7) 35 88 (24.7) 24.9 % -6.00 [ -16.26, 4.26 ]
Marana 1999 58 91.1 (30.2) 58 91.8 (26.4) 24.9 % -0.70 [ -11.02, 9.62 ]
Ottosen 2000 40 102 (31) 40 68 (23) 24.5 % 34.00 [ 22.04, 45.96 ]
Tsai 2003 100 77 (30) 100 102 (18) 25.6 % -25.00 [ -31.86, -18.14 ]
Subtotal (95% CI) 233 233 100.0 % 0.27 [ -23.39, 23.93 ]
Heterogeneity: Tau2 = 556.94; Chi2 = 73.00, df = 3 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.02 (P = 0.98)
2 LH(A) versus AH
Ellstrom 1998 20 138 (38) 20 90 (37) 17.6 % 48.00 [ 24.76, 71.24 ]
Harkki-Siren 2000 25 85.3 (13.5) 25 57.5 (12.5) 23.3 % 27.80 [ 20.59, 35.01 ]
Olsson 1996 71 148 (34.2) 72 93.1 (29.9) 22.4 % 54.90 [ 44.37, 65.43 ]
Seracchioli 2002 60 95.2 (32.4) 62 88.6 (29.3) 22.3 % 6.60 [ -4.37, 17.57 ]
Summitt 1998 34 179 (56.4) 31 146 (69.9) 14.4 % 33.00 [ 1.94, 64.06 ]
Subtotal (95% CI) 210 210 100.0 % 33.45 [ 14.82, 52.08 ]
Heterogeneity: Tau2 = 374.27; Chi2 = 41.57, df = 4 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.52 (P = 0.00043)
3 TLH versus AH
Kluivers 2007 27 121 (36) 32 78 (27) 46.6 % 43.00 [ 26.51, 59.49 ]
Perino 1999 51 104.1 (27) 51 87.8 (20.4) 53.4 % 16.30 [ 7.01, 25.59 ]
Subtotal (95% CI) 78 83 100.0 % 28.74 [ 2.64, 54.85 ]
Heterogeneity: Tau2 = 309.83; Chi2 = 7.65, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 2.16 (P = 0.031)
4 LAVH versus minilaparotomy AH
Sesti 2008a 50 125 (6) 50 133 (7) 100.0 % -8.00 [ -10.56, -5.44 ]
Subtotal (95% CI) 50 50 100.0 % -8.00 [ -10.56, -5.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.14 (P < 0.00001)
Test for subgroup differences: Chi2 = 26.24, df = 3 (P = 0.00), I2 =89%
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Analysis 2.11. Comparison 2 LH versus AH, Outcome 11 Bleeding.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 11 Bleeding
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Marana 1999 0/58 1/58 15.4 % 0.33 [ 0.01, 8.21 ]
Muzii 2007 1/40 1/41 9.9 % 1.03 [ 0.06, 16.98 ]
Subtotal (95% CI) 98 99 25.3 % 0.60 [ 0.08, 4.64 ]
Total events: 1 (LH), 2 (AH)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
2 LH(a) versus AH
Harkki-Siren 2000 0/25 2/25 25.3 % 0.18 [ 0.01, 4.04 ]
Olsson 1996 0/71 3/72 35.7 % 0.14 [ 0.01, 2.74 ]
Subtotal (95% CI) 96 97 61.0 % 0.16 [ 0.02, 1.34 ]
Total events: 0 (LH), 5 (AH)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
3 LH (method unspecified) versus AH
Garry 2004 3/584 1/292 13.7 % 1.50 [ 0.16, 14.51 ]
Subtotal (95% CI) 584 292 13.7 % 1.50 [ 0.16, 14.51 ]
Total events: 3 (LH), 1 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Total (95% CI) 778 488 100.0 % 0.45 [ 0.15, 1.37 ]
Total events: 4 (LH), 8 (AH)
Heterogeneity: Chi2 = 2.37, df = 4 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 2.05, df = 2 (P = 0.36), I2 =2%
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Analysis 2.12. Comparison 2 LH versus AH, Outcome 12 Transfusion.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 12 Transfusion
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 LAVH versus AH
Ferrari 2000 0/31 1/31 3.3 % 0.32 [ 0.01, 8.23 ]
Marana 1999 0/58 2/58 3.7 % 0.19 [ 0.01, 4.11 ]
Muzii 2007 0/40 1/41 3.3 % 0.33 [ 0.01, 8.43 ]
Ottosen 2000 1/40 1/40 4.2 % 1.00 [ 0.06, 16.56 ]
Tsai 2003 1/100 3/100 5.8 % 0.33 [ 0.03, 3.19 ]
Subtotal (95% CI) 269 270 20.3 % 0.38 [ 0.11, 1.34 ]
Total events: 2 (LH), 8 (AH)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 4 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 LH(a) versus AH
Ellstrom 1998 0/20 0/20 Not estimable
Hwang 2002 5/30 1/30 6.0 % 5.80 [ 0.63, 53.01 ]
Olsson 1996 5/71 9/72 12.4 % 0.53 [ 0.17, 1.67 ]
Persson 2006 2/63 3/56 7.8 % 0.58 [ 0.09, 3.60 ]
Schutz 2002 3/28 10/20 9.8 % 0.12 [ 0.03, 0.53 ]
Seracchioli 2002 0/60 1/62 3.4 % 0.34 [ 0.01, 8.48 ]
Summitt 1998 0/34 2/31 3.6 % 0.17 [ 0.01, 3.71 ]
Yuen 1998 0/20 0/24 Not estimable
Subtotal (95% CI) 326 315 43.0 % 0.47 [ 0.17, 1.35 ]
Total events: 15 (LH), 26 (AH)
Heterogeneity: Tau2 = 0.69; Chi2 = 8.81, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 1.40 (P = 0.16)
3 TLH versus AH
Kluivers 2007 0/27 2/32 3.6 % 0.22 [ 0.01, 4.83 ]
Perino 1999 0/51 1/51 3.4 % 0.33 [ 0.01, 8.21 ]
Subtotal (95% CI) 78 83 7.0 % 0.27 [ 0.03, 2.47 ]
Total events: 0 (LH), 3 (AH)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
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(. . . Continued)
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
4 LH (method unspecified) versus AH
Garry 2004 27/584 7/292 15.1 % 1.97 [ 0.85, 4.59 ]
Kongwattanakul 2012 0/25 7/25 3.9 % 0.05 [ 0.00, 0.90 ]
Lumsden 2000 2/95 0/95 3.7 % 5.11 [ 0.24, 107.81 ]
Subtotal (95% CI) 704 412 22.7 % 0.91 [ 0.08, 9.85 ]
Total events: 29 (LH), 14 (AH)
Heterogeneity: Tau2 = 3.09; Chi2 = 6.78, df = 2 (P = 0.03); I2 =70%
Test for overall effect: Z = 0.08 (P = 0.94)
5 LAVH versus minilaparotomy AH
Muzii 2007 0/40 1/41 3.3 % 0.33 [ 0.01, 8.43 ]
Sesti 2008a 2/50 0/50 3.7 % 5.21 [ 0.24, 111.24 ]
Subtotal (95% CI) 90 91 7.0 % 1.38 [ 0.09, 20.52 ]
Total events: 2 (LH), 1 (AH)
Heterogeneity: Tau2 = 1.21; Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 1467 1171 100.0 % 0.58 [ 0.30, 1.10 ]
Total events: 48 (LH), 52 (AH)
Heterogeneity: Tau2 = 0.54; Chi2 = 25.04, df = 17 (P = 0.09); I2 =32%
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 1.27, df = 4 (P = 0.87), I2 =0.0%
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Analysis 2.13. Comparison 2 LH versus AH, Outcome 13 Pelvic haematoma.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 13 Pelvic haematoma
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Marana 1999 0/58 1/58 7.4 % 0.33 [ 0.01, 8.21 ]
Ottosen 2000 0/40 1/40 7.4 % 0.33 [ 0.01, 8.22 ]
Raju 1994 0/40 1/40 7.4 % 0.33 [ 0.01, 8.22 ]
Subtotal (95% CI) 138 138 22.2 % 0.33 [ 0.05, 2.10 ]
Total events: 0 (LH), 3 (AH)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
2 LH(a) versus AH
Langebrekke 1996 3/46 6/54 25.7 % 0.56 [ 0.13, 2.37 ]
Olsson 1996 6/71 5/72 22.7 % 1.24 [ 0.36, 4.25 ]
Persson 2006 0/63 3/56 18.3 % 0.12 [ 0.01, 2.38 ]
Yuen 1998 4/20 1/24 3.6 % 5.75 [ 0.59, 56.35 ]
Subtotal (95% CI) 200 206 70.4 % 0.93 [ 0.44, 1.97 ]
Total events: 13 (LH), 15 (AH)
Heterogeneity: Chi2 = 4.93, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 0.19 (P = 0.85)
3 LAVH versus minilaparotomy AH
Sesti 2008a 0/50 1/50 7.4 % 0.33 [ 0.01, 8.21 ]
Subtotal (95% CI) 50 50 7.4 % 0.33 [ 0.01, 8.21 ]
Total events: 0 (LH), 1 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 388 394 100.0 % 0.75 [ 0.38, 1.47 ]
Total events: 13 (LH), 19 (AH)
Heterogeneity: Chi2 = 6.32, df = 7 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 1.33, df = 2 (P = 0.51), I2 =0.0%
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Analysis 2.14. Comparison 2 LH versus AH, Outcome 14 Unintended laparotomy.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 14 Unintended laparotomy
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus minilaparotomy AH
Muzii 2007 2/40 4/41 100.0 % 0.49 [ 0.08, 2.82 ]
Sesti 2008a 0/50 0/50 Not estimable
Subtotal (95% CI) 90 91 100.0 % 0.49 [ 0.08, 2.82 ]
Total events: 2 (LH), 4 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
0.01 0.1 1 10 100
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Analysis 2.15. Comparison 2 LH versus AH, Outcome 15 Length of hospital stay (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 15 Length of hospital stay (days)
Study or subgroup LH AH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LAVH versus AH
Kunz 1996 35 5 (0.85) 35 11 (2.86) 23.6 % -6.00 [ -6.99, -5.01 ]
Marana 1999 58 4 (1.2) 58 5.9 (2.3) 25.0 % -1.90 [ -2.57, -1.23 ]
Ottosen 2000 40 3.1 (1.4) 40 3.7 (1) 25.4 % -0.60 [ -1.13, -0.07 ]
Tsai 2003 100 3.2 (0.7) 100 5.5 (1.3) 26.0 % -2.30 [ -2.59, -2.01 ]
Subtotal (95% CI) 233 233 100.0 % -2.64 [ -4.16, -1.12 ]
Heterogeneity: Tau2 = 2.30; Chi2 = 92.30, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 3.40 (P = 0.00066)
2 LH(a) versus AH
-4 -2 0 2 4
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(. . . Continued)
Study or subgroup LH AH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Summitt 1998 34 2.12 (1.3) 31 4.13 (1.6) 22.1 % -2.01 [ -2.72, -1.30 ]
Harkki-Siren 2000 25 2.1 (0.3) 25 3.4 (0.7) 33.8 % -1.30 [ -1.60, -1.00 ]
Olsson 1996 71 2.5 (1.6) 72 5 (3.7) 17.0 % -2.50 [ -3.43, -1.57 ]
Seracchioli 2002 60 3.2 (1.3) 62 5.1 (1.7) 27.0 % -1.90 [ -2.44, -1.36 ]
Subtotal (95% CI) 190 190 100.0 % -1.82 [ -2.34, -1.31 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 9.89, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 6.90 (P < 0.00001)
3 TLH versus AH
Kluivers 2007 27 4.2 (1.3) 32 5.4 (2.4) 48.7 % -1.20 [ -2.17, -0.23 ]
Perino 1999 51 2.4 (0.3) 51 6.2 (1.9) 51.3 % -3.80 [ -4.33, -3.27 ]
Subtotal (95% CI) 78 83 100.0 % -2.53 [ -5.08, 0.01 ]
Heterogeneity: Tau2 = 3.22; Chi2 = 21.45, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.95 (P = 0.051)
4 LAVH versus minilaparotomy AH
Sesti 2008a 50 2.9 (0.2) 50 4 (0.3) 100.0 % -1.10 [ -1.20, -1.00 ]
Subtotal (95% CI) 50 50 100.0 % -1.10 [ -1.20, -1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 21.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.20, df = 3 (P = 0.01), I2 =75%
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Analysis 2.16. Comparison 2 LH versus AH, Outcome 16 Vaginal cuff infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 16 Vaginal cuff infection
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Marana 1999 0/58 1/58 13.1 % 0.33 [ 0.01, 8.21 ]
Ottosen 2000 1/40 0/40 4.2 % 3.08 [ 0.12, 77.80 ]
Tsai 2003 1/100 2/100 17.4 % 0.49 [ 0.04, 5.55 ]
Subtotal (95% CI) 198 198 34.7 % 0.75 [ 0.17, 3.37 ]
Total events: 2 (LH), 3 (AH)
Heterogeneity: Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
2 LH(a) versus AH
Ellstrom 1998 0/20 1/20 12.9 % 0.32 [ 0.01, 8.26 ]
Falcone 1999 1/23 0/21 4.3 % 2.87 [ 0.11, 74.28 ]
Harkki-Siren 2000 5/25 1/25 7.0 % 6.00 [ 0.65, 55.66 ]
Hwang 2002 0/30 0/30 Not estimable
Olsson 1996 6/71 4/72 32.0 % 1.57 [ 0.42, 5.82 ]
Persson 2006 1/63 1/56 9.2 % 0.89 [ 0.05, 14.52 ]
Subtotal (95% CI) 232 224 65.3 % 1.79 [ 0.73, 4.37 ]
Total events: 13 (LH), 7 (AH)
Heterogeneity: Chi2 = 2.58, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 430 422 100.0 % 1.43 [ 0.67, 3.04 ]
Total events: 15 (LH), 10 (AH)
Heterogeneity: Chi2 = 4.48, df = 7 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 0.95, df = 1 (P = 0.33), I2 =0.0%
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Analysis 2.17. Comparison 2 LH versus AH, Outcome 17 Wound/abdominal wall infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 17 Wound/abdominal wall infection
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Muzii 2007 0/40 2/41 11.5 % 0.20 [ 0.01, 4.19 ]
Subtotal (95% CI) 40 41 11.5 % 0.20 [ 0.01, 4.19 ]
Total events: 0 (LH), 2 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 LH(a) versus AH
Harkki-Siren 2000 0/25 4/25 20.8 % 0.09 [ 0.00, 1.84 ]
Langebrekke 1996 1/46 0/54 2.1 % 3.59 [ 0.14, 90.36 ]
Summitt 1998 1/34 7/31 33.5 % 0.10 [ 0.01, 0.90 ]
Yuen 1998 1/20 0/24 2.0 % 3.77 [ 0.15, 97.74 ]
Subtotal (95% CI) 125 134 58.4 % 0.35 [ 0.12, 1.03 ]
Total events: 3 (LH), 11 (AH)
Heterogeneity: Chi2 = 6.02, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 1.91 (P = 0.056)
3 LH (method unspecified) versus AH
Lumsden 2000 1/95 4/95 18.6 % 0.24 [ 0.03, 2.21 ]
Subtotal (95% CI) 95 95 18.6 % 0.24 [ 0.03, 2.21 ]
Total events: 1 (LH), 4 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
4 LAVH versus minilaparotomy AH
Muzii 2007 0/40 2/41 11.5 % 0.20 [ 0.01, 4.19 ]
Subtotal (95% CI) 40 41 11.5 % 0.20 [ 0.01, 4.19 ]
Total events: 0 (LH), 2 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 300 311 100.0 % 0.29 [ 0.12, 0.71 ]
Total events: 4 (LH), 19 (AH)
Heterogeneity: Chi2 = 6.30, df = 6 (P = 0.39); I2 =5%
Test for overall effect: Z = 2.72 (P = 0.0064)
Test for subgroup differences: Chi2 = 0.27, df = 3 (P = 0.97), I2 =0.0%
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Analysis 2.18. Comparison 2 LH versus AH, Outcome 18 Urinary tract infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 18 Urinary tract infection
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Ottosen 2000 0/40 1/40 8.5 % 0.33 [ 0.01, 8.22 ]
Subtotal (95% CI) 40 40 8.5 % 0.33 [ 0.01, 8.22 ]
Total events: 0 (LH), 1 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 LH(a) versus AH
Falcone 1999 3/23 2/21 10.5 % 1.43 [ 0.21, 9.49 ]
Hwang 2002 1/30 0/30 2.7 % 3.10 [ 0.12, 79.23 ]
Olsson 1996 5/71 3/72 15.9 % 1.74 [ 0.40, 7.58 ]
Schutz 2002 2/28 2/20 12.5 % 0.69 [ 0.09, 5.38 ]
Yuen 1998 2/20 3/24 14.1 % 0.78 [ 0.12, 5.18 ]
Subtotal (95% CI) 172 167 55.7 % 1.27 [ 0.55, 2.95 ]
Total events: 13 (LH), 10 (AH)
Heterogeneity: Chi2 = 1.08, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
3 LH (method unspecified) versus AH
Kongwattanakul 2012 1/25 0/25 2.7 % 3.12 [ 0.12, 80.39 ]
Lumsden 2000 4/95 6/95 33.1 % 0.65 [ 0.18, 2.39 ]
Subtotal (95% CI) 120 120 35.8 % 0.84 [ 0.26, 2.69 ]
Total events: 5 (LH), 6 (AH)
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Total (95% CI) 332 327 100.0 % 1.04 [ 0.54, 2.00 ]
Total events: 18 (LH), 17 (AH)
Heterogeneity: Chi2 = 2.69, df = 7 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.84, df = 2 (P = 0.66), I2 =0.0%
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Analysis 2.19. Comparison 2 LH versus AH, Outcome 19 Chest infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 19 Chest infection
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LH(a) versus AH
Falcone 1999 1/23 0/21 6.6 % 2.87 [ 0.11, 74.28 ]
Hwang 2002 0/30 2/30 33.1 % 0.19 [ 0.01, 4.06 ]
Subtotal (95% CI) 53 51 39.7 % 0.63 [ 0.10, 3.93 ]
Total events: 1 (LH), 2 (AH)
Heterogeneity: Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.49 (P = 0.62)
2 LH (method not specified) versus AH
Lumsden 2000 0/95 4/95 60.3 % 0.11 [ 0.01, 2.01 ]
Subtotal (95% CI) 95 95 60.3 % 0.11 [ 0.01, 2.01 ]
Total events: 0 (LH), 4 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 148 146 100.0 % 0.31 [ 0.07, 1.35 ]
Total events: 1 (LH), 6 (AH)
Heterogeneity: Chi2 = 2.40, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Chi2 = 1.02, df = 1 (P = 0.31), I2 =2%
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Analysis 2.20. Comparison 2 LH versus AH, Outcome 20 Febrile episodes or unspecified infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 20 Febrile episodes or unspecified infection
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus AH
Ferrari 2000 1/31 5/31 30.3 % 0.17 [ 0.02, 1.58 ]
Marana 1999 2/58 7/58 42.3 % 0.26 [ 0.05, 1.31 ]
Muzii 2007 0/40 3/41 21.4 % 0.14 [ 0.01, 2.72 ]
Ottosen 2000 1/40 1/40 6.1 % 1.00 [ 0.06, 16.56 ]
Subtotal (95% CI) 169 170 100.0 % 0.25 [ 0.09, 0.73 ]
Total events: 4 (LH), 16 (AH)
Heterogeneity: Chi2 = 1.20, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
2 LH(a) versus AH
Ellstrom 1998 1/20 1/20 2.3 % 1.00 [ 0.06, 17.18 ]
Falcone 1999 3/23 0/21 1.1 % 7.34 [ 0.36, 151.09 ]
Hwang 2002 0/30 6/30 15.3 % 0.06 [ 0.00, 1.15 ]
Olsson 1996 5/71 8/72 17.6 % 0.61 [ 0.19, 1.95 ]
Persson 2006 7/63 3/56 6.7 % 2.21 [ 0.54, 8.99 ]
Seracchioli 2002 8/60 18/62 36.7 % 0.38 [ 0.15, 0.95 ]
Yuen 1998 3/20 11/24 20.3 % 0.21 [ 0.05, 0.90 ]
Subtotal (95% CI) 287 285 100.0 % 0.55 [ 0.33, 0.90 ]
Total events: 27 (LH), 47 (AH)
Heterogeneity: Chi2 = 11.26, df = 6 (P = 0.08); I2 =47%
Test for overall effect: Z = 2.36 (P = 0.018)
3 TLH versus AH
Kluivers 2007 3/27 7/32 59.2 % 0.45 [ 0.10, 1.93 ]
Perino 1999 1/51 4/51 40.8 % 0.24 [ 0.03, 2.18 ]
Subtotal (95% CI) 78 83 100.0 % 0.36 [ 0.11, 1.21 ]
Total events: 4 (LH), 11 (AH)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
4 LH (method unspecified) versus AH
Garry 2004 86/584 47/292 94.1 % 0.90 [ 0.61, 1.33 ]
Kongwattanakul 2012 1/25 0/25 0.8 % 3.12 [ 0.12, 80.39 ]
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(. . . Continued)
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lumsden 2000 4/95 3/95 5.1 % 1.35 [ 0.29, 6.19 ]
Subtotal (95% CI) 704 412 100.0 % 0.94 [ 0.65, 1.37 ]
Total events: 91 (LH), 50 (AH)
Heterogeneity: Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
5 LAVH versus minilaparotomy AH
Muzii 2007 0/40 3/41 100.0 % 0.14 [ 0.01, 2.72 ]
Subtotal (95% CI) 40 41 100.0 % 0.14 [ 0.01, 2.72 ]
Total events: 0 (LH), 3 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
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Analysis 2.21. Comparison 2 LH versus AH, Outcome 21 Thromboembolism.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 21 Thromboembolism
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 TLH versus AH
Kluivers 2007 0/27 1/32 30.1 % 0.38 [ 0.01, 9.76 ]
Subtotal (95% CI) 27 32 30.1 % 0.38 [ 0.01, 9.76 ]
Total events: 0 (LH), 1 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 LH (method unspecified) versus AH
Garry 2004 3/584 2/292 59.0 % 0.75 [ 0.12, 4.51 ]
Lumsden 2000 1/95 0/95 10.9 % 3.03 [ 0.12, 75.37 ]
Subtotal (95% CI) 679 387 69.9 % 1.11 [ 0.24, 5.13 ]
Total events: 4 (LH), 2 (AH)
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(. . . Continued)
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 706 419 100.0 % 0.89 [ 0.23, 3.39 ]
Total events: 4 (LH), 3 (AH)
Heterogeneity: Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 2.22. Comparison 2 LH versus AH, Outcome 22 Wound dehiscence.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 2 LH versus AH
Outcome: 22 Wound dehiscence
Study or subgroup LH AH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus minilaparotomy AH
Muzii 2007 1/40 0/41 100.0 % 3.15 [ 0.12, 79.69 ]
Subtotal (95% CI) 40 41 100.0 % 3.15 [ 0.12, 79.69 ]
Total events: 1 (LH), 0 (AH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
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Analysis 2.23. Comparison 2 LH versus AH, Outcome 23 Return to normal activities (descriptive data).
Return to normal activities (descriptive data)
Study LH AH Comments
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Return to normal activities (descriptive data) (Continued)
Langebrekke 1996 n = 46
median = 19.5 days
range (0 to 140)
n = 54
median = 36.5 days
range (23 to 259)
P value < 0.001
Wilcoxon rank-sum test
Persson 2006 n = 63
median = 26 days
range (3 to 86)
n = 56
median = 33.5 days
range (14 to 61)
P value = 0.0081
Raju 1994 n = 40
median = 21 days
range = (7 to 35)
n = 40
median = 42 days
range (21 to 67)
P value < 0.0001
Mann-Whitney U test
Schutz 2002 n = 28
median = 42 days
n = 20
median = 42 days
-
Analysis 2.24. Comparison 2 LH versus AH, Outcome 24 Long-term outcomes: quality of life (descriptive
data).
Long-term outcomes: quality of life (descriptive data)
Study Description LH AH Comments
Garry 2004 Questionnaire assessment
of sexual activity, body im-
age (BIS) and health sta-
tus (SF-12) before and after
surgery (6 weeks, 4months
and 1 year)
SF-12 scores: difference at
each time point (high score
= better quality of life).
Body Image Scale: differ-
ence at each time point
(low score = a better body
image)
SF scores
PHYSICAL
COMPONENT
SUMMARY (PCS-12)
Baseline (n = 447)
Mean = 44.9, SD = 11.7
6 weeks (n = 301)
Mean = 46.8, SD = 10.1
4 months (n = 304)
Mean = 52.6, SD = 8.6
1 year (n = 330)
Mean = 53.6, SD = 8.4
MENTAL
COMPONENT
SUMMARY (MCS-12)
Baseline (n = 447
Mean = 45.8, SD = 11.7
6 weeks (n = 301)
Mean = 50, SD = 11.4
4 months (n = 304)
Mean = 50.9, SD = 10.5
1 year (n = 330)
Mean = 50.7, SD = 10.7
SF scores
PHYSICAL
COMPONENT
SUMMARY (PCS-12)
Baseline (n = 221)
Mean = 45.6, SD = 11.5
6 weeks (n = 148)
Mean = 41.7, SD = 9.7
4 months (n = 134)
Mean = 51.6, SD = 8.6
1 year (n = 148)
Mean = 52.7, SD = 9.3
MENTAL
COMPONENT
SUMMARY (MCS-12)
Baseline (n = 221)
Mean = 45.3, SD = 11.3
6 weeks (n = 148)
Mean = 51.9, SD = 10.8
4 months (n = 134)
Mean = 51.8, SD = 9.5
1 year (n = 148)
Mean = 51.9, SD = 10.2
SF scores
PCS-12
Baseline: difference CI = 0.
6 (-1.2 to 2.5)
6 weeks: difference CI = -
5.1 (-7.1 to -3.2). P value
< 0.0001
4 months: difference CI =
-1.0 (-2.8 to 0.7). P value
= 0.25
1 year = difference in CI =
-0.9 (-2.5 to 0.8). P value
= 0.32
MCS-12
Baseline: difference in CI =
-0.5 (-2.4 to 1.4)
6 weeks: difference in CI =
1.8 (-0.4 to 4). P value = 0.
11
4 months: difference in CI
= 0.8 (-1.3 to 2.9). P value
= 0.44
1 year: difference in CI = 1.
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Long-term outcomes: quality of life (descriptive data) (Continued)
Body Image Scale
Baseline (n = 540)
Mean = 8.8, SD = 8.1
6 weeks (n = 357)
Mean = 3.7, SD = 4.9
4 months (n = 346)
Mean = 3.3, SD = 4.9
1 year (n = 387)
Mean = 3.4, SD = 5.2
Body Image Scale
Baseline (n = 270)
Mean = 9, SD = 7.9
6 weeks (n = 172)
Mean = 5.2, SD = 5.9
4 months (n = 159)
Mean = 4.4, SD = 6.3
1 year (n = 168)
Mean = 4.1, SD = 5.7
1 (-0.9 to 3.2)
P value = 0.27
Body Image Scale
Baseline: difference in CI =
0.2 (-0.9 to 1.4)
6 weeks: difference in CI =
1.5 (0.5 to 2.4). P value =
0.005
4 months: difference in CI
= 1.1 (0.06 to 2.1). P value
= 0.06
1 year: difference in CI = 0.
7 (-0.2 to 1.7). P value = 0.
13
Both aLH and AH groups
had improvements in the
Physical and Mental com-
ponents of SF12 and Body
Image Scale. These were
maintained and improved
at 12 months. Significant
difference in PCS-12 at 6
weeks between aLH and
AH and highly significant
differences in BIS at 6
weeks, but this difference
did not persist at 4 and 12
months
Kluivers 2007 Questionnaire RAND-36.
A high score is a better
quality of life. Statistical
analysis with use of lin-
ear mixed model to evalu-
ate the differences between
2 and 12 weeks while ac-
counting for baseline value
In Nieboer 2012, the
same patients were evalu-
ated with use of the same
questionnaire 4 years after
surgery
n = 27 at baseline
n = 27, 26, 26, 25 and 22
at 1, 2, 4, 6 and 12 weeks
respectively
n = 23 at 4 years
n = 32 at baseline
n = 32, 32, 32, 31, 30 and
30 at 1, 2, 4, 6 and 12
weeks respectively
n = 26 at 4 years
Difference
(95%CI) in favour of LH
(the score range on sub-
scales is 100, score range
on total RAND-36 scales
is 800) over the first 12
weeks:
Physical functioning 7.8 (-
0.3; 15.9)
Social functioning 7.0 (-1.
8; 15.7)
Role physical 1.7 (-7.7; 11.
1)
Role emotional 1.5 (-13.4;
16.5)
Mental health 3.6 (-2.8; 9.
9)
Vitality 12.0 (4.7; 19.3)
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Long-term outcomes: quality of life (descriptive data) (Continued)
Bodily pain 8.4 (-0.1; 17.
4)
General health 0.0 (-8.1; 8.
1)
Total RAND-36 49.6 (-5.
1; 104.2)
Only the difference in the
subscale vitality was statis-
tically significant
Analysis over 4 years fol-
low up after surgery: To-
tal RAND-36 scores over-
all mean difference 50.4
points (95%confidence in-
terval 1.0 -99.7) in favour
of LH. Statistically signif-
icant higher scores were
also found on the domains
physical role functioning,
social role functioning and
vitality
Lumsden 2000 EuroQol Health Ques-
tionnaire used to measure
women’s evaluationof their
health state post surgery
(1, 6 and 12 months af-
ter surgery). Use of a visual
analogue thermometer (0
is worst imaginable health
state and 100 is best imag-
inable health state)
1 month (post-op minus
pre-op): n = 74. Mean = 7,
SD = 24.1. Median = 10,
range (-50 to 50)
6 months: n = 62. Mean =
11.3, SD = 23.9. Median =
15, range (-50 to 60)
1 year: n = 43. Mean = 12.
6, SD = 25. Median = 14,
range (-40 to 73)
1 month: n = 76. Mean =
6.8, SD = 19.2. Median =
8, range (-50 to 60).
6 months: n = 61. Mean =
14.9, SD = 16.7 Median =
15, range (-20 to 60)
1 year: n = 47. Mean = 15.
9, SD = 21. Median = 15,
range (-40 to 60)
Mean difference: 1 month:
-1.6 (-7.2 to 6.9)
6 months: 3.7 (-3.7 to 11)
.
1 year: 4.9 (-6.7 to 12.8)
No evidence of a sig-
nificant differences at 1
month, 6 months or 1 year
after surgery
Olsson 1996 6 to 8 weeks after surgery
participants were asked in
an anonymous question-
naire if they considered the
duration of their post-op-
erative stay adequate
9% of women in the
LAVH group considered
their time in hospital fol-
lowing surgery to be too
short
17% of women in the
AH group considered their
time in hospital following
surgery to be too short
-
Persson 2006 Question-
naires: Psychological Gen-
eral Wellbeing (PGWI),
Women Health Question-
naire (WHQ), Spielberger
Trait Anxiety Inventory
(STAI) and Beck’s Depres-
sion Inventory (BDI)
A higher
n = 63
PGWB: Baseline: mean =
96.7, SD = 17.9. 5 weeks:
mean = 100.4, SD = 16.7.
6 months: mean = 104.7,
SD = 18.5
WHQ: Baseline: mean =
64.9, SD = 13.9. 5 weeks:
mean = 54.6, SD = 12.8. 6
n = 56
PGWB: Baseline: mean =
96.5, SD = 16.5. 5 weeks:
mean = 102.1, SD = 16.4.
6 months: mean = 106.1,
SD = 16.0
WHQ: Baseline: mean =
63.9, SD = 18.2. 5 weeks:
mean = 54.3, SD = 17.1. 6
Main effect between
groups: PGWB P value =
0.719, WHQ P value = 0.
800, STAI P value = 0.418,
BDI P value = 0.788. Main
effect over time: PGWB
P value < 0.0001, WHQ
P value < 0.0001, STAI
P value = 0.0002, BDI P
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Long-term outcomes: quality of life (descriptive data) (Continued)
score in the PGWB shows
a higher degree of wellbe-
ing, whereas in the WHQ,
STAI, BDI a higher score
shows the more undesir-
able outcomes. Assessment
at baseline, and 5 weeks
and 6 months postoper-
atively. Statistical analysis
with the use of ANOVA for
repeated measurements
Persson 2008
analysed wellbeing on a 0
to 100 VAS and stress cop-
ing ability
months: mean = 55.0, SD
= 14.4.
STAI: Baseline: mean =
35.6, SD = 9.1. 5 weeks:
mean = 32.7, SD = 8.7. 6
months: mean = 33.6, SD
= 10.2.
BDI: Baseline: mean = 6.6,
SD = 5.8. 5 weeks: mean =
4.6, SD = 5.5. 6 months:
mean = 5.3, SD = 6.8
months: mean = 54.2, SD
= 17.2.
STAI: Baseline: mean = 34.
7, SD = 10.1. 5 weeks:
mean = 31.7, SD = 10.6. 6
months: mean = 31.7, SD
= 9.2.
BDI: Baseline: mean = 6.9,
SD = 6.1. 5 weeks: mean =
5.0, SD = 6.5. 6 months:
mean = 4.0, SD = 5.2
value = 0.0002
In-
teraction: PGWBP value =
0.772, WHQ P value = 0.
953, STAI P value = 0.762,
BDI P value = 0.223
In Persson 2008:No signif-
icant difference was found
in the day-by-day recovery
of the general wellbeing be-
tween the operating meth-
ods. Stress coping ability
did significantly influence
the day-by-day recovery of
general wellbeing
Analysis 2.25. Comparison 2 LH versus AH, Outcome 25 Operation time (descriptive data).
Operation time (descriptive data)
Study LH AH Comments
Falcone 1999 n = 23
median = 180 mins
range (139 to 225)
n = 21
median = 130 mins
range (97 to 155)
LH(a) vs AH
Wilcoxon rank-sum test
P value < 0.001
Ferrari 2000 n = 31
median = 135 mins
range (115 to 173)
n = 31
median = 120 mins
range (98 to 123)
LAVH vs AH
P value = 0.001
Calculated from the first incision to
closure of all wounds
Garry 2004 n = 584
median = 84 mins
range(10 to 325)
n = 292
median = 50 mins
range (19 to 155)
non-categorisable LH vs AH
Calculated from first incision to last
suture
Hwang 2002 With 2nd procedure
n = 13
median = 119
range (80 to 165)
Without 2nd procedure
n = 17
median = 109 mins
range (85 to 175)
With 2nd procedure
n = 8
median = 117 mins
range (90 to 190)
Without 2nd procedure
n = 22
Median = 98
Range (85 to 150)
LH(a) vs AH
Not tested separately
Langebrekke 1996 n = 46
median = 100 mins
range (50 to 153)
n = 54
median = 60.5 mins
range (22 to 105)
LH(a) vs AH
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Operation time (descriptive data) (Continued)
Muzii 2007 n = 40
median = 86 mins
range (60 to 120)
n = 41
median = 58 mins
range (45 to 75)
LAVH vs minilaparotomy AH
Persson 2006 n = 63
median = 99 mins
range (50 to 190)
n = 56
median = 64 mins
range (35 to 150)
LH(a) vs AH
P value < 0.0001 (students t test)
Raju 1994 n = 40
median = 100 mins
range (61-180)
n = 40
median = 57 mins
range (25 to 151)
LAVH vs AH
P value < 0.0001
Mann-Whitney U test
Calculated from first incision to
time all woundswere closed, dressed
and urinary catheter inserted
Ribeiro 2003 n = 20
Mean 119 mins
(no measure of spread reported)
n = 20
Mean 109 mins (no measure of
spread reported)
TLH vs AH
Schutz 2002 n = 28
median = 133 mins
range (120 to 160)
n = 20
median = 132 mins
range (121 to 145)
LH(a) vs AH
Yuen 1998 n = 20
median = 95 mins
range (79 to 143)
n = 24
median = 105 mins
range (86 to 120)
LH(a) vs AH
Calculated from first surgical inci-
sion to time of last suture
Analysis 2.26. Comparison 2 LH versus AH, Outcome 26 Length of hospital stay (descriptive data).
Length of hospital stay (descriptive data)
Study LH AH Comments
Falcone 1999 n = 23
median = 1.5 days
range (1.0 to 2.3)
n = 21
median = 2.5 days
range (1.5 to 2.5)
P value = 0.038
Wilcoxon rank-sum test
Ferrari 2000 n = 31
median = 3.8 days
range (3.8 to 4.0)
n = 31
median = 5.8 days
range (5.3 to 6.3)
P value < 0.001
Garry 2004 n = 584
median = 3 days
range (1 to 36)
n = 292
median = 4 days
range (1 to 36)
-
Hwang 2002 n = 30
median = 4.7 days
n = 30
median = 5 days
Not tested separately
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Length of hospital stay (descriptive data) (Continued)
range (3 to 7) range (4 to 8)
Langebrekke 1996 n = 46
median = 2 days
range (0 to 5)
n = 54
median = 5 days
range (3 to 12)
P value < 0.001
Wilcoxon rank-sum test
Muzii 2007 n = 40
median = 2 days
range (1 to 3)
n = 41
median = 3 days
range = (1 to 5)
P value = 0.53
Persson 2006 n = 63
median = 2 days
range (1 to 11)
n = 56
median = 3 days
range (2 to 7)
P value = 0.0006
In the same population (described
in Persson 2008), duration of sick
leave was associated with the oc-
currence of postoperative compli-
cations but not with stress-coping
ability
Raju 1994 n = 40
median = 3.5 days
range (1 to 6)
n = 40
median = 6 days
range (3 to 13)
P value < 0.0001
Mann-Whitney U test
Ribeiro 2003 n = 20
all home on day 2
n = 20
all home on day 3
-
Schutz 2002 n = 28
median = 6.5 days
range (5 to 7)
n = 20
median = 10 days
range (8.25 to 11)
-
Yuen 1998 n = 20
median = 4 days
range (4 to 5)
n = 24
median = 6 days
range (5 to 9)
P value < 0.001
Mann-Whitney U test
Analysis 2.27. Comparison 2 LH versus AH, Outcome 27 Pain relief (descriptive data).
Pain relief (descriptive data)
Study Description LH AH Conclusions
Pain scales
Ellstrom 1998 Pain during rest and when
coughing. 100 mm visual
analogue scale, endpoints
’no pain’ and ’worst pain
possible’. Day 0, Day 1
(10am and 6pm) and Day
2
n = 40
DAY 0 (8pm). At rest:
mean = 22, SD = 16.
Coughing: mean = 29, SD
= 20
DAY 1 (10am). At rest:
mean = 17, SD = 16.
n = 40
DAY 0 (8pm). At rest:
mean = 36, SD = 26.
Coughing: mean = 48, SD
= 30
DAY 1 (10am). At rest:
mean = 30, SD = 24.
Lower pain score follow-
ing LAVH compared to
AH at 10am on 1st and
2nd day when coughing
(P value <0.05 andP value
< 0.01 respectively). No
significant difference with
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Pain relief (descriptive data) (Continued)
Coughing: mean = 32, SD
= 19. P value < 0.05
DAY 1 (6pm). At rest:
mean = 24, SD = 20.
Coughing: mean = 31, SD
= 25
DAY 2 (10am). At rest:
mean = 10, SD = 10.
Coughing: mean = 15, SD
= 14. P value < 0.01
Coughing: mean = 53, SD
= 30. P value < 0.05
DAY 1 (6pm). At rest:
mean = 28, SD = 24.
Coughing: mean = 52, SD
= 28
DAY 2 (10am). At rest:
mean = 20, SD = 22.
Coughing: mean = 47, SD
= 31
P value < 0.01
the pain scores at rest
Falcone 1999 Weekly visual analogue
scales for pain (from “no
pain” to “most severe
pain”. Reported in graph
form
n = 22
Data portrayed in graph
n = 20
Data portrayed in graph
No significant difference
in
change over time (group
by time interaction) be-
tween groups. No differ-
ence in mean pain scores
over the postoperative in-
terval (P value = 0.38).
The number of weeks be-
fore a pain score of less
than 1 was recorded was
not significantly different
between the 2 groups (P
value = 0.95)
Garry 2004 Daily diary using a visual
analogue scale, scored on
day 0 (operation day), and
days 2, 7 and 21. Analysis
of covariance used to ad-
just pain scores over days 0
to 6 by the number of days
that opiates were used
VH: n = 168
vLH: n = 336
Adjusted means: 3.1 VH
and 3.5 vLH, mean differ-
ence of -0.3 (CI -0.7, 0.
002), P value = 0.07)
AH: n = 292
aLH: n = 584
Adjusted means: 3.9 AH
and 3.5 aLH, mean differ-
ence of 0.4 CI (0.09, 0.7,
P value = 0.01)
A higher proportion of
AH participants used opi-
ates than aLH.AH ismore
painful than aLH and LH
has a tendency to be less
painful than vLH
Marana 1999 10-point visual analogue
scale. Evaluation of pain
on postoperative days 1, 2
and 3
n = 58
DAY 0: mean = 40, SD =
1.2, P value < 0.001
DAY 1: mean = 5.2, SD =
2.6, P value < 0.05
DAY 2: mean = 2.3, SD =
2.3, P value < 0.001
DAY 3: mean 1.3, SD = 1.
6, P value < 0.005
n = 58
DAY 0: mean = 5.9, SD =
2.3, P value < 0.001
DAY 1: mean = 6.3, SD =
1.6, P value < 0.05
DAY 2: mean = 4.4, SD =
1.9, P value < 0.001
DAY 3: mean = 2.8, SD =
2.3, P value < 0.005
Significant difference be-
tween 2 groups at 3 eval-
uations. Lower pain score
following LAVH com-
pared to AH
Muzii 2007 VAS scores (no further de-
scription)
Postoperative day 1 and 2
n = 40
Day 1 median = 2.8
Range (0 to 6)
n = 41
Day 1 median = 4.4
Range (2 to 6.2)
Day 1 P value < 0.05
Day 2 P value < 0.05
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Pain relief (descriptive data) (Continued)
Day 2 median = 0.8
Range (0 to 3.7)
Day 2 median = 2.9
Range (2 to 5.5)
Olsson 1996 Visual
analogue scale (range 0 to
7), 2 days after surgery
n = 71
Median = 3.6, P value < 0.
05
n = 72
Median = 4.2, P value < 0.
05
Postoperative pain 2 days
after surgery was sig-
nificantly less following
LAVH compared to AH
Perino 1999 10-point visual analogue
scale, 0 = no pain to
10 = maximum pain. As-
sessed pain for 3 days after
surgery
n = 51
DAY 1: mean = 4.1, SD =
1.2.
DAY 2: mean = 2.3, SD =
1.6.
DAY 3: mean 1.0, SD = 0.
7.
P value < 0.001
n = 51
DAY 1: mean = 6.9, SD =
1.8. DAY 2: mean = 5.4,
SD = 1.3.
DAY 3: mean = 3.1, SD =
0.9.
P value < 0.001
Participants who under-
went LH had less intense
postoperative pain than
those in the AH group
Schutz 2002 10-point visual analogue
scale on days 1, 3 and 5.
Pain index on 4th postop-
erative day (WHO scale)
n = 28
Pain index: median = 0 (0
to 1.75), P value < 0.05
n = 20
Pain index: median = 5 (4
to 6), P value < 0.05
Pain index was 0 on post-
operative day 4 in the
LH group and 5 in the
AH group, LH was sig-
nificantly less painful than
AH
Postoperative analgesics
Falcone 1999 Length of time
PCA pump was required
(hours) and number of
narcotic (oxycodone) or
acetaminophen pills used
in the hospital and after
discharge was recorded
n = 23
PCA: Median = 22.1
hours, range (15.9 to 23.
5), P value < 0.001
Number of narcotics (in
hospital): median = 6,
range (2.0 to 9.0), P value
= 0.21. After discharge:
median = 19.5, range(2 to
26), P value = 0.28.
Number of non-narcotics
(in hospital): median = 0,
range (0 to 4), P value =
0.36. After discharge: me-
dian = 11, range (2 to 31)
, P value = 0.71
n = 21
PCA: Median = 36.7
hours, range (26.2 to 45),
P value < 0.001
Number of narcotics (in
hospital): Median = 8.5,
range (4 to 10), P value =
0.21. After discharge: Me-
dian = 8, range (0 to 23.5)
, P value = 0.28
Number of non-narcotics
(in hospital): Median = 0,
range (0 to 3.5), P value
= 0.004. After discharge:
median = 13.5, range (1 to
66), P value = 0.71
Participants in the LH
group required less PCA
time
Ferrari 2000 Analgesic re-
quirement recorded daily
for 3 groups (number
who require analgesia for
more than 24 hours after
surgery):
Group 1: n = 31
Median = 7, n% = 23, P
value < 0.001
Group 2: n = 20. Median
= 1, n% = 5, P value = 0.
0001
Group 1: n = 31. Median
= 24, n% = 77, P value <
0.001.
Group 2: n = 21. Median
= 16, n% = 76, P value =
0.0001
LAVH
was associated with a sig-
nificantly lower adminis-
tration of analgesics af-
ter the first 24 postop-
erative hours. Group 2,
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Pain relief (descriptive data) (Continued)
1) Whole series of partic-
ipants
2) Participants with uteri
weighing under 500 g and
3) uteri weighing greater
than 500 g
Group 3: n = 11). Median
= 6, n% = 55
Group 3: n = 10. Median
= 8, n% = 80
uteri weighing less than
500 g, LAVH was associ-
atedwith less analgesic ad-
ministration
Kluivers 2007 Number of participants
receiving opioids during
the first 3 days after
surgery were recorded
n = 27
Use of opioids: 10
n = 32
Use of opioids: 22
Less women in LH versus
AH group required opi-
oids (P value < 0.01)
Langebrekke 1996 Number of participants
receiving analgesics (par-
enterally, oral and rectal
analgesics) during the hos-
pital stay and 5 days post-
operatively
n = 46
Data portrayed as bar
chart
n = 54
Data portrayed as bar
chart
The need for both kinds
of analgesics was reduced
in the LH group
Raju 1994 Duration of postoperative
analgesia (days)
n = 40
Median = 6.6 days, range
(0 to 23). P value < 0.0001
n = 40
Median = 13.3 days, range
(2 to 38)
P value < 0.0001
Participants in the LAVH
group required fewer days
of analgesia than partici-
pants in the AH group
Summitt 1998 Use of intramuscular nar-
cotics and oral pain med-
ication
n = 34
26 of the 34 participants
required IM narcotics on
the day of surgery, P value
= 0.018
n = 31
30 of the 31 participants
required IM narcotics on
the day of surgery, P value
= 0.18
A statistically
greater number of patients
in the AH group required
IM narcotics on the day of
surgery compared to those
in the LH group
Recovery from pain (days)
Raju 1994 Number of days until par-
ticipants are free from
pain
n = 40
Median = 13 days, range
(6 to 34). P value < 0.0001
n = 40
Median = 26 days, range
(10 to 46)
P value < 0.0001
Partici-
pants who had LAVH re-
covered from pain quicker
than those who had AH
Analysis 2.28. Comparison 2 LH versus AH, Outcome 28 Cost (descriptive data).
Cost (descriptive data)
Study Description LH AH Comments
Ellstrom 1998 Analysis of cost over a pe-
riod of 12 weeks, starting
on the day the participant
entered the hospital.Direct
n = 38
Direct costs (average) =
SEK 23,169
Indirect costs (average) =
n = 38
Direct costs (average) =
SEK22,780. Indirect costs
(average) = SEK20,743
The change in costs be-
tween LH and AH are
negligible as approximately
50% of hospital costs are
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Cost (descriptive data) (Continued)
costs (hospital costs) and
indirect costs (loss of pro-
duction value) were anal-
ysed separately. Units of
currency = Swedish crowns
(SEK)
SEK 10,314 fixed costs
Falcone 1999 Hospital costs (amount
a provider must pay for
goods and services) were
assessed through the hospi-
tal accounting system. The
direct and indirect costs
were calculated for each pa-
tient from 3 different com-
ponents: operating room
costs, anaesthesia costs and
ward costs
n = 24
Difference
inmedians (LH-AH): total
hospital costs = USD 277
(CI -163 to 1097), P value
= 0.21
n = 24
(see LH)
Total hospital costs were
not significantly higher in
the LH group than the AH
group
Lumsden 2000 Single set of unit costs ap-
plied to each unit of re-
source to provide a NHS
cost for each woman.
1997/98 prices
n = 95
Total cost (operation, in-
patient stay and readmis-
sions): median = GBP
2112, mean = GBP 2479
Cost
excluding disposables: me-
dian = GBP 1740, mean =
GBP 2173
n = 95
Total cost:
median = £1667, mean =
£1832. Cost excluding dis-
posables: median = £1667,
mean = £1832
AH had significantly lower
total costs than LH, re-
sulting principally from
the difference in operation
costs.When the cost of dis-
posable equipment was re-
moved, the difference was
non-significant
Raju 1994 Cost analysis of each type
of procedure on the ma-
jor points of difference
between either operation:
cost of disposable consum-
ables and the compara-
tive costs of postoperative
lengths of stay in hospital
n = 40
Cost of operation (average)
= GBP 225.
Cost of mean length of stay
including operation time
and cost of disposable in-
struments = GBP 1260
n = 40
Cost of operation (average)
= GBP 30.
Cost of mean length of stay
including operation time
and cost of disposable in-
struments = GBP 1750
-
Summitt 1998 Hospital charges for both
groups
n = 34
Mean = USD 8161, SD =
3600, range (3061 to 23,
591). P value > 0.05
n = 31
Mean = USD 6974, SD =
2843, range (3183 to 16,
086). P value > 0.05
Lack of a statistical dif-
ference in total hospital
charges
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Analysis 3.1. Comparison 3 LH versus VH, Outcome 1 Return to normal activities (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 1 Return to normal activities (days)
Study or subgroup LH VH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 LAVH versus VH
Ottosen 2000 40 19.7 (7.5) 40 21.3 (8.5) 79.6 % -1.60 [ -5.11, 1.91 ]
Subtotal (95% CI) 40 40 79.6 % -1.60 [ -5.11, 1.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
2 LH(a) versus VH
Hwang 2002 30 30 (16) 30 29 (11) 20.4 % 1.00 [ -5.95, 7.95 ]
Subtotal (95% CI) 30 30 20.4 % 1.00 [ -5.95, 7.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 70 70 100.0 % -1.07 [ -4.21, 2.06 ]
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
-4 -2 0 2 4
Favours LH Favours VH
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Analysis 3.2. Comparison 3 LH versus VH, Outcome 2 Ureter injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 2 Ureter injury
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Roy 2011 0/30 0/15 Not estimable
Subtotal (95% CI) 30 15 Not estimable
Total events: 0 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 TLH versus VH
Roy 2011 0/30 0/15 Not estimable
Subtotal (95% CI) 30 15 Not estimable
Total events: 0 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LH (method unspecified) versus VH
Garry 2004 1/336 0/168 100.0 % 1.51 [ 0.06, 37.18 ]
Subtotal (95% CI) 336 168 100.0 % 1.51 [ 0.06, 37.18 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 396 198 100.0 % 1.51 [ 0.06, 37.18 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours LH Favours VH
169Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.3. Comparison 3 LH versus VH, Outcome 3 Bladder injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 3 Bladder injury
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Ottosen 2000 0/40 1/40 19.8 % 0.33 [ 0.01, 8.22 ]
Roy 2011 0/30 0/15 Not estimable
Subtotal (95% CI) 70 55 19.8 % 0.33 [ 0.01, 8.22 ]
Total events: 0 (LH), 1 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 LH(a) versus VH
Darai 2001 1/40 0/40 6.4 % 3.08 [ 0.12, 77.80 ]
Summitt 1992 1/29 0/27 6.6 % 2.89 [ 0.11, 74.15 ]
Subtotal (95% CI) 69 67 13.0 % 2.98 [ 0.30, 29.43 ]
Total events: 2 (LH), 0 (VH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
3 TLH versus VH
Ribeiro 2003 0/20 1/20 19.5 % 0.32 [ 0.01, 8.26 ]
Roy 2011 0/30 0/15 Not estimable
Subtotal (95% CI) 50 35 19.5 % 0.32 [ 0.01, 8.26 ]
Total events: 0 (LH), 1 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
4 LH (method unspecified) versus VH
Garry 2004 3/336 2/168 35.3 % 0.75 [ 0.12, 4.52 ]
Richardson 1995 1/22 1/23 12.5 % 1.05 [ 0.06, 17.85 ]
Subtotal (95% CI) 358 191 47.7 % 0.83 [ 0.18, 3.79 ]
Total events: 4 (LH), 3 (VH)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
Total (95% CI) 547 348 100.0 % 0.91 [ 0.32, 2.56 ]
Total events: 6 (LH), 5 (VH)
Heterogeneity: Chi2 = 1.88, df = 5 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Chi2 = 1.84, df = 3 (P = 0.61), I2 =0.0%
0.01 0.1 1 10 100
Favours LH Favours VH
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Analysis 3.4. Comparison 3 LH versus VH, Outcome 4 Urinary tract (bladder or ureter) injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 4 Urinary tract (bladder or ureter) injury
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Ottosen 2000 0/40 1/40 19.8 % 0.33 [ 0.01, 8.22 ]
Roy 2011 0/30 0/15 Not estimable
Subtotal (95% CI) 70 55 19.8 % 0.33 [ 0.01, 8.22 ]
Total events: 0 (LH), 1 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 LH(a) versus VH
Darai 2001 1/40 0/40 6.4 % 3.08 [ 0.12, 77.80 ]
Summitt 1992 1/29 0/27 6.6 % 2.89 [ 0.11, 74.15 ]
Subtotal (95% CI) 69 67 13.0 % 2.98 [ 0.30, 29.43 ]
Total events: 2 (LH), 0 (VH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
3 TLH versus VH
Ribeiro 2003 0/20 1/20 19.6 % 0.32 [ 0.01, 8.26 ]
Roy 2011 0/30 0/15 Not estimable
Subtotal (95% CI) 50 35 19.6 % 0.32 [ 0.01, 8.26 ]
Total events: 0 (LH), 1 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
4 LH (method unspecified) versus VH
Garry 2004 4/336 2/168 35.2 % 1.00 [ 0.18, 5.52 ]
Richardson 1995 1/22 1/23 12.5 % 1.05 [ 0.06, 17.85 ]
Subtotal (95% CI) 358 191 47.7 % 1.01 [ 0.23, 4.38 ]
Total events: 5 (LH), 3 (VH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
Total (95% CI) 547 348 100.0 % 1.00 [ 0.36, 2.75 ]
Total events: 7 (LH), 5 (VH)
Heterogeneity: Chi2 = 1.82, df = 5 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 1.82, df = 3 (P = 0.61), I2 =0.0%
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Analysis 3.5. Comparison 3 LH versus VH, Outcome 5 Bowel injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 5 Bowel injury
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Roy 2011 0/30 0/15 Not estimable
Subtotal (95% CI) 30 15 Not estimable
Total events: 0 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 TLH versus VH
Roy 2011 0/60 0/30 Not estimable
Subtotal (95% CI) 60 30 Not estimable
Total events: 0 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 LH (method unspecified) versus VH
Garry 2004 0/336 0/168 Not estimable
Subtotal (95% CI) 336 168 Not estimable
Total events: 0 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 426 213 Not estimable
Total events: 0 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 3.6. Comparison 3 LH versus VH, Outcome 6 Vascular injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 6 Vascular injury
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LH(a) versus VH
Darai 2001 0/40 0/40 Not estimable
Summitt 1992 1/29 0/27 10.8 % 2.89 [ 0.11, 74.15 ]
Subtotal (95% CI) 69 67 10.8 % 2.89 [ 0.11, 74.15 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 LH (method unspecified) versus VH
Garry 2004 8/336 2/168 57.5 % 2.02 [ 0.43, 9.64 ]
Richardson 1995 0/22 1/23 31.7 % 0.33 [ 0.01, 8.63 ]
Subtotal (95% CI) 358 191 89.2 % 1.42 [ 0.39, 5.22 ]
Total events: 8 (LH), 3 (VH)
Heterogeneity: Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
Total (95% CI) 427 258 100.0 % 1.58 [ 0.48, 5.27 ]
Total events: 9 (LH), 3 (VH)
Heterogeneity: Chi2 = 1.11, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Chi2 = 0.16, df = 1 (P = 0.69), I2 =0.0%
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Analysis 3.7. Comparison 3 LH versus VH, Outcome 7 Fistula.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 7 Fistula
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LH(a) versus VH
Summitt 1992 0/29 1/27 100.0 % 0.30 [ 0.01, 7.67 ]
Subtotal (95% CI) 29 27 100.0 % 0.30 [ 0.01, 7.67 ]
Total events: 0 (LH), 1 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
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Analysis 3.8. Comparison 3 LH versus VH, Outcome 8 Urinary dysfunction.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 8 Urinary dysfunction
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Ottosen 2000 1/40 0/40 100.0 % 3.08 [ 0.12, 77.80 ]
Subtotal (95% CI) 40 40 100.0 % 3.08 [ 0.12, 77.80 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 3.9. Comparison 3 LH versus VH, Outcome 9 Operation time (mins).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 9 Operation time (mins)
Study or subgroup LH VH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LAVH versus VH
Agostini 2006 24 100.2 (27.9) 24 83.9 (34.6) 16.1 % 16.30 [ -1.48, 34.08 ]
Ottosen 2000 40 102 (31) 40 81 (28) 18.5 % 21.00 [ 8.05, 33.95 ]
Sesti 2008a 50 125 (6) 50 70 (3) 22.2 % 55.00 [ 53.14, 56.86 ]
Sesti 2008b 40 129 (7) 40 71 (3) 22.1 % 58.00 [ 55.64, 60.36 ]
Zhu 2009 34 86.7 (17.9) 35 77 (8.9) 21.1 % 9.70 [ 3.00, 16.40 ]
Subtotal (95% CI) 188 189 100.0 % 33.60 [ 20.13, 47.07 ]
Heterogeneity: Tau2 = 211.87; Chi2 = 221.63, df = 4 (P<0.00001); I2 =98%
Test for overall effect: Z = 4.89 (P < 0.00001)
2 LH(a) versus VH
Darai 2001 40 160 (50) 40 108 (35) 27.5 % 52.00 [ 33.09, 70.91 ]
Soriano 2001 37 160 (50) 40 108 (35) 26.0 % 52.00 [ 32.58, 71.42 ]
Summitt 1992 29 120.1 (28.5) 27 64.7 (27) 46.5 % 55.40 [ 40.86, 69.94 ]
Subtotal (95% CI) 106 107 100.0 % 53.58 [ 43.67, 63.49 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 10.60 (P < 0.00001)
3 TLH versus VH
Candiani 2009 30 99.3 (25.4) 30 82 (29.6) 100.0 % 17.30 [ 3.34, 31.26 ]
Subtotal (95% CI) 30 30 100.0 % 17.30 [ 3.34, 31.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Chi2 = 18.21, df = 2 (P = 0.00), I2 =89%
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Analysis 3.10. Comparison 3 LH versus VH, Outcome 10 Bleeding.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 10 Bleeding
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Roy 2011 1/30 0/15 32.7 % 1.58 [ 0.06, 41.03 ]
Roy 2012 0/10 0/10 Not estimable
Subtotal (95% CI) 40 25 32.7 % 1.58 [ 0.06, 41.03 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
2 TLH versus VH
Roy 2011 1/30 0/15 32.7 % 1.58 [ 0.06, 41.03 ]
Subtotal (95% CI) 30 15 32.7 % 1.58 [ 0.06, 41.03 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
3 LH (method unspecified) versus VH
Garry 2004 1/336 0/168 34.6 % 1.51 [ 0.06, 37.18 ]
Subtotal (95% CI) 336 168 34.6 % 1.51 [ 0.06, 37.18 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 406 208 100.0 % 1.55 [ 0.24, 10.09 ]
Total events: 3 (LH), 0 (VH)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 0.00, df = 2 (P = 1.00), I2 =0.0%
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Analysis 3.11. Comparison 3 LH versus VH, Outcome 11 Transfusion.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 11 Transfusion
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Agostini 2006 0/24 0/24 Not estimable
Ottosen 2000 1/40 2/40 14.4 % 0.49 [ 0.04, 5.60 ]
Roy 2011 0/30 0/15 Not estimable
Sesti 2008a 2/50 2/50 14.1 % 1.00 [ 0.14, 7.39 ]
Subtotal (95% CI) 144 129 28.5 % 0.74 [ 0.16, 3.41 ]
Total events: 3 (LH), 4 (VH)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
2 LH(a) versus VH
Darai 2001 1/40 1/40 7.2 % 1.00 [ 0.06, 16.56 ]
Hwang 2002 5/30 1/30 6.1 % 5.80 [ 0.63, 53.01 ]
Soriano 2001 1/37 1/40 6.9 % 1.08 [ 0.07, 17.97 ]
Subtotal (95% CI) 107 110 20.2 % 2.49 [ 0.63, 9.86 ]
Total events: 7 (LH), 3 (VH)
Heterogeneity: Chi2 = 1.30, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.20)
3 TLH versus VH
Roy 2011 1/30 0/15 4.6 % 1.58 [ 0.06, 41.03 ]
Subtotal (95% CI) 30 15 4.6 % 1.58 [ 0.06, 41.03 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
4 LH (method unspecified) versus VH
Garry 2004 17/336 5/168 46.6 % 1.74 [ 0.63, 4.79 ]
Subtotal (95% CI) 336 168 46.6 % 1.74 [ 0.63, 4.79 ]
Total events: 17 (LH), 5 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Total (95% CI) 617 422 100.0 % 1.60 [ 0.80, 3.18 ]
Total events: 28 (LH), 12 (VH)
Heterogeneity: Chi2 = 2.63, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Chi2 = 1.39, df = 3 (P = 0.71), I2 =0.0%
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Analysis 3.12. Comparison 3 LH versus VH, Outcome 12 Pelvic haematoma.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 12 Pelvic haematoma
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Agostini 2006 2/24 1/24 19.0 % 2.09 [ 0.18, 24.73 ]
Ottosen 2000 0/40 1/40 30.7 % 0.33 [ 0.01, 8.22 ]
Sesti 2008a 2/50 0/50 9.9 % 5.21 [ 0.24, 111.24 ]
Subtotal (95% CI) 114 114 59.6 % 1.70 [ 0.40, 7.26 ]
Total events: 4 (LH), 2 (VH)
Heterogeneity: Chi2 = 1.55, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 LH(a) versus VH
Darai 2001 1/40 2/40 40.4 % 0.49 [ 0.04, 5.60 ]
Subtotal (95% CI) 40 40 40.4 % 0.49 [ 0.04, 5.60 ]
Total events: 1 (LH), 2 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Total (95% CI) 154 154 100.0 % 1.21 [ 0.36, 4.03 ]
Total events: 5 (LH), 4 (VH)
Heterogeneity: Chi2 = 2.23, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 3.13. Comparison 3 LH versus VH, Outcome 13 Unintended laparotomy.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 13 Unintended laparotomy
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Agostini 2006 0/24 0/24 Not estimable
Ottosen 2000 4/40 1/40 7.0 % 4.33 [ 0.46, 40.61 ]
Roy 2011 0/30 0/15 Not estimable
Sesti 2008a 0/50 0/50 Not estimable
Sesti 2008b 0/40 0/40 Not estimable
Subtotal (95% CI) 184 169 7.0 % 4.33 [ 0.46, 40.61 ]
Total events: 4 (LH), 1 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 LH(a) versus VH
Darai 2001 3/40 0/40 3.5 % 7.56 [ 0.38, 151.28 ]
Soriano 2001 3/37 0/40 3.4 % 8.22 [ 0.41, 164.68 ]
Summitt 1992 1/29 0/27 3.8 % 2.89 [ 0.11, 74.15 ]
Subtotal (95% CI) 106 107 10.7 % 6.11 [ 1.06, 35.21 ]
Total events: 7 (LH), 0 (VH)
Heterogeneity: Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.043)
3 TLH versus VH
Roy 2011 1/30 0/15 4.9 % 1.58 [ 0.06, 41.03 ]
Subtotal (95% CI) 30 15 4.9 % 1.58 [ 0.06, 41.03 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
4 LH (method unspecified) versus VH
Garry 2004 9/336 7/168 70.3 % 0.63 [ 0.23, 1.73 ]
Richardson 1995 1/22 1/23 7.2 % 1.05 [ 0.06, 17.85 ]
Subtotal (95% CI) 358 191 77.5 % 0.67 [ 0.26, 1.74 ]
Total events: 10 (LH), 8 (VH)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 678 482 100.0 % 1.55 [ 0.76, 3.16 ]
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(. . . Continued)
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 22 (LH), 9 (VH)
Heterogeneity: Chi2 = 6.34, df = 6 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Chi2 = 5.98, df = 3 (P = 0.11), I2 =50%
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Analysis 3.14. Comparison 3 LH versus VH, Outcome 14 Vaginal cuff infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 14 Vaginal cuff infection
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Ottosen 2000 1/40 1/40 28.3 % 1.00 [ 0.06, 16.56 ]
Subtotal (95% CI) 40 40 28.3 % 1.00 [ 0.06, 16.56 ]
Total events: 1 (LH), 1 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 LH(a) versus VH
Darai 2001 2/40 1/40 27.5 % 2.05 [ 0.18, 23.59 ]
Hwang 2002 0/30 0/30 Not estimable
Summitt 1992 0/29 1/27 44.2 % 0.30 [ 0.01, 7.67 ]
Subtotal (95% CI) 99 97 71.7 % 0.97 [ 0.16, 5.73 ]
Total events: 2 (LH), 2 (VH)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 139 137 100.0 % 0.98 [ 0.22, 4.39 ]
Total events: 3 (LH), 3 (VH)
Heterogeneity: Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 3.15. Comparison 3 LH versus VH, Outcome 15 Wound/abdominal wall infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 15 Wound/abdominal wall infection
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Roy 2011 2/30 0/15 55.7 % 2.72 [ 0.12, 60.29 ]
Subtotal (95% CI) 30 15 55.7 % 2.72 [ 0.12, 60.29 ]
Total events: 2 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 LH(a) versus VH
Darai 2001 1/40 0/40 44.3 % 3.08 [ 0.12, 77.80 ]
Subtotal (95% CI) 40 40 44.3 % 3.08 [ 0.12, 77.80 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 TLH versus VH
Roy 2011 0/30 0/15 Not estimable
Subtotal (95% CI) 30 15 Not estimable
Total events: 0 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 100 70 100.0 % 2.88 [ 0.31, 27.06 ]
Total events: 3 (LH), 0 (VH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 3.16. Comparison 3 LH versus VH, Outcome 16 Urinary tract infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 16 Urinary tract infection
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Ottosen 2000 0/40 1/40 46.7 % 0.33 [ 0.01, 8.22 ]
Roy 2011 2/30 0/15 19.1 % 2.72 [ 0.12, 60.29 ]
Subtotal (95% CI) 70 55 65.9 % 1.02 [ 0.15, 6.89 ]
Total events: 2 (LH), 1 (VH)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 LH(a) versus VH
Hwang 2002 1/30 0/30 15.0 % 3.10 [ 0.12, 79.23 ]
Subtotal (95% CI) 30 30 15.0 % 3.10 [ 0.12, 79.23 ]
Total events: 1 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
3 TLH versus VH
Roy 2011 2/30 0/15 19.1 % 2.72 [ 0.12, 60.29 ]
Subtotal (95% CI) 30 15 19.1 % 2.72 [ 0.12, 60.29 ]
Total events: 2 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 130 100 100.0 % 1.66 [ 0.40, 6.82 ]
Total events: 5 (LH), 1 (VH)
Heterogeneity: Chi2 = 1.32, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 0.49, df = 2 (P = 0.78), I2 =0.0%
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Analysis 3.17. Comparison 3 LH versus VH, Outcome 17 Chest infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 17 Chest infection
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LH(a) versus VH
Hwang 2002 0/30 2/30 100.0 % 0.19 [ 0.01, 4.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.19 [ 0.01, 4.06 ]
Total events: 0 (LH), 2 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
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Analysis 3.18. Comparison 3 LH versus VH, Outcome 18 Febrile episodes or unspecified infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 18 Febrile episodes or unspecified infection
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LAVH versus VH
Agostini 2006 1/24 0/24 1.1 % 3.13 [ 0.12, 80.68 ]
Ottosen 2000 1/40 1/40 2.3 % 1.00 [ 0.06, 16.56 ]
Roy 2011 8/30 2/15 4.5 % 2.36 [ 0.43, 12.87 ]
Sesti 2008b 0/40 1/40 3.4 % 0.33 [ 0.01, 8.22 ]
Subtotal (95% CI) 134 119 11.3 % 1.55 [ 0.49, 4.85 ]
Total events: 10 (LH), 4 (VH)
Heterogeneity: Chi2 = 1.41, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
2 LH(a) versus VH
Darai 2001 3/40 2/40 4.3 % 1.54 [ 0.24, 9.75 ]
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Favours LH Favours VH
(Continued . . . )
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(. . . Continued)
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hwang 2002 0/30 2/30 5.7 % 0.19 [ 0.01, 4.06 ]
Summitt 1992 1/29 0/27 1.1 % 2.89 [ 0.11, 74.15 ]
Subtotal (95% CI) 99 97 11.1 % 0.99 [ 0.28, 3.51 ]
Total events: 4 (LH), 4 (VH)
Heterogeneity: Chi2 = 1.77, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
3 TLH versus VH
Ghezzi 2010 0/38 2/38 5.7 % 0.19 [ 0.01, 4.08 ]
Roy 2011 2/30 2/15 5.8 % 0.46 [ 0.06, 3.67 ]
Subtotal (95% CI) 68 53 11.5 % 0.33 [ 0.06, 1.74 ]
Total events: 2 (LH), 4 (VH)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
4 LH (method unspecified) versus VH
Garry 2004 36/336 24/168 66.1 % 0.72 [ 0.41, 1.25 ]
Subtotal (95% CI) 336 168 66.1 % 0.72 [ 0.41, 1.25 ]
Total events: 36 (LH), 24 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
Total (95% CI) 637 437 100.0 % 0.80 [ 0.51, 1.24 ]
Total events: 52 (LH), 36 (VH)
Heterogeneity: Chi2 = 5.76, df = 9 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 2.62, df = 3 (P = 0.45), I2 =0.0%
0.01 0.1 1 10 100
Favours LH Favours VH
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Analysis 3.19. Comparison 3 LH versus VH, Outcome 19 Thromboembolism.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 19 Thromboembolism
Study or subgroup LH VH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 TLH versus VH
Candiani 2009 0/30 1/30 69.1 % 0.32 [ 0.01, 8.24 ]
Subtotal (95% CI) 30 30 69.1 % 0.32 [ 0.01, 8.24 ]
Total events: 0 (LH), 1 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
2 LH (method unspecified) versus VH
Garry 2004 2/336 0/168 30.9 % 2.52 [ 0.12, 52.76 ]
Subtotal (95% CI) 336 168 30.9 % 2.52 [ 0.12, 52.76 ]
Total events: 2 (LH), 0 (VH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 366 198 100.0 % 1.00 [ 0.15, 6.67 ]
Total events: 2 (LH), 1 (VH)
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Chi2 = 0.82, df = 1 (P = 0.36), I2 =0.0%
0.01 0.1 1 10 100
Favours LH Favours VH
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Analysis 3.20. Comparison 3 LH versus VH, Outcome 20 Length of hospital stay (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 3 LH versus VH
Outcome: 20 Length of hospital stay (days)
Study or subgroup LH VH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LAVH versus VH
Agostini 2006 24 5.6 (1.14) 24 5.5 (1.09) 5.1 % 0.10 [ -0.53, 0.73 ]
Ottosen 2000 40 3.1 (1.4) 40 2.8 (1.1) 6.5 % 0.30 [ -0.25, 0.85 ]
Sesti 2008a 50 2.9 (0.2) 50 1.9 (0.1) 42.6 % 1.00 [ 0.94, 1.06 ]
Sesti 2008b 40 3 (0.2) 40 2 (0.1) 41.9 % 1.00 [ 0.93, 1.07 ]
Subtotal (95% CI) 154 154 96.1 % 0.91 [ 0.76, 1.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.83, df = 3 (P = 0.003); I2 =78%
Test for overall effect: Z = 12.06 (P < 0.00001)
2 LH(a) versus VH
Darai 2001 40 5.7 (3) 40 5.3 (2.1) 1.7 % 0.40 [ -0.73, 1.53 ]
Soriano 2001 37 5.7 (3.1) 40 5.3 (2.1) 1.6 % 0.40 [ -0.79, 1.59 ]
Subtotal (95% CI) 77 80 3.3 % 0.40 [ -0.42, 1.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
3 TLH versus VH
Candiani 2009 30 2.7 (5.3) 30 3.2 (0.6) 0.6 % -0.50 [ -2.41, 1.41 ]
Subtotal (95% CI) 30 30 0.6 % -0.50 [ -2.41, 1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 261 264 100.0 % 0.88 [ 0.73, 1.03 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 18.14, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 11.38 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.48, df = 2 (P = 0.18), I2 =43%
-2 -1 0 1 2
Favours LH Favours VH
Analysis 3.21. Comparison 3 LH versus VH, Outcome 21 Return to normal activities (descriptive data).
Return to normal activities (descriptive data)
Study LH VH Comments
Richardson 1995 n = 22
mean = 23.1 days
range (7 to 56)
n = 23
mean = 22.2
range (7 to 56)
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Return to normal activities (descriptive data) (Continued)
Roy 2011 TLH: n = 30
median = 15 days
min-max = 7 to 30 days
LAVH: n = 30
median = 20 days
min-max = 8 to 40 days
n = 30
median = 14 days
min-max = 7 to 25 days
P value = 0.7
Roy 2012 n = 10
median = 20 days
min-max = 10 to 30 days
n = 10
median = 16 days
min-max = 12 to 24 days
P value = 0.05
Analysis 3.22. Comparison 3 LH versus VH, Outcome 22 Long-term outcomes: quality of life (descriptive
data).
Long-term outcomes: quality of life (descriptive data)
Study Description LH VH Comment
Roy 2011 Patient satisfaction was eval-
uated
using HRQOL (Health Re-
lated Quality Of Life) ques-
tionnaire and SF-12 (12-
item Short Form health sur-
vey) and follow-up visits in
outpatient clinic were done
at 1, 3 and 6 months
TLH: n = 30
LAVH: n = 30
n = 30 After 6 months of surgery, there was significant
higher satisfaction rate among patients who un-
derwent TLH and NDVH (non-descent vaginal
hysterectomy) than those who underwent LAVH
(P value = 0.003). The satisfaction was similar be-
tween the TLH and NDVH group
Analysis 3.23. Comparison 3 LH versus VH, Outcome 23 Operation time (descriptive data).
Operation time (descriptive data)
Study LH VH Comments
Hwang 2002 With 2nd proc:
n = 13
Median = 119
Range (80 to 165)
Without 2nd proc:
n = 17
Median = 109
Range (85 to 175)
With 2nd proc:
n = 3
Median = 93
Range (80 to 110)
Without 2nd proc:
n = 27
Median = 74
Range (40 to 120)
Kruskal Wallis test:
P value = 0.12
P value < 0.001
Ribeiro 2003 n = 20
mean 119 mins (no measure of
spread)
n = 20
mean 78 mins (no measure of
spread)
-
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Operation time (descriptive data) (Continued)
Richardson 1995 n = 22
mean = 131.4 mins
range (76 to 180)
n = 23
mean = 76.7 mins
range (35 to 150)
Some of
these cases include oophorectomies.
Oophorectomy (mean): LH 129.7
mins, VH 95.3 mins; no oophorec-
tomy (mean): LH 132.7 mins, VH
64.7 mins
Roy 2012 n = 10
median = 90 mins
min-max = 60 to 165 mins
n = 10
median = 75
min-max = 40 to 105
Not statistically significant
Analysis 3.24. Comparison 3 LH versus VH, Outcome 24 Length of hospital stay (descriptive data).
Length of hospital stay (descriptive data)
Study LH VH Comments
Hwang 2002 n = 30
median = 4.7 days
range (3 to 7)
n = 30
median = 4.7 days
range (3 to 7)
Not tested separately
Richardson 1995 n = 22
mean = 3.2 days
range (2 to 7)
n = 23
mean = 3.3 days
range (1 to 18)
-
Roy 2011 TLH: n = 30
median = 2 days
min-max = 2 to 12 days
LAVH: n = 30
median = 3 days
min-max = 4 days
VH: n = 30
median = 2 days
min-max = 1 to 4 days
P value = 0.15
Roy 2012 n = 10
median = 3 days
min-max = 2 to 4 days
n = 10
median = 2 days
min-max = 2 to 4 days
Not statistically significant
Analysis 3.25. Comparison 3 LH versus VH, Outcome 25 Pain relief (descriptive data).
Pain relief (descriptive data)
Study Description LH VH Conclusion
Pain scales
Ghezzi 2010 VAS pain scores at several
times post surgery
n = 41
VAS score after 1 h: mean
= 4.7, SD = 2.6
n = 41
VAS score after 1 h:
mean = 7.8, SD = 1.7
P value < 0.0001
P value < 0.0001
P value < 0.0001
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Pain relief (descriptive data) (Continued)
VAS score after 3 h: mean
= 3.2, SD = 2.5
VAS score after 8 h: mean
= 2.1, SD = 2.2
VAS score after 24 h:
mean = 1.8, SD = 1.7
VAS score after 3 h:
mean = 6.6, SD = 2.0
VAS score after 8 h:
mean = 5.3, SD = 2.1
VAS score after 24 h:
mean = 3.6, SD = 2.6
P value = 0.001
Sesti 2008b VAS pain 24 hours post
surgery
6 patients (15%) reported
absence of pain 24 hours
post surgery
20 patients (50%) re-
ported absence of pain
(VAS = 0) 24 hours post
surgery
Patients undergo-
ing LAVH had more post-
operative pain compared
with patients undergoing
VH
Postoperative analgesics
Ghezzi 2010 The need for additional
use of analgesics after the
operation
n = 41
7 (17.1%)
n = 41
32 (78.0%)
P value < 0.0001
Richardson 1995 The number of postoper-
ative opoid injections and
the number of days anal-
gesia was required was
recorded
n = 22
Opoid injections: mean =
2.3, range (0 to 8)
Analgesia required: mean
= 2.9 days, range (0 to 20)
n = 23
Opoid injections: mean =
2.6, range (0 to 15)
Analgesia required: mean
= 2.6 days, range (1 to 17)
The number of opoid in-
jections and analgesia re-
quirements were similar in
each group
Soriano 2001 Total consumption of
paracetamol, NSAID and
subcutaneous opoid
n = 37
Paracetamol: mean = 11.1
g, SD = 5.6
NSAID:mean = 137 mg,
SD = 148
Opoid: mean 6.8 mg, SD
= 13.7
n = 40
Paracetamol: mean = 10.1
g, SD = 6.7
NSAID: mean = 137 mg,
SD = 155
Opoid: mean = 8.7 mg,
SD = 15.7
No significant difference
in the total consumption
of paracetamol, NSAID
and subcutaneous opoid
between the 2 groups
Summitt 1992 Pain control was assessed
by documenting the in-
tramuscular narcotic use
on the day of surgery and
the number of pain tablets
used on the day of surgery
and the first 2 postopera-
tive days
n = 28
Number of oral pain
tablets.
Day of surgery: mean = 3.
13, SD = 2.1, range(0 to
9). P value = NS
Postop Day 1: mean = 3.
67, SD = 2.5, range (1 to
10). P value = NS
Postop Day 2: mean = 2.
71, SD = 2.9, range (0 to
12). P value = 0.27
Number of participants
requiring IM narcotics
within the first 6 hours af-
ter surgery: 9
n = 27
Number of oral pain
tablets.
Day of surgery: mean = 3.
82, SD = 1.8, range (0 to
7). P value = NS
Postop Day 1: mean = 3.
61, SD = 2.3, range (0 to
10). P value = NS
Postop Day 2: mean = 1.
57, SD = 1.5, range (0 to
5). P value = 0.27
Number of participants
requiring IM narcotics
within the first 6 hours af-
ter surgery: 8
-
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Analysis 3.26. Comparison 3 LH versus VH, Outcome 26 Cost (descriptive data).
Cost (descriptive data)
Study Description LH VH
Summitt 1992 Mean total hospital charge when
surgery was performed on an out-
patient basis. Charges consisted of:
operating room fee, operating room
time, anaesthesia time, charges for
disposable staples, scissors, graspers
and a charge for recovery in the am-
bulatory surgery unit, including lab-
oratory fees
n = 29
Mean = USD 7905, SD = 501, range
(7197 to 8289), P value = 0.035
n = 27
Mean = USD 4891, SD = 355, range
(4311 to 5247),
P value = 0.035
Analysis 4.1. Comparison 4 RH versus LH, Outcome 1 Return to normal activities (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 4 RH versus LH
Outcome: 1 Return to normal activities (days)
Study or subgroup RH LH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sarlos 2012 50 28.8 (15.9) 50 31.2 (15.4) -2.40 [ -8.54, 3.74 ]
-10 -5 0 5 10
Favours RH Favours LH
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Analysis 4.2. Comparison 4 RH versus LH, Outcome 2 Intraoperative visceral injury (dichotomous).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 4 RH versus LH
Outcome: 2 Intraoperative visceral injury (dichotomous)
Study or subgroup RH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ureter injury
Sarlos 2012 0/50 1/50 100.0 % 0.33 [ 0.01, 8.21 ]
Subtotal (95% CI) 50 50 100.0 % 0.33 [ 0.01, 8.21 ]
Total events: 0 (RH), 1 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Vascular injury
Sarlos 2012 1/50 1/50 100.0 % 1.00 [ 0.06, 16.44 ]
Subtotal (95% CI) 50 50 100.0 % 1.00 [ 0.06, 16.44 ]
Total events: 1 (RH), 1 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Wound/abdominal wall infection
Sarlos 2012 0/50 1/50 100.0 % 0.33 [ 0.01, 8.21 ]
Subtotal (95% CI) 50 50 100.0 % 0.33 [ 0.01, 8.21 ]
Total events: 0 (RH), 1 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
4 Wound dehiscence
Sarlos 2012 0/50 1/50 100.0 % 0.33 [ 0.01, 8.21 ]
Subtotal (95% CI) 50 50 100.0 % 0.33 [ 0.01, 8.21 ]
Total events: 0 (RH), 1 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
0.01 0.1 1 10 100
Favours RH Favours LH
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Analysis 4.3. Comparison 4 RH versus LH, Outcome 3 Operation time.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 4 RH versus LH
Outcome: 3 Operation time
Study or subgroup RH LH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sarlos 2012 50 106 (29) 50 75 (21) 69.6 % 31.00 [ 21.08, 40.92 ]
Paraiso 2013 26 246 (117) 26 172 (76) 30.4 % 74.00 [ 20.37, 127.63 ]
Total (95% CI) 76 76 100.0 % 44.09 [ 5.31, 82.88 ]
Heterogeneity: Tau2 = 537.35; Chi2 = 2.39, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours RH Favours LH
Analysis 4.4. Comparison 4 RH versus LH, Outcome 4 Transfusion.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 4 RH versus LH
Outcome: 4 Transfusion
Study or subgroup RH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Paraiso 2013 2/26 1/26 2.08 [ 0.18, 24.51 ]
0.01 0.1 1 10 100
Favours RH Favours LH
Analysis 4.5. Comparison 4 RH versus LH, Outcome 5 Return to normal activities (descriptive data).
Return to normal activities (descriptive data)
Study Description RH LH Comment
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Return to normal activities (descriptive data) (Continued)
Paraiso 2013 Percentage to return to nor-
mal baseline activities
at 1, 2, 3, 4, 5 and 6 weeks
postoperatively
1 week (n = 17): 22%
2 weeks (n = 17): 46%
3 weeks (n = 17): 54%
4 weeks (n = 17): 60%
5 weeks (n = 17): 66%
6 weeks (n = 16): 72%
1 week (n = 19): 29%
2 weeks (n = 19): 46%
3 weeks (n = 18): 58%
4 weeks (n = 18): 64%
5 weeks (n = 17): 73%
6 weeks (n = 17): 82%
P value (overall) = 0.25
Analysis 5.1. Comparison 5 SP-LH versus LH, Outcome 1 Bladder injury.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 5 SP-LH versus LH
Outcome: 1 Bladder injury
Study or subgroup SP-LH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SP-TLH versus TLH
Jung 2011 1/30 0/34 100.0 % 3.51 [ 0.14, 89.42 ]
Subtotal (95% CI) 30 34 100.0 % 3.51 [ 0.14, 89.42 ]
Total events: 1 (SP-LH), 0 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
0.01 0.1 1 10 100
SP-LH LH
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Analysis 5.2. Comparison 5 SP-LH versus LH, Outcome 2 Operation time (mins).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 5 SP-LH versus LH
Outcome: 2 Operation time (mins)
Study or subgroup SP-LH LH
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 SP-LAVH versus LAVH
Chen 2011 50 122 (40) 50 127 (22) -5.00 [ -17.65, 7.65 ]
2 SP-TLH versus TLH
Jung 2011 30 89 (25) 34 80 (27) 9.00 [ -3.74, 21.74 ]
-50 -25 0 25 50
SP-LH LH
Analysis 5.3. Comparison 5 SP-LH versus LH, Outcome 3 Transfusion.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 5 SP-LH versus LH
Outcome: 3 Transfusion
Study or subgroup SP-LH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SP-LAVH versus LAVH
Chen 2011 0/50 1/50 52.0 % 0.33 [ 0.01, 8.21 ]
Song 2013 2/20 1/19 32.3 % 2.00 [ 0.17, 24.07 ]
Subtotal (95% CI) 70 69 84.3 % 0.97 [ 0.16, 5.86 ]
Total events: 2 (SP-LH), 2 (LH)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 SP-TLH versus TLH
Jung 2011 1/30 0/34 15.7 % 3.51 [ 0.14, 89.42 ]
Subtotal (95% CI) 30 34 15.7 % 3.51 [ 0.14, 89.42 ]
Total events: 1 (SP-LH), 0 (LH)
Heterogeneity: not applicable
0.01 0.1 1 10 100
SP-LH LH
(Continued . . . )
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(. . . Continued)
Study or subgroup SP-LH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 100 103 100.0 % 1.37 [ 0.30, 6.26 ]
Total events: 3 (SP-LH), 2 (LH)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
0.01 0.1 1 10 100
SP-LH LH
Analysis 5.4. Comparison 5 SP-LH versus LH, Outcome 4 Pelvic haematoma.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 5 SP-LH versus LH
Outcome: 4 Pelvic haematoma
Study or subgroup SP-LH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SP-LAVH versus LAVH
Chen 2011 1/50 0/50 100.0 % 3.06 [ 0.12, 76.95 ]
Subtotal (95% CI) 50 50 100.0 % 3.06 [ 0.12, 76.95 ]
Total events: 1 (SP-LH), 0 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
0.01 0.1 1 10 100
SP-LH LH
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Analysis 5.5. Comparison 5 SP-LH versus LH, Outcome 5 Wound/abdominal wall infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 5 SP-LH versus LH
Outcome: 5 Wound/abdominal wall infection
Study or subgroup SP-LH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SP-LAVH versus LAVH
Chen 2011 0/50 1/50 100.0 % 0.33 [ 0.01, 8.21 ]
Subtotal (95% CI) 50 50 100.0 % 0.33 [ 0.01, 8.21 ]
Total events: 0 (SP-LH), 1 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
SP-LH LH
Analysis 5.6. Comparison 5 SP-LH versus LH, Outcome 6 Febrile episodes or unspecified infection.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 5 SP-LH versus LH
Outcome: 6 Febrile episodes or unspecified infection
Study or subgroup SP-LH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SP-TLH versus TLH
Jung 2011 7/30 2/34 100.0 % 4.87 [ 0.93, 25.62 ]
Subtotal (95% CI) 30 34 100.0 % 4.87 [ 0.93, 25.62 ]
Total events: 7 (SP-LH), 2 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
0.005 0.1 1 10 200
SP-LH LH
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Analysis 5.7. Comparison 5 SP-LH versus LH, Outcome 7 Postoperative ileus.
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 5 SP-LH versus LH
Outcome: 7 Postoperative ileus
Study or subgroup SP-LH LH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 SP-TLH versus TLH
Jung 2011 2/30 1/34 100.0 % 2.36 [ 0.20, 27.39 ]
Subtotal (95% CI) 30 34 100.0 % 2.36 [ 0.20, 27.39 ]
Total events: 2 (SP-LH), 1 (LH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
0.01 0.1 1 10 100
SP-LH LH
Analysis 5.8. Comparison 5 SP-LH versus LH, Outcome 8 Length of hospital stay (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 5 SP-LH versus LH
Outcome: 8 Length of hospital stay (days)
Study or subgroup SP-LH LH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 SP-LAVH versus LAVH
Chen 2011 50 3.7 (0.7) 50 3.9 (0.8) 100.0 % -0.20 [ -0.49, 0.09 ]
Subtotal (95% CI) 50 50 100.0 % -0.20 [ -0.49, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
-100 -50 0 50 100
SP-LH LH
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Analysis 5.9. Comparison 5 SP-LH versus LH, Outcome 9 Operation time (descriptive data).
Operation time (descriptive data)
Study SP-LH Conventional LH Comments
Song 2013 n = 20 SP-LAVH
Mean = 92 min
Range 57 to 220 min
n = 19 LAVH
Mean = 95 min
Range 70 to 154 min
P value = 0.47
Analysis 5.10. Comparison 5 SP-LH versus LH, Outcome 10 Length of hospital stay (descriptive data).
Length of hospital stay (descriptive data)
Study SP-LH LAVH Comments
Jung 2011 n = 30 SP-TLH
Median postoperative hospital stay =
3.4 days
Range 3.0 to 4.3 days
n = 34 TLH
Median postoperative hospital stay =
3.0 days
Range 3.0 to 3.0 days
P value = 0.075
Song 2013 n = 20 SP-LAVH
Mean = 3 days
Range 2 to 4 days
n = 19 LAVH
Mean = 3 days
Range 2 to 4 days
P value = 0.95
198Surgical approach to hysterectomy for benign gynaecological disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.1. Comparison 6 TLH versus LAVH, Outcome 1 Intraoperative visceral injury (dich).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 6 TLH versus LAVH
Outcome: 1 Intraoperative visceral injury (dich)
Study or subgroup TLH LAVH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bladder injury
Long 2002 1/41 2/60 100.0 % 0.73 [ 0.06, 8.27 ]
Roy 2011 0/30 0/30 Not estimable
Subtotal (95% CI) 71 90 100.0 % 0.72 [ 0.06, 8.27 ]
Total events: 1 (TLH), 2 (LAVH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
2 Ureter injury
Long 2002 2/41 1/60 100.0 % 3.03 [ 0.27, 34.52 ]
Roy 2011 0/30 0/30 Not estimable
Subtotal (95% CI) 71 90 100.0 % 3.03 [ 0.27, 34.52 ]
Total events: 2 (TLH), 1 (LAVH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
3 Urinary tract (bladder or ureter) injury
Long 2002 3/41 3/60 100.0 % 1.50 [ 0.29, 7.83 ]
Roy 2011 0/30 0/30 Not estimable
Subtotal (95% CI) 71 90 100.0 % 1.50 [ 0.29, 7.83 ]
Total events: 3 (TLH), 3 (LAVH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
4 Bowel injury
Long 2002 0/41 0/60 Not estimable
Roy 2011 0/30 0/30 Not estimable
Subtotal (95% CI) 71 90 Not estimable
Total events: 0 (TLH), 0 (LAVH)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Vascular injury
Long 2002 1/41 1/60 100.0 % 1.48 [ 0.09, 24.27 ]
Subtotal (95% CI) 41 60 100.0 % 1.48 [ 0.09, 24.27 ]
Total events: 1 (TLH), 1 (LAVH)
Heterogeneity: not applicable
0.005 0.1 1 10 200
Favours TLH Favours LAVH
(Continued . . . )
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(. . . Continued)
Study or subgroup TLH LAVH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.27 (P = 0.79)
6 Conversion to laparotomy
Long 2002 1/42 2/62 76.8 % 0.73 [ 0.06, 8.34 ]
Roy 2011 1/30 0/30 23.2 % 3.10 [ 0.12, 79.23 ]
Subtotal (95% CI) 72 92 100.0 % 1.28 [ 0.21, 7.85 ]
Total events: 2 (TLH), 2 (LAVH)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
0.005 0.1 1 10 200
Favours TLH Favours LAVH
Analysis 6.2. Comparison 6 TLH versus LAVH, Outcome 2 Long-term complications (dich).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 6 TLH versus LAVH
Outcome: 2 Long-term complications (dich)
Study or subgroup TLH LAVH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dyspareunia
Long 2002 5/41 3/60 13.9 % 2.64 [ 0.59, 11.72 ]
Subtotal (95% CI) 41 60 13.9 % 2.64 [ 0.59, 11.72 ]
Total events: 5 (TLH), 3 (LAVH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 Orgasm (< 1 of 3)
Long 2002 18/41 29/60 86.1 % 0.84 [ 0.38, 1.86 ]
Subtotal (95% CI) 41 60 86.1 % 0.84 [ 0.38, 1.86 ]
Total events: 18 (TLH), 29 (LAVH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 82 120 100.0 % 1.09 [ 0.54, 2.17 ]
Total events: 23 (TLH), 32 (LAVH)
Heterogeneity: Chi2 = 1.77, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 1.77, df = 1 (P = 0.18), I2 =44%
0.01 0.1 1 10 100
Favours TLH Favours LAVH
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Analysis 6.3. Comparison 6 TLH versus LAVH, Outcome 3 Operation time (mins).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 6 TLH versus LAVH
Outcome: 3 Operation time (mins)
Study or subgroup TLH LAVH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Long 2002 41 140.4 (38.7) 60 115.1 (38.3) 25.30 [ 10.00, 40.60 ]
-20 -10 0 10 20
Favours TLH Favours LAVH
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Analysis 6.4. Comparison 6 TLH versus LAVH, Outcome 4 Short-term outcomes (dich).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 6 TLH versus LAVH
Outcome: 4 Short-term outcomes (dich)
Study or subgroup TLH LAVH Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Transfusion
Long 2002 2/41 4/60 0.72 [ 0.13, 4.11 ]
Roy 2011 1/30 0/30 3.10 [ 0.12, 79.23 ]
2 Vaginal cuff infection
Long 2002 1/41 5/60 0.28 [ 0.03, 2.45 ]
3 Abdominal wall/wound infection
Roy 2011 0/30 2/30 0.19 [ 0.01, 4.06 ]
4 UTI
Roy 2011 2/30 2/30 1.00 [ 0.13, 7.60 ]
5 Febrile episodes or unspecified infection
Long 2002 3/41 3/60 1.50 [ 0.29, 7.83 ]
Roy 2011 2/30 8/30 0.20 [ 0.04, 1.02 ]
0.005 0.1 1 10 200
Favours TLH Favours LAVH
Analysis 6.5. Comparison 6 TLH versus LAVH, Outcome 5 Length of hospital stay (days).
Review: Surgical approach to hysterectomy for benign gynaecological disease
Comparison: 6 TLH versus LAVH
Outcome: 5 Length of hospital stay (days)
Study or subgroup TLH LAVH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Long 2002 41 3.5 (0.9) 60 3.5 (1.4) 0.0 [ -0.45, 0.45 ]
-0.5 -0.25 0 0.25 0.5
Favours TLH Favours LAVH
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Analysis 7.1. Comparison 7 Mini-LH versus TLH, Outcome 1 Operation time (descriptive data).
Operation time (descriptive data)
Study Mini-TLH Conventional TLH Comments
Ghezzi 2011 n = 38
Median = 58 mins
Range: 30 to 135 mins
n = 38
Median = 60 mins
Range: 30 to 155 mins
P value = 0.55
Analysis 7.2. Comparison 7 Mini-LH versus TLH, Outcome 2 Length of hospital stay (descriptive data).
Length of hospital stay (descriptive data)
Study mini-TLH Conventional TLH Comment
Ghezzi 2011 n = 38
Median = 1 day
Range: 0 to 2
n = 38
Median = 1 day
Range: 1 to 2
P value = 0.73
A D D I T I O N A L T A B L E S
Table 1. Sub-categorisation of laparoscopic hysterectomy
Type of LH LH versus AH RCTs LH versus VH RCTs LH versus LH RCTs
LAVH Ferrari 2000 Agostini 2006 Chen 2011
Kunz 1996 Ottosen 2000 Roy 2011
Marana 1999 Roy 2011 Song 2013
Muzii 2007 Roy 2012
Ottosen 2000 Sesti 2008(a)
Raju 1994b Sesti 2008(b)
Sesti 2008(a)
Tsai 2003
LH(a) Ellstrom 1998 Darai 2001
Falcone 1999 Hwang 2002
Harkki-Siren 2000 Soriano 2001
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Table 1. Sub-categorisation of laparoscopic hysterectomy (Continued)
Hwang 2002 Summitt 1992
Langebrekke 1998 Zhu 2009
Olsson 1996
Persson 2006
Schutz 2002
Seracchioli 2002
Summitt 1998
Yuen 1998
Zhu 2009
TLH Kluivers 2007 Candiani 2009 Ghezzi 2011
Perino 1999 Ghezzi 2010 Jung 2011
Ribeiro 2003 Morelli 2007 Paraiso 2013
Ribeiro 2003 Roy 2011
Roy 2011 Sarlos 2012
Non-categorisable LH Garry 2004 Garry 2004
Kongwattanakul 2012 Richardson 1998
Lumsden 2000
AH: abdominal hysterectomy
LAVH: laparoscopic-assisted vaginal hysterectomy
LH: laparoscopic hysterectomy
RCT: randomised controlled trial
TLH: total laparoscopic hysterectomy
VH: vaginal hysterectomy
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Table 2. Staging of laparoscopic hysterectomy - Richardson 1995
Stage Laparoscopic content
0 Laparoscopy done but no laparoscopic procedure before vaginal hysterectomy
1 Procedure includes laparoscopic adhesiolysis and/or excision of endometriosis
2 Either or both adnexa freed laparoscopically
3 Bladder dissected from the uterus laparoscopically
4 Uterine artery transected laparoscopically
5 Anterior and/or posterior colpotomy or entire uterus freed laparoscopically
Table 3. Steps of laparoscopic hysterectomy - Nezhat 1995
Step Laparoscopic content
1 Severing the round ligaments and dissection of the upper portion of the broad ligament
2 Severing the tubo-uterine junction and the utero-ovarian ligament if the adnexa are to be preserved, or severing the infundibu-
lopelvic ligaments
3 Severing the uterine vessels
4 Preparation of the bladder flap
5 Severing the cardinal uterosacral ligaments complex
6 Performing anterior and posterior culdotomy and separation of the cervix
7 Closure of the vaginal cuff
Table 4. Studies reporting dropouts
Trial No. dropouts Details
Chen 2011 2 Excluded from analysis postoperatively, because they underwent
accessory adnexal surgery
Falcone 1999 4 (1 LH; 3 AH) Withdrew pre-operatively
Garry 2004 34 (23 LH (11 aLH; 12 vLH); 6 AH; 5 VH) Withdrew pre-operatively
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Table 4. Studies reporting dropouts (Continued)
Long 2002 13 3 laparotomy conversions were excluded from analysis; 7 incom-
plete records; 3 combined procedures that were excluded post-ran-
domisation
Lumsden 2000 10 10 dropouts were not analysed. 7 women did not attend surgery
and 3 records were not available
Kluivers 2007 1 Refused assignment procedure
Lumsden 2000 10 7 withdrew pre-operatively; 3 case records not available
Paraiso 2013 6 6 withdrew after randomisation but before the intervention was
performed
Persson 2006 6 5 allocated to AH and 1 to LH withdrew after informed consent
prior to the operation or withdrew in the postoperative period
before the 5-week follow-up
Roy 2011 9 5 excluded because they needed adenectomy during surgery and 4
excluded from all analyses because they did not show up for follow-
up after intervention
Roy 2012 1 1 LH patient excluded from analysis due to conversion
Sarlos 2012 5 After randomisation 5 did not complete the study and were ex-
cluded from the analysis
Song 2013 1 1 lost to follow-up because of dissatisfaction with hospital care
Summitt 1998 2 Refused assignment procedure
Yuen 1998 6 4 declined operation; 2 refused to participate postoperatively
AH: abdominal hysterectomy
aLH: laparoscopic cases in the abdominal arm of the eVALuate trial
LH: laparoscopic hysterectomy
VH: vaginal hysterectomy
vLH: laparoscopic cases in the vaginal arm of the eVALuate trial
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A P P E N D I C E S
Appendix 1. MDSG search
MDSG Specialised Register SS for NJ473 11.11.10
Keywords CONTAINS “Hysterectomy” or Title CONTAINS “Hysterectomy”
AND
Keywords CONTAINS “Hysterectomy,abdominal” or “Hysterectomy, Vaginal” or “hysterectomy -laparoscopic” or “hysterectomy,
laparoscopically assisted vaginal” or “Hysterectomy, subtotal” or “hysterectomy techniques” or “laparoscopic assisted vaginal hysterec-
tomy” or “laparoscopic hysterectomy” or “LAVH” or Title CONTAINS “Hysterectomy,abdominal” or “Hysterectomy, Vaginal” or
“hysterectomy -laparoscopic” or “hysterectomy, laparoscopically assisted vaginal” or “Hysterectomy, subtotal” or “hysterectomy tech-
niques” or “laparoscopic assisted vaginal hysterectomy” or “laparoscopic hysterectomy” or “LAVH” or “TVH” or “TLH” or “vaginal
hysterectomy”or “abdominal hysterectomy”or “abdominal myomectomy”or“laparoscopic”or“laparoscopic procedure”or“laparoscopic
surgical treatment”or“laparoscopically assisted hysterectomy”or“laparoscopically assisted vaginal hysterectomy”or“laparoscopy”or “la-
parotomy”or“mini-laparoscopy”or “mini-laparotomy”or “abdominal hysterectomy”
Appendix 2. CENTRAL search
Cochrane Central Register of Controlled Trials (CENTRAL) in all fields (on Ovid platform)
1. Hysterectomy
2. Abdominal
3. Vaginal
4. Laparoscopic assisted
5. Laparo-vaginal
6. Laparoscopic
7. 1 and 2 or 3 or 4 or 5 or 6
Appendix 3. MEDLINE search
Ovid MEDLINE(R) (1946 to 2014 week 32)
Search strategy:
1 exp HYSTERECTOMY/ (24605)
2 hysterectom$.tw. (26883)
3 1 or 2 (37348)
4 abdom$.tw. (253636)
5 vaginal$.tw. (74351)
6 (lap$ adj assist$).tw. (3843)
7 (lap$ adj5 vaginal$).tw. (1692)
8 LAVH.tw. (324)
9 LVH.tw. (3897)
10 (Ah or Vh or Lh).tw. (62452)
11 TLH.tw. (309)
12 exp Laparoscopy/ (69937)
13 Laparoscop$.tw. (84412)
14 route$.tw. (121604)
15 technique$.tw. (1094816)
16 approach$.tw. (1056843)
17 exp Laparotomy/ (15750)
18 laparotom$.tw. (38835)
19 minilaparotom$.tw. (927)
20 or/4-19 (2520921)
21 3 and 20 (16470)
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22 randomized controlled trial.pt. (385723)
23 controlled clinical trial.pt. (89662)
24 randomized.ab. (305899)
25 placebo.tw. (162963)
26 clinical trials as topic.sh. (172008)
27 randomly.ab. (220260)
28 trial.ti. (131972)
29 (crossover or cross-over or cross over).tw. (62251)
30 or/22-29 (950838)
31 exp animals/ not humans.sh. (3994784)
32 30 not 31 (876347)
33 21 and 32 (1715)
34 2014$.ed. (619882)
35 2014$.dp. (613080)
36 34 or 35 (1063755)
37 33 and 36 (106)
Appendix 4. EMBASE search
EMBASE (1980 to 2014 Week 32)
1 Controlled study/ or randomised controlled trial/
2 double blind procedure/
3 single blind procedure/
4 crossover procedure/
5 drug comparison/
6 placebo/
7 random$.ti,ab,hw,tn,mf.
8 latin square.ti,ab,hw,tn,mf.
9 crossover.ti,ab,hw,tn,mf.
10 cross-over.ti,ab,hw,tn,mf.
11 placebo$.ti,ab,hw,tn,mf.
12 ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw,tn,mf.
13 (comparative adj5 trial$).ti,ab,hw,tn,mf.
14 (clinical adj5 trial$).ti,ab,hw,tn,mf.
15 or/1-14
16 nonhuman/
17 animal/ not (human/ and animal/)
18 or/16-17
19 15 not 18
20 exp HYSTERECTOMY/
21 hysterectom$.tw.
22 20 or 21
23 abdom$.tw.
24 vaginal$.tw.
25 (Lap$ adj Assist$).tw.
26 (Lap$ adj Vaginal$).tw.
27 LAVH.tw.
28 LH.tw.
29 or/23-28
30 exp Surgical Technique/
31 route$.tw.
32 technique$.tw.
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33 approach$.tw.
34 or/30-33
35 22 and 29
36 34 and 35
37 19 and 36
Appendix 5. CINAHL search
CINAHL search strategy for NJ473 28.01.14
# Query Results
S38 S22 AND S36
S37 S22 AND S36
S36 S23 OR S24 or S25 or S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35
S35 TX allocat* random*
S34 (MH “Quantitative Studies”)
S33 (MH “Placebos”)
S32 TX placebo*
S31 TX random* allocat*
S30 (MH “Random Assignment”)
S29 TX randomi* control* trial*
S28 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S27 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S26 TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S25 TX clinic* n1 trial*
S24 PT Clinical trial
S23 (MH “Clinical Trials+”)
S22 S3 AND S21
S21 S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19
OR S20
S20 TX minilaparotom*
S19 TX laparotom*
S18 (MM “Laparotomy”)
S17 TX approach*
S16 TX technique*
S15 TX route*
S14 TX Laparoscop*
S13 (MM “Laparoscopy”)
S12 TX TLH
S11 TX (Ah or Vh or Lh)
S10 TX LVH
S9 TX LAVH
S8 TX (lap* N2 vagina*)
S7 TX (lap* N2 assist*)
S6 TX vagina*
S5 (MM “Hysterectomy, Vaginal”)
S4 TX abdomin*
S3 S1 OR S2
S2 TX Hysterectom*
S1 (MH “Hysterectomy+”)
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Appendix 6. Biological abstracts search
Biological Abstracts (1969 to August 2008, not included in searches beyond 2008)
1 exp HYSTERECTOMY/ (0)
2 hysterectom$.tw. (10663)
3 1 or 2 (10663)
4 abdom$.tw. (149794)
5 vaginal$.tw. (31662)
6 (lap$ adj assist$).tw. (691)
7 (lap$ adj5 vaginal$).tw. (540)
8 LAVH.tw. (71)
9 LVH.tw. (1654)
10 Laparoscop$.tw. (16487)
11 route$.tw. (373620)
12 technique$.tw. (3259392)
13 approach$.tw. (354093)
14 laparo$.tw. (29111)
15 or/4-14 (3796162)
16 3 and 15 (7312)
17 limit 16 to yr=“2007 - 2008” (529)
18 from 17 keep 1-529 (529)
Appendix 7. PsycINFO search
PsycINFO <1806 to August Week 1 2014>
Search strategy:
1 exp Hysterectomy/ (384)
2 hysterectom$.tw. (677)
3 or/1-2 (698)
4 abdom$.tw. (4874)
5 vaginal$.tw. (3769)
6 (lap$ adj assist$).tw. (6)
7 (lap$ adj5 vaginal$).tw. (10)
8 LAVH.tw. (2)
9 LVH.tw. (23)
10 Laparoscop$.tw. (304)
11 route$.tw. (11033)
12 technique$.tw. (151513)
13 approach$.tw. (369519)
14 or/4-13 (509044)
15 3 and 14 (149)
16 limit 15 to yr=“2014 -Current” (2)
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Appendix 8. Clinical Trials Register
1. Hysterectomy
2. Abdominal
3. Vaginal
4. Laparoscopic assisted
5. Laparo-vaginal
6. Laparoscopic
7. 1 and 2 or 3 or 4 or 5 or 6
Appendix 9. Data extraction
• Trial characteristics
◦ Method of randomisation, in order of preference, as follows:
⋄ third party randomisation, for example by pharmacy, computer, or telephone;
⋄ true randomisation by carer, for example by opaque numbered envelope or register;
⋄ not stated.
◦ Study design:
⋄ blinding;
⋄ duration of follow-up;
⋄ type of follow-up.
◦ Size of study:
⋄ number of women recruited;
⋄ number of women randomised;
⋄ number of women excluded;
⋄ number of women withdrawn and lost to follow-up;
⋄ number of women analysed.
◦ Study setting:
⋄ single centre or multicentre;
⋄ location;
⋄ timing and duration;
⋄ source of funding stated or not.
◦ Analyses:
⋄ whether a power calculation was performed and adhered to;
⋄ whether ’intention-to-treat’ analysis was performed by authors, was possible from the data but not performed by
authors, not possible or uncertain.
◦ Criteria for hysterectomy:
⋄ indications specified;
⋄ data broken down by indications for hysterectomy.
• Characteristics of the study participants
◦ Baseline characteristics:
⋄ age;
⋄ parity;
⋄ indication for hysterectomy;
⋄ investigative work up, for example pelvic ultrasound scan, endometrial sampling;
⋄ previous treatments;
⋄ exclusion criteria.
◦ Treatment characteristics:
⋄ pre-operative preparation, for example pre-operative medical treatment;
⋄ level of training of surgeons.
• Interventions
◦ Approach to hysterectomy, percentage of patients having subtotal hysterectomy
◦ Subcategory in case of LH (i.e. LAVH, LH(a) and TLH)
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◦ Use of technique to support the vaginal vault
◦ Proportion undergoing bilateral elective oophorectomy versus ovarian conservation
◦ Other strategies to reduce the likelihood of complications
◦ Absence of co-interventions in treatment and control groups
◦ If the trial compared a surgical approach performed by one (group of ) surgeon(s) with another surgical approach
performed by a second (group of ) surgeon(s)
• Outcomes
◦ Primary outcomes:
◦ 1. Return to normal activities
◦ 2. Satisfaction and quality of life
◦ 3. Intra-operative visceral injury: bladder injury, ureter injury, urinary tract (bladder or ureter) injury, bowel injury, vascular
injury
◦ 4. Major long-term complications: fistula, pelvi-abdominal pain, urinary dysfunction, bowel dysfunction, pelvic floor
condition (prolapse), sexual dysfunction
◦ Secondary outcomes:
◦ 5. Operation time
◦ 6. Other intra-operative complication: estimated blood loss, (sequelae of ) bleeding, including substantial bleeding,
haemoglobin or haematocrit drop, transfusion, pelvic haematoma, unintended laparotomy for approaches not involving routine
laparotomy
◦ 7. Short-term outcomes and complications: length of hospital stay, infections: vaginal cuff, abdominal wall or wound,
urinary tract infection, chest infection, febrile episodes or unspecified infections, thromboembolism, perioperative mortality,
postoperative ileus, wound dehiscence, pain scales and pain relief
◦ 8. Costs
WH A T ’ S N E W
Last assessed as up-to-date: 14 August 2014.
Date Event Description
20 October 2014 New citation required and conclusions have changed This review has been updated. We have included 17 new
studies (Candiani 2009; Chakraborty 2011; Chen 2011;
Ghezzi 2010; Ghezzi 2011; Jung 2011; Kongwattanakul
2012; Paraiso 2013; Roy 2011; Roy 2012; Sarlos 2012;
Sesti 2008a; Sesti 2008b; Song 2013; Nieboer 2012;
Persson 2006; Zhu 2009). Some of the conclusions have
changed.
We have included three new types of intervention in
the review; these have emerged as new approaches to
hysterectomy in randomised controlled trials, i.e. robot-
assisted hysterectomy, mini laparoscopic hysterectomy
and single-port laparoscopic hysterectomy
We have excluded Drahonovsky 2006 and Morelli 2007
in this update of the review
20 October 2014 New search has been performed The addition of new studies has led to a change in the
conclusions of this review
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H I S T O R Y
Protocol first published: Issue 2, 2002
Review first published: Issue 1, 2005
Date Event Description
12 February 2009 New citation required and conclusions have changed New authors: Theodoor E Nieboer, Sabine van Voorst,
Ben Willem J Mol, Kirsten B Kluivers
Seven new studies were included.
The following comparisons became statistically signifi-
cant in the update: a shorter operation time in LAVH
compared to TLH; more substantial bleeding in LH
compared to VH; more febrile episodes or unspecified
infections in TLH compared to LAVH; higher score on
subscale vitality after LH compared to AH; higher sat-
isfaction in VH compared to AH
New comparison: TLH versus LAVH.
9 June 2008 Amended Converted to new review format.
5 February 2008 New citation required and conclusions have changed Substantive amendment.
C O N T R I B U T I O N S O F A U T H O R S
Johanna WM Aarts: selected trials and extracted data for the current update, data entry, wrote current update of the review.
Theodoor E Nieboer: selected trials and extracted data for the current update, data entry, wrote current update of the review.
Neil Johnson: conceptualised the first review, wrote the protocol and the review, having supervised the selection of trials and data
extraction, and commented on the current update.
Emma Tavender: trial selection, data extraction, trial quality assessment, data entry, wrote part of the description of studies and the
methodological quality of included studies sections in the first review. Commented on the current update.
Ray Garry: assisted with data extraction and interpretation, commented on the protocol and the current update.
Ben Willem Mol: assisted with data extraction and interpretation, wrote the current update.
Kirsten Kluivers: selected trials and extracted data for the current update, data entry, wrote and supervised the current update of the
review.
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D E C L A R A T I O N S O F I N T E R E S T
Ray Garry is the principal investigator in a UK-based multicentre randomised trial comparing laparoscopic with both abdominal and
vaginal hysterectomy (Garry 2004).
Neil Johnson is involved in fertility and endometriosis research with the University of Auckland, has a public hospital appointment at
Auckland District Health Board, and has private appointments with private medical practice groups called Endometriosis Auckland
and IVF Auckland (with whom he is a shareholder); Neil Johnson has accepted funding towards conference expenses and research
meetings from the following industry sponsors within the last five years, none of these sums being greater than USD 5000: Organon,
Serono, Schering and Device Technologies.
S O U R C E S O F S U P P O R T
Internal sources
• No internal source of support, Other.
External sources
• No external source of support, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Three new types of intervention have been included in the review, as they emerged as new approaches to hysterectomy in randomised
controlled trials, i.e. robot-assisted hysterectomy, mini laparoscopic hysterectomy and single-port laparoscopic hysterectomy.
Haemoglobin or haematocrit drop has been removed from the list of secondary outcomes.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Robotic Surgical Procedures; Genital Diseases, Female [∗surgery]; Hysterectomy [adverse effects; ∗methods]; Hysterectomy, Vaginal
[adverse effects; methods]; Laparoscopy [adverse effects; ∗methods]; Randomized Controlled Trials as Topic; Recovery of Function
MeSH check words
Female; Humans
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